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Abstract 
Rho-associated kinase 1 (ROCK1) is a serine/threonine kinase important for the 
regulation of the cellular cytoskeleton through the induction of actin stress fibres 
and acto-myosin contractility. The cleavage and subsequent activation of ROCK1 
by caspase 3 during apoptosis is believed to cause many morphological 
phenomena associated with programmed cell death such as dynamic membrane 
blebbing. I now formally prove the necessity of ROCK1 cleavage for apoptotic 
blebbing by knocking-in a caspase cleavage resistant mutant of ROCK1 in a 
genetically modified model. In addition, animals homozygous for non-cleavable 
ROCK1 demonstrate a phenotype consistent with auto-immune disease 
suggesting that apoptotic blebbing is important to mediate rapid efferocytosis, 
which is a rapid phagocytic clearance of the cellular corpse, and thus maintain 
self-tolerance. Furthermore, apoptotic blebbing is important for the clearance of 
apoptotic cells and I demonstrate a novel mechanism for ROCK to mediate the 
release of factors participating in macrophage migration to dying cells. ROCK 
induced apoptotic blebs and bodies lose membrane integrity prior to secondary 
necrosis and leak intracellular material. Using quantitative mass spectrometry I 
identified numerous proteins that were previously unrecognized to be released 
during apoptosis. The release of protein was found to be impaired following ROCK 
antagonism with Y27632 which underscores the importance of ROCK activity in 
apoptotic protein release. One of these proteins, gelsolin, was released following 
caspase cleavage and encourages macrophage motility towards apoptotic cells. 
Finally, I now demonstrate that the three nonsynonymous somatic mutations in the 
ROCK1 gene identified in the Cancer Genome Project lead to elevated kinase 
activity and drive actin cytoskeleton rearrangements that promote increased 
motility and decreased adhesion, characteristics of cancer progression. Mapping 
of the kinase-interacting regions of the carboxy-terminus combined with structural 
modeling provides insight into how these mutations likely affect the regulation of 
ROCK1. Consistent with the frequency of ROCK1 mutations in human cancer, 
these results support the conclusion that there is selective pressure for the 
ROCK1 gene to acquire ‘driver’ mutations that result in kinase activation. 3 
Table of Contents 
1.  Rho-associated protein kinase (ROCK): regulation and function in apoptosis 
and cancer ...................................................................................13 
1.1  ROCK: structure, and regulation ..............................................13 
1.2  ROCK: expression, substrates, and cellular contractility..................15 
1.3  Cellular consequences of ROCK activation ..................................17 
1.4  ROCK1 and cell motility.........................................................17 
1.5  Programmed cell death and ROCK1...........................................19 
1.5.1  Apoptotic Initiation and effector stages................................19 
1.5.2  ROCK and the execution of apoptosis...................................20 
1.5.3  Apoptotic cell clearance and auto-immune disease..................22 
1.5.4  ROCK1 blebbing and auto-immune disease ............................25 
1.6  ROCK functions in embryonic development .................................27 
1.7  ROCK inhibitor specificity ......................................................29 
1.8  ROCK and cancer.................................................................30 
1.8.1  Proliferation.................................................................30 
1.8.2  ROCK and cell survival.....................................................33 
1.8.3  ROCK in tumour cell invasion and metastasis..........................34 
2.  Consequences of apoptotic blebbing: ROCK1 cleavage and auto-immune 
disease........................................................................................41 
2.1  Introduction.......................................................................41 
2.2  Results.............................................................................41 
2.2.1  Generation of ROCK1 non-cleavable (ROCK1nc) knock-in mouse...41 
2.2.2  Breeding strategy for ROCK1nc ..........................................42 
2.2.3  ROCK1nc mutation does not alter kinase function....................43 
2.2.4  ROCK1nc is resistant to apoptotic cleavage ...........................44 
2.2.5  ROCK1nc expression abolishes apoptotic blebbing ...................45 
2.2.6  ROCK1nc expression does not affect phosphatidyl serine (PS) 
externalization ........................................................................45 
2.2.7  Homozygous ROCK1 mice are viable and thrive.......................45 
2.2.8  Homozygous ROCK1nc mice have apoptotic cell accumulation.....46 
2.2.9  Homozygous ROCK1nc mice display an inflammatory/auto-immune 
phenotype ..............................................................................46 
2.3  Discussion .........................................................................65 
3.  ROCK mediates apoptotic cell protein release to modulate innate immune 
responses.....................................................................................67 
3.1  Introduction.......................................................................67 
3.2  Results.............................................................................68 
3.2.1  Apoptotic bodies and blebs lose membrane integrity................68 
3.2.2  ROCK activity triggers apoptotic body formation but does not affect 
membrane integrity...................................................................69 
3.2.3  ROCK antagonism does not affect time course of apoptotic cell 
membrane disruption.................................................................70 
3.2.4  Apoptotic cells release intracellular proteins in a ROCK dependent 
manner 71 
3.2.5  Proteomic analysis of AC-CM by quantitative mass spectrometry..71 
3.2.6  Validation of SILAC data...................................................72 
3.2.7  ROCK inhibition does not affect caspase cleavage....................73 
3.2.8  Apoptotic protein release alters macrophage migration.............74 
3.3  Discussion .........................................................................93 4 
4.  Activating Somatic ROCK1 Mutations in Cancer ..................................96 
4.1  Introduction.......................................................................96 
4.2  Results.............................................................................97 
4.2.1  Cancer Associated Mutations in ROCK1 .................................97 
4.2.2  Cancer associated somatic mutations of ROCK1 are activating.....97 
4.2.3  ROCK1 Mutations are Constitutively Active in Cells ..................98 
4.2.4  ROCK1 mutants enhanced motility and migration ....................98 
4.2.5  C-terminus of ROCK1 contains multiple kinase interacting Domains
 99 
4.2.6  Specific ROCK1 C-terminal Interacting Domains Mediate Kinase 
inhibition ............................................................................. 100 
4.2.7  ROCK1 C-terminal Interacting Domain Modeling .................... 100 
4.3  Discussion ....................................................................... 115 
5.  Materials and Methods.............................................................. 118 
5.1  Chapter 2 methods ............................................................ 118 
5.1.1  ROCK1nc knock-in animal generation................................. 118 
5.1.1.1  Home office project and personal licensing.................... 118 
5.1.1.2  Targeting vector generation ...................................... 118 
5.1.1.3  Mouse embryonic stem cell (mES) vector transfection ....... 119 
5.1.1.4  mES screening for homologous recombination................. 121 
5.1.1.5  mES blastocyst injection and embryo implantation........... 121 
5.1.1.6  Animal genotyping.................................................. 122 
5.1.2  In vitro ROCK1 kinase assay............................................. 122 
5.1.3  Mouse embryonic fibroblast (MEF) generation....................... 122 
5.1.4  Microscopy................................................................. 123 
5.1.4.1  Fluorescent .......................................................... 123 
5.1.4.2  Timelapse ............................................................ 123 
5.1.5  In-cell western blot ...................................................... 124 
5.1.6  Western blot .............................................................. 124 
5.1.7  Flow cytometry........................................................... 124 
5.1.8  Histological tissue collection, fixation, processing, and staining 125 
5.1.9  Haematology .............................................................. 125 
5.2  Chapter 3 methods ............................................................ 126 
5.2.1  Cell culture................................................................ 126 
5.2.2  Western blot .............................................................. 126 
5.2.3  Creation of membrane tagged GFP expressing NIH 3T3............ 126 
5.2.4  Induction of apoptosis, and generation of conditioned medium . 126 
5.2.5  Microscopy................................................................. 127 
5.2.6  Flow cytometry........................................................... 127 
5.2.6.1  Apoptotic body PI permeability .................................. 127 
5.2.6.2  Apoptotic body proteinase K permeability ..................... 128 
5.2.6.3  Apoptotic body generation ........................................ 128 
5.2.6.4  Apoptotic cell permeability....................................... 128 
5.2.7  Lactate dehydrogenase activity measurements..................... 129 
5.2.8  SILAC ....................................................................... 129 
5.2.9  Gelsolin knockdown...................................................... 129 
5.2.10  RAW 264.7 transwell migration ........................................ 130 
5.3  Chapter 4 methods ............................................................ 130 
5.3.1  Cell culture, transfections and plasmids ............................. 130 
5.3.2  Cell extraction and immunoblotting .................................. 130 
5.3.3  Immunoprecipitations and kinase assays ............................. 130 
5.3.3.1  Fluorescence polarization ROCK1 kinase assay ................ 131 
5.3.4  Peptide arrays ............................................................ 131 5 
5.3.5  Immunofluorescence..................................................... 131 
5.3.6  FACS expression .......................................................... 132 
5.3.7  Protein fragment production ........................................... 132 
5.3.8  Cell motility............................................................... 133 
5.3.9  Protein binding assay .................................................... 133 
5.3.10  Transwell dissociation assay............................................ 133 
5.3.11  Protein modeling ......................................................... 133 
References................................................................................. 135 6 
List of Tables 
Table 1.1. Anti-proliferative effects of ROCK antagonism.....................................33 
Table 3.1. Apoptotic protein release .....................................................................76 
Table 3.2. ROCK dependent apoptotic protein release.........................................77 7 
List of Figures 
Figure 1.1. Rho associated kinase structure, homology, and regulation...............36 
Figure 1.2. Diagram of intracellular ROCK signalling............................................37 
Figure 1.3. The generation of apoptotic blebs.......................................................38 
Figure 1.4. Non-canonical activation of ROCK1/2.................................................39 
Figure 1.5. Apoptotic blebbing in efferocytosis and auto-immune disease ...........40 
Figure 2.1. Homologous recombination targeting strategy to generate ROCK1 non-
cleavable allele .....................................................................................................50 
Figure 2.2. 3’ homologous recombination screening strategy and results ............51 
Figure 2.3. 5’ homologous recombination screening strategy and results ............52 
Figure 2.4. Animal genotyping using quantitative PCR.........................................53 
Figure 2.5. ROCK1nc breeding strategy and Mendelian ratios.............................54 
Figure 2.6. ROCK1nc function is identical to wild type kinase ..............................55 
Figure 2.7. Cellular ROCK1 activity is identical in viable homozygous ROCK1wt 
and ROCK1nc fibroblasts .....................................................................................56 
Figure 2.8. ROCK1nc is resistant to apoptotic cleavage.......................................57 
Figure 2.9. Apoptotic ROCK1nc MEFs fail to bleb................................................58 
Figure 2.10. Externalization of phosphatidyl serine is not dependent on ROCK1 
cleavage ...............................................................................................................59 
Figure 2.11. Apoptotic cell accumulation in ROCK1nc mice.................................60 
Figure 2.12. ROCK1nc mice have auto-immune kidney IgG deposition...............61 
Figure 2.13. ROCK1nc mice have reduced erythrocyte volume and haematocrit.62 
Figure 2.14. ROCK1nc mice have increased erythrocyte phagocytosis ...............63 
Figure 2.15. ROCK1nc mice accumulate splenic follicular haemosiderin and 
invasive macrophages with age............................................................................64 
Figure 3.1. Apoptotic bodies lose membrane integrity before secondary necrosis78 
Figure 3.2. Apoptotic blebs lose membrane integrity before secondary necrosis. 79 
Figure 3.3. Apoptotic bodies are permeable to nucleases....................................80 
Figure 3.4. Apoptotic bodies are permeable to proteinase K................................81 
Figure 3.5. ROCK induced acto-myosin contractility induces apoptotic body 
formation...............................................................................................................82 
Figure 3.6. ROCK does not affect apoptotic body membrane stability..................83 
Figure 3.7. ROCK and acto-myosin contractility do not alter onset of secondary 
necrosis. ...............................................................................................................84 
Figure 3.8. Acto-myosin dependent release of lactate dehydrogenase from 
apoptotic cells.......................................................................................................85 
Figure 3.9. Experimental flow chart for quantitative SILAC mass spectrometry....86 
Figure 3.10. ROCK catalyses release of many proteins during apoptosis............87 
Figure 3.11. Apoptotic cells release gelsolin following caspase cleavage. ...........88 
Figure 3.12. Apoptotic gelsolin release is dependent on acto-myosin contractility.
..............................................................................................................................89 
Figure 3.13. Rock inhibition does not affect apoptotic gelsolin cleavage..............90 
Figure 3.14. Apoptotic gelsolin release ensures macrophage migration...............91 
Figure 3.15. Schematic model of apoptotic gelsolin release.................................92 
Figure 4.1. ROCK1 domain structure for wild-type (WT) and cancer associated 
mutations. ...........................................................................................................102 
Figure 4.2. ROCK1 somatic cancer mutants are active......................................103 
Figure 4.3. ROCK1 mutants are active in cells. ..................................................104 
Figure 4.4. ROCK1 somatic cancer mutants promote cellular actin 
rearrangements...................................................................................................105 8 
Figure 4.5. Expression of MYC-tagged ROCK1 constructs in NIH 3T3 mouse 
fibroblasts. ..........................................................................................................106 
Figure 4.6. ROCK1 somatic cancer mutants promote cell migration...................107 
Figure 4.7. ROCK1 somatic cancer mutants promote random cell motility.........108 
Figure 4.8. ROCK1 somatic cancer mutants encourage cellular dissociation.....109 
Figure 4.9. ROCK1 kinase domain has multiple and distinct c-terminal interacting 
sites. ...................................................................................................................110 
Figure 4.10. Validation of ROCK1 C-terminal interacting regions.......................111 
Figure 4.11. ROCK1 kinase-binding regions inhibit kinase activity.....................112 
Figure 4.12. ROCK1 and ROCK2 are highly conserved in the C-terminal regulatory 
domain................................................................................................................113 
Figure 4.13. Structural modelling of the ROCK1 interacting regions...................114 9 
Abbreviations 
ACAMP  Apoptotic cell-associated molecular patterns 
AC-CM  Apoptotic cell conditioned medium 
AIHA  Auto-immune haemolytic anaemia 
ANA Anti-nuclear  antibodies 
ANOVA  Analysis of variance 
Arg Arginine 
CHX Cycloheximide 
DAPI 4',6-diamidino-2-phenylindole 
DAPK  Death-associated protein kinase 
DC Dendritic  cell 
DIC  Differential interference contrast 
DNA Deoxyribonucleic  acid 
ΔROCK1  Cleaved ROCK1 
dRP S19  Dimer of ribosomal protein S19 
ECM Extracellular  matrix 
EOB  Eyelids open at birth 
FACS  Fluorescence activated cell sorting 
FBS  Foetal bovine serum 
GAP  GTPase activating protein 
GDP Guanosine  diphosphate 
GEF  Guanine nucleotide exchange factors 
GFP  Green fluorescent  
GlcNAc n-acetylglucosamine 
GSN Gelsolin 
GST Glutathione  S-transferase 
GTP Guanosine-5'-triphosphate 
H&E  Haematoxylin and eosin 
HMGB-1  High-mobility group box 
LC-MS  Liquid chromatography and mass spectrometry 
LDH Lactate  dehydrogenase 
LIMK LIM  kinase 
LPC Lysophosphatidylcholine 
Lys Lysine 
MCV  Mean corpuscular volume 
MEF  Mouse embryonic fibroblasts 
mES  Mouse embryonic stem cell 
MFG-E8  Milk fat globule epidermal growth factor 8 
MLC  Myosin light chain 
MLCK  Myosin light chain kinase 
PAF  Platelet activating factor 
PARP  Poly (ADP-ribose) polymerase 
PCR  Polymerase chain reaction 
PH Pleckstrin  homology  domain 
PI Propidium  iodide 
PIP2  Phosphatidylinositol (4,5)-bisphosphate (PIP2), 10 
PIP3 Phosphatidylinositol (3,4,5)-trisphosphate 
pMLC  Phosphorylation of MLC 
PS Phosphatidyl  serine 
RBC  Red blood cell 
RBD  Rho binding domain 
RNA Ribonucleic  acid 
RNAi RNA  interference 
ROCK Rho-assocaited  kinase 
ROCK1nc ROCK1  non-cleavable 
RP  Splenic red pulp 
S1P Sphingosine-1-phosphate 
SDS-PAGE  Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis 
SEM  Standard error of the mean 
SILAC  Stable isotope labeling with amino acids in cell 
culture 
SLE  Systemic lupus erythematosus 
TGF-b  Transforming growth factor 
TNFa  Tumor necrosis factor 
TyrRS  Tyrosyl tRNA synthetase 
WP  Splenic white pulp 
WT Wild  type 
ZIPK  Zipper-interacting protein kinase 
Z-VAD-FMK N-benzyloxycarbonyl-Val-Ala-Asp-
fluoromethylketone 
 11 
Acknowledgment 
I owe everything to Mike, all his ideas are always right (at least most of the time). 
Also, he’s a decent sort of guy. Thanks to everyone at The Beatson Institute and 
especially CRUK for funding my laboratory play time. I would like to thank Debs 
and my weans, Finlay and Esme, for supporting me during the last 4 years and 
helping to make this a success.  12 
Author’s Declaration 
I am the sole author of this thesis. The work presented in this thesis is entirely my 
own unless otherwise stated. 13 
1. Rho-associated protein kinase (ROCK): regulation 
and function in apoptosis and cancer  
(Text extracted from Wickman, G., Samuel, P., Lochhead, P., Olson M.F. The Rho-Regulated 
ROCK kinases in cancer. In: K. van Golen (ed.) The Rho GTPases in Cancer. Springer Press. 
(2010) pp. 163-192. and Wickman, G. and Olson M.F. A review of ROCK induced blebbing in 
apoptotic cell clearance and auto-immune disease. In review at Cell Death and Differentiation) 
Rho-associated protein kinases (ROCK) are central and prominent downstream 
effectors of the RhoA, RhoB and RhoC GTP-binding proteins. The predominant 
function of ROCK is the regulation and modulation of the cytoskeleton. 
Specifically, ROCK promotes the stabilization and bundling of actin filaments (F-
actin) and the generation of acto-myosin contractility via the phosphorylation of 
downstream substrates. As a result, ROCK proteins are indispensable for many 
cellular processes dependent upon the cytoskeleton including, but not limited to: 
cell motility, adhesion, apoptosis and phagocytosis. Given the critical role of 
ROCK1 and 2 in these diverse physiological processes, it is unsurprising that 
these kinases are involved in the development and progression of multiple 
diseases including cancer 
1. While ROCKs are also implicated in diabetic 
nephropathy and a diverse array of cardiovascular diseases, the involvement of 
ROCK in the pathology of these disorders is outside the scope of this thesis 
2,3. 
1.1 ROCK: structure, and regulation 
There are two isoforms of the ROCK serine/threonine kinases, ROCK1 (ROKβ) 
and ROCK2 (Rho kinase or ROKα), which share 64% overall homology with 89% 
homology within the kinase domain 
4 (Figure 1.1a). ROCK is most closely related 
to the myotonic dystrophy kinase (DMPK, 48% identity in kinase domain with 
ROCK1) and the DMPK-related Cdc42-binding kinases MRCKα and MRCKβ 
(each with 53% kinase domain identity with ROCK1), which appear to share some 
overlapping functions in the regulation of the cytoskeleton 
5. The ROCK kinases 
contain an amino-terminal kinase domain, a central coiled-coil domain (55% 
identity), followed by a split pleckstrin homology domain containing a C1 
conserved region (80% identity) (Figure 1.1a). A Rho-binding domain (RBD) lies 
within the coiled-coil region of ROCK, structural studies have revealed that the 
RBD forms a coiled-coil that interacts with the switch I and II regions of GTP-
bound RhoA 
6,7. Several lines of investigation have revealed that ROCK1 and    14 
ROCK2 form homo- and heterodimers that influence kinase activity, inhibitor 
sensitivity and normal function in vivo 
8-10. Experiments using either wild-type 
RhoA loaded with non-hydrolyzable GTP-γS or GTPase-deficient RhoAG14V, 
revealed that Rho-GTP can increase ROCK specific activity in kinase assays and 
the formation of ROCK-dependent actin stress fibres and focal adhesions in 
cultured cells 
11. Studies examining the mechanism of ROCK activation by Rho-
GTP revealed that expression of ROCK RBD and PH fragments attenuate 
activation which suggests that the carboxyl terminal domain of ROCK negatively 
regulates kinase activity 
11,12. While it is clear from these data that Rho-GTP 
binding to the RBD within the carboxyl terminus of ROCK relieves this negative 
regulation leading to increased kinase activity, the precise mechanistic details of 
this auto-inhibition remained elusive (Figure 1.1b). 
The association of additional proteins to ROCK, including other small GTP-binding 
proteins, appears to regulate kinase activity. RhoE, Gem, and Rad have each 
been shown to bind ROCK at sites distinct from the RBD
13,14. The binding of Gem 
to ROCK1 was found to attenuate phosphorylation of the MYPT1 regulatory 
subunit of the PP1M phosphatase complex but not LIM kinase, suggesting that 
Gem induces a shift in ROCK substrate specificity 
14. In addition, the 
overexpression of Gem and Rad in endothelial cells result in reduced stress fibres 
and focal adhesions, consistent with inhibition of ROCK activity 
14. Similar effects 
on stress fibres are reported for RhoE overexpression 
15, which was found to bind 
within the amino terminal kinase domain and may sterically interfere with kinase-
substrate interactions 
13. Alternatively, RhoE and RhoA appear to be competitive 
for ROCK binding, despite their binding at distinct sites, thus RhoE may 
antagonize ROCK function by inhibiting RhoA-mediated activation 
13.  In further 
support of a role for RhoE in ROCK regulation, the protein kinase PDK 1 has been 
shown to enhance ROCK1 activity, not through phosphorylation, but by blocking 
the association of RhoE 
16. RhoE, Rad/Gem display discrete subcellular 
distributions, being located at the Golgi apparatus and the cytoskeleton 
respectively, and it has been suggested that the distribution of these negative 
regulators is important for the modulation of ROCK activity at specific intracellular 
sites 
17. 
The lipid second messengers arachadonic acid (AA) and sphingophosphocholine 
(SPC) appear to be highly efficacious ROCK activators. ROCK purified from    15 
chicken gizzard was activated 5-6 fold following exposure to AA, independent of 
RhoA 
18. In addition, SPC enhanced contractility of vascular smooth muscle in a 
ROCK inhibitor sensitive, but GTP-independent, manner 
19. Together these 
observations suggest that lipid activation is sufficient to stimulate ROCK and 
catalyze acto-myosin contractility. However, the relevance of these two lipid 
signaling pathways in the regulation of ROCK in non-smooth muscle cell types 
remains to be demonstrated. A role for phosphatidyl inositides in ROCK activation 
has also been observed. Purified ROCK2, but not ROCK1, binds 
phosphatidylinositol (3,4,5)-trisphosphate (PIP3) and phosphatidylinositol (4,5)-
bisphosphate (PIP2), which activate kinase activity independent of Rho-GTP 
20. It 
has been suggested that the differential binding properties of ROCK1 and ROCK2 
towards PIP3 and PIP2 may be important for subcellular regulation allowing ROCK 
to initiate discrete spatial functions. 
Phosphorylation of ROCK2 at several sites by polo like kinase 1 appears to 
promote RhoA dependent activation 
21. Although additional serine/threonine and 
tyrosine phosphorylation sites have been identified (http://www.phosphosite.org), 
which may be involved in ROCK regulation, the prevalence and function of these 
phosphorylations remain to be determined. Interestingly, structural studies 
revealed that phosphorylation within the kinase domain was not necessary for the 
formation of a catalytically competent conformation 
9. 
1.2 ROCK: expression, substrates, and cellular 
contractility 
Both ROCK isoforms are ubiquitously expressed in normal tissue and appear to 
have enhanced expression in brain, liver, and skeletal muscle 
22. Examination of 
intracellular localization revealed a predominantly cytosolic distribution pattern 
23,24. However, more detailed analysis has revealed ROCK localized to: plasma 
membranes 
23,25, acto-myosin filaments 
23,26, nucleus 
27, mitotic cleavage furrow 
28,29 and centrosomes 
30. These observations are consistent with a role for ROCK 
as a mediator of the actin cytoskeleton, and suggest that proper subcellular 
localization likely plays a key regulatory role. 
More than 20 ROCK substrates have been identified, and while many have only 
been tested with one isoform, it seems likely that most substrates would be    16 
phosphorylated in vitro by either kinase given the 89% identity between ROCK1 
and ROCK2. If there were differences in substrate phosphorylation by each 
isoform, this would probably result from more subtle differences in subcellular 
localization and/or protein-protein interactions. ROCK regulates the cytoskeleton 
via phosphorylation of numerous downstream target proteins (Figure 1.2). ROCK 
phosphorylates LIM kinases-1 and –2 (LIMK1 and LIMK2) at Threonine-508 and-
505 in their respective activation loops, which result in increased LIMK catalytic 
activity and the subsequent phosphorylation and inactivation of the actin-severing 
protein cofilin, thereby stabilizing filamentous actin 
31-34. Cofilin induced actin 
severing and the generation of barbed ends appear to be an important component 
of intracellular actin cycling which in-turn dictates cytoskeletal structure. The LIM 
kinases can also be phosphorylated and regulated by p21 activated protein 
kinases (PAK) 1 and 4 suggesting that multiple signaling networks converge on 
LIMK to modify the cellular cytoskeleton and subsequent cellular function 
35,36. In 
addition, ROCK participates in the phosphorylation of the myosin II light chains 
(MLC), a key mechanism for regulation of acto-myosin contractility 
37. MLC 
phosphorylation promotes the release of the myosin heavy chain tail allowing for 
assembly into filaments, and facilitates the association of the myosin head with F-
actin. The myosin head uses ATP to ‘walk’ towards the barbed end, when 
multimeric myosin is associated with more than one actin filament to provide 
traction, this process then allows for sliding of actin filaments in the opposite 
direction, thereby generating contractile force. While ROCK has been shown to 
phosphorylate recombinant MLC at the same site (Ser 19) as the Ca
2+ dependent 
myosin light chain kinase (MLCK) 
38, experiments with GTPγS in airway smooth 
muscle failed to demonstrate significant MLC phosphorylation or cell contraction in 
Ca
2+ depleted and therefore MLCK inactive conditions 
39. These observations 
suggest that ROCK-mediated phosphorylation of MLC at Ser19 may not be a 
physiologically significant pathway to regulate cell contractility, at least in some cell 
types. Instead, the regulation of MLC phosphorylation, and thus cellular 
contraction, by ROCK may be mediated by inhibition of the myosin light chain 
phosphatase PP1M. This protein complex is made up of a PP1Cδ catalytic 
subunit, a myosin light chain binding subunit (MBS) and a smaller M20 subunit of 
unknown function 
40. ROCK has been found to phosphorylate the ubiquitously 
expressed MYPT1 myosin binding subunit at two sites (Thr 696 and Thr 853 in the 
human form), which inhibits MLC dephosphorylation 
41-43. As a result, a net gain in    17 
MLC phosphorylation would actually require less activity by kinases such as MLCK 
directed towards MLC than under conditions in which PP1M was not inhibited, 
leading to an increase in MLC phosphorylation and greater cellular contractility 
39,44. In addition, many ROCK effects may be amplified by direct phosphorylation 
and activation of the Zipper-interacting protein kinase (ZIPK), which 
phosphorylates many of the same substrates as ROCK 
45. Taken together, ROCK 
activation leads to a concerted series of events that promote acto-myosin 
mediated force generation and subsequent morphological changes (Figure 1.2). 
1.3 Cellular consequences of ROCK activation 
The increase in cellular contractility stimulated by ROCK leads to the prominent 
formation of actin stress fibres. These are bundles of contractile actin and myosin 
II filaments found along the length of the cell body of cultured cells and terminate 
at discreet points at the membrane known as focal adhesions. In fact, stress fibre 
formation was one of the first cellular activities identified for the Rho-associated 
kinases and either ROCK antagonists or dominant negative expression can impair 
their formation 
11,22,46. In addition, the formation of focal adhesion complexes and 
the subsequent aggregation of integrins also appears to be dependent upon Rho-
ROCK contractility 
46,47. The formation of these structures can be induced by 
multiple factors including, but not limited to: platelet-derived growth factor, and 
lysophosphatidic acid 
48-50. While ROCK is clearly involved in the generation of 
stress fibres, it should be noted that expression of ROCK alone generates 
“stellate” fibres with an architecture distinctively different from those stimulated by 
Rho 
22. Expression of ROCK with another Rho binding protein, the Diaphanous-
related formin mDia1, gave rise to stress fibres similar to those seen induced by 
Rho 
51, indicating that although ROCK plays a central and critical role, Rho 
induction of stress fibre formation requires the input of additional signaling 
pathways. Nonetheless, ROCKs are clearly vital enzymes for cytoskeletal 
modification which in turn is responsible for many important biological processes 
such as cell migration, apoptosis, and embryonic development. 
1.4 ROCK1 and cell motility 
The dynamic reorganization of the cytoskeleton has long been understood as the 
underlying mechanism allowing cell migration and invasion 
52. Given the    18 
importance of ROCK in cytoskeletal remodeling and acto-myosin contractility, it is 
not surprising that the enzyme has been implicated in cell migration. Expression of 
constitutively active ROCK in MM1 hepatoma cells significantly enhanced invasion 
and dissemination of tumour cells in an in vivo model 
53. This enhanced migration 
was also observed with MM1 cells expressing RhoAG14V and was reversed with 
the ROCK antagonist Y27632 
53. These observations are supported by a 
significant body of evidence implicating a role for ROCK in two dimensional in vitro 
migration experiments 
17. However, significant morphological differences are 
observed in cells grown in monolayer culture versus a more physiological 3D 
matrix 
54. These differences call into question the relevance of 2D models of 
cellular migration for studying in vivo cell movement. Instead, three dimensional 
migration studies are required to recapitulate a more realistic environment as a 
model for physiological migration and invasion. 
Single cell migration within a 3D matrix can be categorized into two distinct modes, 
mesenchymal and amoeboid 
55. Mesenchymal migration is characterized by: a 
fibroblast/spindle like morphology; dependence upon focal adhesions; integrin 
binding; and matrix proteolysis. The amoeboid form is marked by: a rounded cell 
body; limited dependence upon matrix adhesions; and limited requirement for 
proteolytic matrix remodeling. Mesenchymal migration appears to have limited 
dependence upon ROCK; in contrast, amoeboid migration is heavily dependent 
upon ROCK. In evidence, Y27632 was found to significantly inhibit the matrigel 
invasion of several amoeboid cell lines, while it failed to inhibit mesenchymal-like 
invasion 
56. Consistent with these observations, the amoeboid migration of DMS79 
cells in collagen gels was associated with membrane blebbing, a cellular feature of 
ROCK activation 
57,58. Membrane blebbing appears to be a general characteristic 
of cells undergoing amoeboid migration, and is likely important for cell movement 
within three dimensional matrices without necessitating proteolytic remodeling 
56,59. Furthermore, several cell lines have demonstrated plasticity in migration 
strategies and, in the presence of protease inhibitors, can be shifted from Y27632 
insensitive mesenchymal migration to amoeboid, whereupon cell movement is 
sensitive to Y27632 treatment 
56. These observations clearly suggest a significant 
role for ROCK in cellular migration; however, a precise mechanism of control 
remains to be demonstrated. Nonetheless, ROCK has been proposed to regulate 
contraction of cortical actin rings which initiate membrane blebbing and 
deformation of the extracellular matrix 
55,56,60.    19 
1.5 Programmed cell death and ROCK1 
Programmed cell death, or apoptosis, is a vital process mediating the removal of 
aged, damaged, or developmentally unnecessary cells in multicellular organisms 
61,62. ROCK appears to play a vital role in several processes of programmed cell 
death. First defined in 1972, apoptosis is an active process involving 4 well defined 
stages; initiation, effector, execution, and clearance 
63.  
1.5.1  Apoptotic Initiation and effector stages 
Apoptosis is now recognized to be initiated by multiple stimulatory cues that can 
be divided into extracellular (extrinsic) or intracellular (intrinsic) signals which are 
not mutually exclusive. Viable cells can be induced to execute programmed cell 
death following the activation of death receptors by various extracellular (extrinsic) 
ligands such as Fas ligand, and tumour necrosis factor alpha (TNFα) 
64. The 
activation of death receptors initiates a caspase cleavage cascade culminating in 
caspase-3 activation. Caspases are cysteine-dependent aspartate-directed 
proteases that are expressed as inactive proforms and their function is vital to the 
execution of apoptosis. Caspases are activated in complex proteolytic cascades 
involving initiator caspases, such as caspase 8/9, which cleave and activate 
executioner caspases, such as caspase 3, that are necessary and sufficient to 
execute the apoptotic programme. Alternatively, cell death can be initiated in the 
absence of extrinsic factors. This intrinsic pathway can be activated by cellular 
stress or DNA damage and is dependent upon the pro-apoptotic activity of 
proteins, such as the Bcl family, that permeabilize the outer mitochondrial 
membrane causing the release of proteins normally contained only within the 
mitochondria. These proteins, such as cytochrome c, Smac, and Omi, upon 
release trigger the activation of caspase 9 which in turn cleaves and activates 
caspase 3 
65. Regardless of the induction mechanism the activation of caspase 3 
is a critical effector protease leading to the execution of programmed cell death. 
Once activated caspase 3 proteolytically cleaves over 100 intracellular proteins at 
a specific Asp-x-x-Asp motif 
66. Caspase cleavage of target proteins can cause 
either a gain- or loss-of-function which dramatically alters their regulation and 
function 
66. The altered activity of these proteins is collectively responsible for the 
execution of the apoptotic programme. The importance of caspase cleavage in 
apoptosis is underscored in experiments using caspase inhibitors, such as N-   20 
benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (Z-VAD-fmk). These 
compounds, which bind to the catalytic site and inhibit the further cleavage of 
cellular substrates, consistently allow cells to escape programmed cell death 
induced by both intrinsic and extrinsic signals 
67. Thus the activation of executioner 
caspases is a key switch triggering a multitude of independent cellular cascades 
resulting in the characteristic rapid compartmentalization and fragmentation of the 
cell associated with apoptotic cell death. 
1.5.2  ROCK and the execution of apoptosis 
Apoptotic cells can be easily discriminated from viable counterparts based on 
several morphological hallmarks. Not only do apoptotic cells have a very 
conspicuous nuclear condensation and fragmentation, but they also have very 
characteristic plasma membrane blebs. These are balloon-like protrusive blisters 
of the cellular plasma membrane that can be retracted and reformed in a dynamic 
cycling process which can cover the entire cellular surface of apoptotic cells 
(Figure 1.3a). The formation of apoptotic blebs is more of a physical, rather than a 
biochemical, process and they are believed to form as a result of increased 
hydrostatic pressure following acto-myosin dependent cellular contraction 
68,69. 
During their formation, the plasma membrane tears away from the underlying 
cytoskeletal cortex and rapidly forms an enveloped area filled with cytoplasm 
(Figure 1.3b). When newly formed, the bleb is devoid of polymerized actin and 
other cytoskeletal proteins into which an actin cortex will rapidly polymerize 
followed by the recruitment of cytoskeletal bundling proteins and myosin, which 
then power bleb retraction 
70. In apoptotic cells this cyclic process of bleb 
formation and retraction can occur over several hours and as programmed cell 
death progresses blebs become packed with cellular organelles and condensed 
chromatin and form the basis of sub-cellular membrane clad apoptotic bodies 
71. 
However, it must be noted that apoptotic blebbing is not a universal feature of 
programmed cell death; some cell types do not appear to generate membrane 
blebs nor undergo fragmentation 
72. Nonetheless, blebbing remains a very 
common feature of apoptotic cells and is considered a major morphological 
hallmark of programmed cell death.  
In 2001 it was discovered that apoptotic blebbing is dependent upon ROCK 
activity 
73,74. Moreover it was apparent that apoptotic ROCK activation, which is    21 
vital to drive blebbing, is independent of its canonical activator Rho. This non-
classical activation of ROCK was associated with cleavage of ROCK1, but not 
ROCK2, by caspase 3 at a conserved site near the C-terminus 
(1110DETD1113)(Figure 1.4). Further investigation revealed that caspase cleaved 
ROCK1 yields a highly active kinase fragment that is sufficient to induce 
membrane blebbing identical to that seen in apoptotic cells. In addition, the 
cleaved ROCK1 fragment appears to be important for disruption of nuclear 
integrity and the packaging of fragmented DNA into membrane blebs and 
apoptotic bodies 
73,75. Thus the generation of constitutively active ROCK kinase 
fragments appears to be a bona fide regulatory mechanism for the complete 
execution of cellular apoptosis. When cell death has been triggered by extrinsic 
factors such as TNFα, ceramide or Fas-receptor ligation, ROCK1 activation is a 
relatively late event 
57,76 and ROCK inhibition does not halt the apoptotic process 
57. However, in some contexts chronic or high intensity ROCK activity may 
contribute to the initiation of apoptosis. Data from ROCK1 knockout mice revealed 
that cardiac pressure overload was less effective at inducing cardiomyocyte 
apoptosis in relative to controls, suggesting a potential role for ROCK1 in 
myocardial failure 
77. While ROCK cleavage is tightly associated with the formation 
of apoptotic blebs, formal proof for the necessity of cleavage remains to be 
provided. Although ROCK2 is not cleaved by caspase 3 and is therefore unlikely to 
be involved in apoptotic blebbing induced by conventional intrinsic and extrinsic 
stimulus, it is cleaved by granzyme B 
78. Granzyme B is a serine protease injected 
into target cells by cytotoxic T-cells and natural killer cells to induce cell death by 
mitochondrial disruption and direct caspase 3 cleavage. Interestingly granzyme B 
cleaves ROCK2 at a homologous site to caspase 3 cleavage of ROCK1; cleavage 
of ROCK2 at D1131 liberates the C-terminal regulatory domain causing 
constitutive activation capable of inducing membrane blebs (Figure 1.4). Due to 
the activation of caspase 3 granzyme B induced apoptosis also leads to the 
cleavage of ROCK1 and thus the importance of ROCK2 cleavage towards the 
formation of apoptotic blebs remains unclear. Furthermore, as ROCK2 is not 
cleaved during apoptosis induced with conventional signals, the post-translational 
modification to produce a constitutively active ROCK2 appears to be unnecessary 
for apoptotic blebbing.  
While the cleavage of ROCK1 is clearly vital to blebbing, it seems dispensable for 
many other apoptotic phenomena including caspase activation and    22 
phosphatidylserine externalization. This leaves open the question of precisely 
what the biological significance of ROCK1 cleavage, and by extension apoptotic 
membrane blebbing, might be. One tantalizing possibility for the importance of 
ROCK1 activation during apoptosis is to aid phagocytosis of cellular remains.  
1.5.3  Apoptotic cell clearance and auto-immune disease 
The apoptotic programme is ultimately responsible for the final act of cellular 
disposal, or efferocytosis. As a testament to the efficiency and rapidity of 
efferocytosis it is surprisingly difficult to histologically detect apoptosis despite >10
9 
cells executing apoptotic programmes per day in adult tissues 
79-81. There are 
several broadly defined phases of phagocytic clearance of apoptotic cells which 
include 1) Find-me, characterized by the release of soluble signals which attract 
macrophages to the dying cell; 2) Eat-me, in which a phagocyte becomes 
stimulated by engaging with signals expressed on the apoptotic cell membrane; 3) 
Engulfment, a series of cytoskeletal modifications in the phagocyte to take up the 
dead cell; and finally 4) Processing, digestion of the cellular remains through 
lysosomal degradation 
82-84.  
Importantly, the apoptotic cells are active participants in these processes and 
display significant modifications to their membranes that aid recognition and 
uptake. This material can include lipid, protein, and modified carbohydrates. The 
best characterised of these externalized factors is phosphatidyl serine (PS), which 
is normally restrained to the inner leaflet of the plasma membrane 
85. During early 
apoptosis membrane asymmetry is lost; PS becomes externalized and serves as a 
major factor for apoptotic cell recognition. Externalized PS can be recognized by 
the protein milk fat globule epidermal growth factor 8 (MFG-E8), which tethers the 
phospholipid to integrin αvβ3 expressed on macrophages and monocytes 
86 (Figure 
1.5). Alternatively PS can be recognized directly by one or more receptors 
expressed on macrophages, including; Bai1, Tim5, and Stabilin2 
62. Curiously, PS 
externalization has also been demonstrated in viable cells suggesting that PS 
serine exposure alone may be insufficient to mediate phagocytosis and that other 
signals are necessary 
87,88. Thus, it has been proposed that the ‘eat-me’ signal 
received by phagocytes must be sufficiently strong to initiate efferocytosis 
89. The 
strength of such a signal could be augmented by the binding of additional ‘eat-me’ 
molecules, such as MFG-E8. Alternatively, the spatial concentration of PS on    23 
apoptotic cell membranes may also serve as a phagocytosis signal which will be 
discussed in greater detail below 
89. In addition to PS externalization, apoptotic 
cells have numerous modifications of their membrane contents. The generation of 
apoptotic bodies causes the cell to lose membrane which is replaced from 
intracellular organelles such as the Golgi and endoplasmic reticulum 
90. This 
scavenging of intracellular membranes results in the externalization of protein and 
glycan groups, including n-acetylglucosamine (GlcNAc), which are normally 
expressed only on intracellular membranes 
91. Externalization of GlcNAc is 
recognized as a determinant of apoptotic thymocyte phagocytosis 
92. Moreover, 
many of the newly externalized proteins are modified by cleavage, likely by 
activated caspases, which might easily affect their function and/or recognition 
66,93. 
The abnormal externalization of intracellular material is believed to collectively 
serve as apoptotic cell-associated molecular patterns (ACAMPs), which either 
alone or in conjunction with plasma proteins such as MFG-E8, complement C1q, 
mannose-binding lectin, and surfactant protein A are then recognized by 
macrophages to mediate clearance (Figure 1.5)
89,94-96. The binding of a 
macrophage to a target apoptotic cell creates an engulfment synapse and the 
diverse molecular interactions between ACAMP and macrophage mediate 
important components of efferocytosis such as, binding, and engulfment 
97-99. 
The proper execution of apoptosis and subsequent corpse clearance provides 
powerful anti-inflammatory signals to the engulfing cells and, importantly, remains 
immunologically silent 
100-102. Furthermore, the engulfment of early apoptotic cells 
is regarded to induce a tolerogenic response and proteins will be appropriately 
recognized as ‘self’, thus avoiding the activation of adaptive immunity towards 
apoptotic material 
103. Collectively, it is the combination of rapid apoptotic cell 
clearance linked to suppression of immune activation that allow apoptosis to 
proceed rapidly and efficiently with a minimum of tissue disturbance consequently 
maintaining tissue homeostasis. One of the key features of apoptotic cells that 
assist in the rapid silent removal of the cellular fragments is a stable intact 
membrane, generally detected by the exclusion of impermeable dyes (such as 
propidium iodide) that prevents the release of intracellular proteins and 
subsequent immunological activation 
104. This is in contrast to necrotic cell death, 
wherein cells inappropriately lyse and spill their intracellular contents leading to a 
rapid pro-inflammatory response (Figure 1.5) 
101,105. For this reason defects in 
efferocytosis are believed to cause inappropriate pathological inflammation leading    24 
to the generation of auto-immune disease. Indeed, numerous genetically modified 
mouse models removing vital elements of cell recognition and clearance 
machinery including, but not limited to: complement C1q, and MFG-E8 display an 
auto-immune phenotype characteristic of systemic lupus erythematosus (SLE). 
SLE is a chronic systemic auto-immune disease which affects nearly 5 million 
people globally, 90% of which are female 
106. The disease is characterized by: the 
generation of auto reactive antibodies, particularly against nuclear antigens; the 
formation of antibody-immune complexes; and pro-inflammatory cytokine 
production 
107,108. Animal models with defective efferocytosis develop a similar age 
and female dominant pathology associated with increased anti-nuclear antibodies 
(ANA), splenomegaly (enlarged spleen), and glomerulonephritis (kidney immune-
complex deposition) 
109,110. Given the systemic nature of the disease it is not 
surprising that SLE affects multiple organ systems including joints, skin, lymph and 
kidneys. While the pathophysiology of SLE is multifactorial, the best defined 
abnormality associated with the disease is a failure in apoptotic cell clearance. Not 
only are macrophages from SLE patients deficient in autologous efferocytosis in 
vitro, but the number of tingible body macrophages, which are responsible for the 
ingestion of apoptotic corpses in lymphoid tissue germinal centres, are frequently 
reduced in SLE sufferers 
111,112. Consistent with these observations, SLE is 
associated with greater numbers of circulating apoptotic bodies and an 
accumulation of apoptotic cells in the germinal centres of lymph nodes 
113,114. 
Furthermore, complement C1q deficiency, which is associated with increased 
undigested apoptotic debris, is a potent trigger for SLE 
115. The increase in free 
un-phagocytised apoptotic debris in SLE is a likely cause of SLE’s classic 
diagnostic feature, ANA. As mentioned previously, the failure to timely clear 
apoptotic cells can result in immune activation towards intracellular material, 
including nuclear proteins and DNA. Supporting this possibility, SLE associated 
ANA can be specific for novel antigens revealed only after apoptotic enzymatic 
modification, such as cleavage 
93. Furthermore, these autoreactive antibodies are 
somatically mutated IgG isotypes suggesting that they are the products of B-cell 
affinity maturation and thus the result of an antigen driven immune response 
116,117. Collectively these observations underscore the importance of apoptotic cell 
clearance in the maintenance of self-tolerance. 
However, it is important to note that apoptotic clearance failure in itself may be 
insufficient to promote auto-immune disease; in fact, mannose-binding lectin-   25 
deficient mice have demonstrated apoptotic clearance defects without 
autoimmunity 
118. This suggests that additional determinants, apart from 
clearance, participate in the immunological processing of apoptotic cell debris. It 
has been proposed that immunosuppressive TGF-β release stimulated by binding 
of apoptotic cells to macrophages may be sufficient to avoid potentially 
problematic auto-antibody generation, even in the absence of clearance 
119. 
Nonetheless, defective cell clearance, as evidenced by mutation or elimination of 
the myriad components of efferocytosis, are undoubtedly linked to autoimmune 
disease as well as several other disorders in human and mice, including; 
atherosclerosis, neuropathy, arthritis, and anaemia 
62,120. 
1.5.4  ROCK1 blebbing and auto-immune disease 
Numerous studies have attempted to define the importance of blebbing towards 
apoptotic clearance and found several, potentially contradictory, roles for blebs 
and apoptotic bodies. There have been several key in vitro studies demonstrating 
that inhibition of apoptotic blebbing can significantly impair corpse clearance by 
monocytes and macrophages 
91,121,122. Further investigation revealed that impaired 
corpse clearance following defective blebbing could be rescued by the PS bridging 
protein, MFG-E8. The implication of these studies is twofold: firstly, apoptotic 
blebbing directly mediates efferocytosis; and secondly, PS externalization may be 
a mechanism linking blebbing and phagocytosis. While the apoptotic 
externalisation of PS appears to be independent of ROCK activity, the sub-cellular 
localization of the phospholipid might be 
57,122. In fact, microscopic analysis reveals 
that apoptotic blebs become highly enriched for the externalized phospholipid 
123. 
Thus it appears that apoptotic blebs are serving as focal points for externalized PS 
to accumulate, which is then recognized by macrophages to trigger engulfment. 
The possibility that apoptotic blebs provide context for macrophage recognition are 
consistent with data demonstrating PS exposure on viable cells is insufficient to 
trigger phagocytosis. Surprisingly, MFG-E8 failed to further enhance the in vitro 
phagocytic uptake of normal blebbing apoptotic cells, as might be expected. This 
suggests that apoptotic blebbing itself is sufficient to mediate corpse clearance, 
alternatively, in the instance of defective blebbing, efferocytosis can be achieved 
with the aid of bridging molecules like MFG-E8; thus there appears to be a 
significant redundancy in clearance mechanisms. These redundant compensating 
mechanisms may explain why many genetically modified mice with defective    26 
clearance mechanisms are neither developmentally lethal nor display severe auto-
immune phenotypes (if displayed at all), as measured by survival and overall 
health.  
One of the most striking examples highlighting the potential importance of 
apoptotic blebs is the demonstration of their robust opsonization with C1q in 
human endothelial cells 
123-125. Complement fixation in these cells was restricted 
entirely to the surface of blebs while the remainder of the cell surface remained 
clear of C1q binding 
124. This high density opsonization on the surface of apoptotic 
blebs likely binds multiple macrophage receptors which efficiently trigger 
efferocytosis. The importance of this mechanism is underscored by the 
autoimmune disorders observed in C1q deficient mice 
110. Collectively, ROCK 
dependent blebbing and the subsequent release of ‘come-find-me’ and/or the sub-
cellular accumulation of ‘eat-me’ factors would be expected to facilitate rapid 
efferocytosis and thus maintain self-tolerance. 
Apoptotic blebs are also intimately associated with the generation of auto-reactive 
antibodies. In fact, many of the newly externalised bleb-associated proteins are 
frequent auto-antigens in SLE including: nucleosomes, Ro, and La (Figure 1.5 
126,127 
89,125. This outcome is in opposition to the typical physiological response and 
cannot be explained by macrophage phagocytosis. Other than macrophages, 
apoptotic blebs may also be cleared by professional antigen presenting dendritic 
cells (DC)(Figure 1.5)
128,129. The uptake of apoptotic cells by dendritic cells or 
macrophages appears to have opposing consequences. As previously mentioned, 
macrophage phagocytosis is anti-inflammatory while DC uptake leads to secretion 
of pro-inflammatory cytokines and the presentation of self-antigens for auto-
antibody generation 
128-131.  
Collectively, all of these studies demonstrate that apoptotic blebbing, as a 
mechanism to mediate cell clearance, is a double edged sword. While blebs 
appear to be important for rapid uptake and clearance they also are 
simultaneously sources of auto-antigens. It appears that the same material that is 
recognized by macrophages to mediate clearance is also recognized by other cell 
types, such as dendritic cells, to generate auto-immune antibodies. The 
mechanisms leading to these opposing outcomes is currently unclear, however, 
defects in macrophage uptake or increases in apoptosis appear to be important    27 
determinants. Hypothetically, the accumulation of apoptotic debris would likely 
lead to an increased probability of DC activation and, over time, this inappropriate 
activation overcomes self-tolerance and generates auto-reactive antibodies 
characteristic of SLE. While the linkage between apoptotic blebbing and 
autoimmune disease is broadly recognized, definitive proof of the importance of 
apoptotic blebbing has not been forthcoming. The studies investigating apoptotic 
blebbing in the context of clearance and auto-immune disease are largely limited 
to in vitro experimentation that cannot recapitulate the complexity of interactions 
between apoptotic cells and their environment. Furthermore, they also typically 
suffer from their dependence on chemical inhibitors to interfere with apoptotic 
blebbing. The removal of these agents prior to analysis of macrophage 
phagocytosis is vital and, unfortunately, can never be guaranteed. In addition, the 
apoptotic cells have to be subjected to extensive additional washing steps which 
may alter the stability and structure of the apoptotic cells and thus affect outcome 
in subsequent assays. As a result, many of the observations regarding the 
importance of blebbing towards autoimmune disease are severely limited. Thus 
the current investigational methods are incapable of providing physiologically 
relevant insight into the role of ROCK induced apoptotic blebbing in the clearance 
of corpses and generation of autoimmune disease. Ultimately proof that apoptotic 
blebs are important for cell clearance and/or the generation of autoimmune 
disease requires a biological model of defective blebbing. Of note, a ROCK1 
knockout mouse has been generated, however no evidence of either defective 
apoptotic blebbing in vitro or auto-immune disease in vivo has been reported.  
1.6 ROCK functions in embryonic development 
Targeted deletion in mice has revealed distinct roles for ROCK1 and ROCK2 in 
embryonic development. Knock-out mice generated by targeted deletion of exons 
3-4 of the ROCK1 gene (in the C57Bl/6 strain background) were born at the 
expected Mendelian ratio, but were not viable and consequently were cannibalized 
by the mother 
132. Developmental abnormalities of ROCK1
-/- mice included failure 
in the closure of eyelids (eyelids open at birth phenotype – EOB) and of the ventral 
body wall. The latter phenomenon results in the protrusion of the abdominal 
contents into an omphalocele. Closer scrutiny revealed that polymerization of 
filamentous actin at the umbilical ring was reduced, resulting in incomplete closure 
of the abdominal wall and herniation of abdominal organs, particularly the liver and    28 
intestine. Furthermore, actin cable structures within the leading edge of cells 
composing the eyelid epithelial sheets were disorganized, accounting for EOB. In 
both cases, phosphorylation of MLC was not observed. Two further versions of 
ROCK1 knockout mice have been generated either by targeted deletion of exon 5 
(and studied in the FVB strain of mice)
133 or exon 1 (and studied in the C57Bl/6 
strain)
134. In neither case were EOB or omphalocele phenotypes observed, which 
might be explained by strain-specific genetic differences. However, in each case 
under-representation of homozygous ROCK1 knock-out mice in litters was 
observed. In addition, ROCK1-deficient animals were resistant to reactive cardiac 
fibrosis resulting from physical stress on the cardiac muscle, which may be 
mediated by reduced ROCK1-mediated expression of fibrogenic cytokines and 
extracellular matrix protein production by cardiac fibroblasts 
133,134. 
Genetic deletion of ROCK2 on the C57Bl/6 background also exhibited EOB and 
omphaloceles 
135, suggesting that either there is a requirement for each individual 
ROCK protein, or for a minimum level of total ROCK activity, in the actin driven 
movement of epithelial sheets required for these developmental processes. This 
second possibility is supported by the observation that ROCK1/ROCK2 double 
heterozygous mice also exhibited EOB and omphaloceles 
135, although at a lower 
frequency than ROCK1
-/- or ROCK2
-/- mice. The lack of effect in phenotype in other 
tissues suggests that ROCK1 and ROCK2 are able to functionally compensate for 
each other, or that the requirement for total ROCK activity is lower. Interestingly, 
approximately 90% of ROCK2 knock-out mice on the mixed C57Bl/6-129/Sv strain 
background died in utero at around 13.5 days postcoitum from coagulation of 
blood within the placental labyrinth layer 
136.Surviving   ROCK2
-/- mice were runted, 
suggesting nutritional deficiency resulting from placental impairment, with 
hemorrhages observed in hind limbs supporting the conclusion that there were 
defects in blood coagulation. Actin structures within the placental labyrinth layer of 
ROCK2
-/- mice were apparently normal, suggesting an actin-independent role for 
ROCK2 in the placenta. Interestingly, there may be a role for ROCK1 within the 
placenta where it robustly associates with caveolin1 within lipid rafts of syncitial 
trophoblasts 
137. The strain-specific differences in the effects of ROCK deletion 
strongly suggest the influence of modifier genes or strain-specific differences in 
ROCK activity.    29 
1.7 ROCK inhibitor specificity 
Many studies that have aimed to identify the biological activities of ROCK have 
made use of the potent small molecule inhibitors that are commercially available. 
The most commonly used inhibitor is Y27632 
138; others include Y-32885 
138, H-89 
139, HA-1077 (fasudil)
140, HA-1100 (hydroxyfasudil)
141, H-7 and H-8 
142, H-1152 
143, 
Rockout 
144 and [N-(4-Pyridyl)-N’-(2,4,6-trichlorophenyl)urea]
145. There are always 
questions about the specificity and selectivity of small molecule inhibitors, given 
that the majority act as ATP-competitors and the 3-dimensional structure of protein 
kinases, including the ATP-binding regions, are highly related 
146. Recently, a 
panel of ROCK inhibitors (Y27632, H-7, H-8, HA-1077, H-89, H-1152) was tested 
against a panel of 70 protein kinases 
147. These experiments revealed that none of 
the ROCK inhibitors is absolutely specific, with the Rho-regulated PRK2 being 
inhibited to the same extent by all tested ROCK inhibitors and both MSK1 and 
RSK1 being at least 50% inhibited by all the tested compounds at concentrations 
that inhibited ROCK2 by at least 90%. These studies indicate that although ROCK 
inhibitors are useful tools, they should not be relied upon to be conclusive. 
Therefore, a greater confidence would be engendered in studies that make use of 
ROCK inhibitors if a number of additional conditions were satisfied including: 
1. Structurally unrelated inhibitors should produce the same biological 
endpoints at concentrations that produce equivalent kinase inhibition. The 
lowest effective doses should be used to reduce off-target effects. 
2.  Dose-response experiments to establish rank order of potency for a set of 
inhibitors, i.e. the most potent ROCK inhibitors should be the most effective 
if a biological response is mediated by ROCK. 
3. Examination of the relationship between ROCK inhibitor dose, substrate 
phosphorylation and biological endpoint.  
4. Where possible additional methods should be used to inhibit ROCK 
function, such as RNAi-mediated knockdown. 
Although care should be taken in interpreting the results of inhibitor studies, they 
are undoubtedly useful and convenient tools. Our understanding of the biological    30 
functions of ROCK has been vastly aided by the ready availability of these 
inhibitors. However, their utility is most robust in excluding the possible 
involvement of a particular signaling pathway in specific biological responses when 
adequate positive controls are in place. 
1.8 ROCK and cancer 
Given the diverse array of cellular functions of ROCK it is unsurprising that the 
kinases have been significantly implicated in the pathogenesis of cancer. 
Increased expression of Rho GTP-binding proteins has been reported for a wide 
variety of cancers 
148,149. Although the mechanisms leading to elevated Rho 
expression have not been widely investigated, it was recently reported that 
metastatic breast cancer cells overexpress a microRNA that increases the 
expression of RhoC 
150. In addition to increased levels of Rho proteins, specific 
examples of elevated expression or mutation of Rho activating guanine nucleotide 
exchange factors and downregulation or deletion of Rho inactivating GTPase 
accelerating proteins have been detected 
149. These findings suggest that there 
may be increased ROCK activity associated with cancer. Consistent with this 
possibility, elevated expression of ROCK1 and ROCK2 was observed in bladder 
151 testicular cancer 
152,153, and squamous-cell carcinoma 
154. In the case of 
bladder cancer, elevated expression was significantly correlated with poor survival 
151. Finally, recent efforts to identify somatic mutations in human cancers have 
identified mutations in both ROCK1 and 2 
155. Statistical analysis of the mutation 
rate of ROCK1 suggests that the mutations are perhaps drivers of the oncogenic 
process. These mutations will be discussed in greater detail in Chapter 4. The 
increased expression and activity of ROCK could contribute to cancer initiation 
and progression in several ways. In the sections below, I summarize the evidence 
that supports a role for ROCK in promoting proliferation, survival and metastasis.  
1.8.1  Proliferation 
The ready availability of potent ROCK inhibitors, especially Y27632 
138, has made 
it possible to examine the role of ROCK in mitogen-induced proliferation in a wide 
variety of cell types, both in tissue culture and in vivo (Table 1.1), albeit with the 
caveats noted above. In some instances, RNAi-mediated knockdown of ROCK 
expression has been found to impair proliferation 
156. ROCK inhibitors antagonise    31 
a wide range of mitogenic stimuli including agonists for G-protein-coupled 
serpentine receptors and tyrosine kinase growth factor receptors to mechanical 
stretching. The single most common cell type in which ROCK inhibition has an 
apparent anti-proliferative effect is in vascular smooth muscle, with a number of 
reports indicating a similar effect in airway and prostatic smooth muscle cells. The 
prevalence of reports on vascular smooth muscle cells may reflect two factors; the 
critical role of ROCK in regulating both the contraction and proliferation of smooth 
muscle cells, and the high level of interest in ROCK inhibitors as agents to treat 
cardiovascular diseases. The lower occurrence of publications reporting an effect 
of ROCK inhibitors on proliferation in other tissues may reflect a role for ROCK in 
a limited number of cell types, or may be a function of lower interest in 
investigating the contribution of ROCK to proliferation in non-muscle cells 
Consistent with the anti-proliferative effect of ROCK inhibitors, expression of active 
forms of ROCK1 and ROCK2 have been shown to induce proliferation of bovine 
endothelial cells and mouse fibroblasts respectively 
157,158. In addition, active 
ROCK1 was found to co-operate with a weakly activated form of Raf1 to promote 
oncogenic transformation of immortalized mouse fibroblasts. In a recent paper it 
was discovered that conditional activation of ROCK2 in skin leads to contractility 
dependent epithelial hyperproliferation and skin thickening 
154. The proliferative 
effect of ROCK2 in epithelial cells is a result of mechanical paracrine stimulation of 
β-catenin due to increased extracellular collagen deposition. The activation of 
ROCK2 in this model was further associated with increased tumour formation 
following chemical carcinogenesis. This work suggests that ROCK activation and 
subsequent acto-myosin contractility help create an extracellular environment or 
‘niche’ that is permissive for hyperproliferation and the generation of cancerous 
lesions.  
There are a limited number of studies reporting stimulation of proliferation by 
Y27632, indicating that replication of some cell types may be restrained by ROCK 
activity. Treatment of rat embryonic kidney cells 
159 human primary keratinocytes 
160 and human embryonic stem cells 
161 induced proliferation, while expression of a 
conditionally activated ROCK2 in primary keratinocytes led to cell cycle arrest and 
terminal differentiation upon induction of catalytic activity 
160. Similarly, expression 
of a constitutively active ROCK2 inhibited the proliferation of endothelial cells while 
Y27632 partially rescued cells from an inhibition of proliferation induced by TNF-α    32 
162. Taken together, the literature supports the conclusion of a general role for 
ROCK as a promoter of cell replication, with anti-proliferative functions in selected 
cell types. What is missing from consideration are studies in which activation or 
inhibition of ROCK had no effect on proliferation, with a few exceptions (e.g. 
references 
163-165), lack-of-effect results are generally left unpublished.    33 
 
Table 1.1. Anti-proliferative effects of ROCK antagonism 
Cell type  ROCK 
Inhibitor
Mitogen References 
Glioma cell lines  Y-27632  Lysophosphatidic 
acid 
166 
Astrocytes Y-27632  PAR-1  agonists 
167 
Mouse Embryo 
Fibroblasts  Y-27632  Macrophage 
migration inhibitory 
168 
Tenon's Capsule 
Fibroblasts  H-1152P Wound  healing 
169 
Oral squamous
 
carcinoma cells  Y-27632 Sonic  hedgehog 
170 
Gastric epithelial cells  Y-27632  Glycine-extended 
gastrin 
171 
Umbilical
 vein 
endothelial cells  Y-27632 Oxidized  LDL 
172 
Vascular smooth 
muscle cells  Y-27632 PDGF-BB 
173 
Airway smooth muscle 
cells  Y-27632 Serum 
174 
Prostatic smooth 
muscle cells  Y-27632  
175 
Cardiac myocytes  Y-27632  Serum 
176 
Atrial myofibroblast cells  Y-27632  Serum 
177 
Myoblasts Y-27632  Serum 
178 
T cells  Y-27632  Concanavalin A 
179 
CD34
+ hematopoietic 
progenitor stem
 cells  Y-27632 CXCL12 
180 
Chondrocytes Y-27632  Serum 
181 
Hepatic stellate cells  Y-27632  Serum 
182 
Pancreatic stellate cells  Y-27632 
Fasudil 
Serum, 
PDGF-BB 
183 
Adrenal Zona 
glomerulosa cells  Y-27632 Serum 
184 
 
1.8.2  ROCK and cell survival 
There also appears to be a role for ROCK in cell survival. Inhibition of ROCK 
activity induces cell death in corneal epithelial cells 
185, airway epithelial cells 
186,    34 
neointimal smooth muscle cells 
187-189, vascular smooth muscle cells 
190,191, 
endothelial cells 
192 hepatic stellate cells 
193, spinal cord motor neurons 
194, 
rheumatoid synovial cells 
195 and in H202 treated intestinal epithelial cells 
196. 
These effects were not limited to non-transformed cells as ROCK inhibition also 
induced cell death in anaplastic thyroid cancer cells 
197 glioma cells 
198 CD34
+ 
chronic myeloid leukemia progenitor cells 
199 and H202 or camptothecin treated 
neuroblastoma cells 
200. 
Whether ROCK activation is pro-apoptotic or pro-survival is likely context specific 
and dependent upon cell type and death stimulus. Although there are some 
examples of ROCK inhibitors resulting in tumour regression in vivo (e.g.
198,201), it 
remains to be determined whether this resulted from the inhibition of ROCK-
mediated protection in the tumour cells. It is also remains to be determined 
whether a pro-survival activity of ROCK plays a significant role in human cancers. 
The precise molecular mechanisms through which ROCK might mediate its effects 
on cell survival remain to be elucidated. 
1.8.3  ROCK in tumour cell invasion and metastasis 
Tumour cells are recognized to utilize the complete array of migration strategies, 
from the migration of multicellular sheets to individual cell motility 
55. As previously 
discussed ROCK activity is particularly vital for the amoeboid migration of cancer 
cells 
56,60. Treatment of morphologically round cancer cell types (A375, WM266.4, 
LS174T) with the ROCK inhibitor Y27632 was found to significantly impair cell 
motility, while in contrast migration of cancer cells with an elongated morphology 
(BE and SW962) was highly resistant to Y27632 
56. Furthermore, amoeboid 
tumour cell migration and invasion are dependent upon matrix deformation rather 
than proteolytic remodeling 
60. Interestingly, cancer cells display a remarkable 
plasticity in migration strategy and can switch between mesenchymal and blebbing 
strategies to maintain motility. This strategy switching involves a complex signaling 
interplay between competitive Rho and Rac signals 
56,202. Although cancer cells 
can use several different migration strategies, the amoeboid ROCK-dependent 
motility appears to favor metastatic disease. In fact, overexpression of RhoC, an 
effector of ROCK, is not only correlated but is essential for metastatic disease in 
several in vivo models 
203-205. This increased metastatic phenotype is associated 
with increased membrane blebs suggesting an important role for ROCK induced    35 
amoeboid motility 
203. These observations are further supported by numerous 
studies that directly implicate ROCK in tumour cell invasion by examining in vivo 
metastasis in the presence of ROCK inhibitors. In one study, HA-1077 (fasudil) 
reduced tumour burden and ascites resulting from peritoneally disseminated MM1 
(rat hepatocellular carcinoma) cells in rats by half, decreased lung nodule 
formation in mice by HT1080 (human fibrosarcoma) cells by 40% and limited 
breast cancer formation in mice by MDA-MB-231 (human breast carcinoma) cells 
three-fold 
206. ROCK inhibitors also were found to reduce the in vivo invasiveness 
of human hepatocellular carcinoma 
207,208, human prostate cancer 
209 and mouse 
lung cancer cells 
210. A positive role for ROCK in cancer cell invasiveness in vivo 
was further demonstrated with human colorectal cancer cell lines expressing a 
conditionally active version of ROCK2 
211. These cells formed highly vascularized 
tumours in mouse xenografts that aggressively and individually invaded into the 
surrounding stroma upon ROCK activation. These results suggest that ROCK2 
activity is not only sufficient for tumour invasion, but is also sufficient for the 
induction of angiogenesis possibly by increasing the plasticity of tumour tissue 
thereby facilitating invasion by endothelial cells, potentially aiding tumour growth 
and dissemination. This possibility is supported in a recent paper demonstrating 
that ROCK driven actomyosin contractility encourages the loss of tumour cell 
cohesion and the switch from collective to individual migration 
212. Collectively, 
these studies are consistent with ROCK as a central mediator of tumour cell 
invasiveness and metastasis through blebbing motility.    36 
 
Figure 1.1. Rho associated kinase structure, homology, and regulation 
(a) Line diagram of ROCK1 and 2 protein domains and homology. Domain location from N-
terminus indicated above and below diagram for ROCK1/2 respectively. Kinase domain is in grey; 
Coiled-coil in dark green; Rho-binding domain (RBD) in light green; Split pleckstrin homology (PH) 
in orange; and cysteine-rich (C1) domain in blue. Percent sequence homology for ROCK1 and 2 
shown below line diagram. (b) Line diagram illustrating activation of ROCK following Rho GDP-
GTP exchange by Rho. Rho-GDP (guanosine diphosphate) is exchanged for GTP (guanosine 
triphosphate) with the aid of a Rho-guanine nucleotide exchange factor (GEF). Rho-GTP then 
binds to the Rho binding domain (light green) and induced a conformational change which relives 
kinase auto-inhibition. The kinase is then returned to an inactive state by hydrolysis of GTP to 
GDP after binding of a Rho- GTPase activating protein (GAP) to the Rho protein.     37 
 
Figure 1.2. Diagram of intracellular ROCK signalling 
Stimulatory inputs are indicated by green arrows and inhibitory in red. LIMK, LIM kinase; MYPT, 
myosin phosphatase target subunit; MLC, myosin light chain. The net activity of ROCK activation 
is to stabilize actin filaments and increase acto-myosin contractility, the outcome is profound 
changes to cell size and shape.     38 
 
Figure 1.3. The generation of apoptotic blebs 
(a) Representative immunofluorescence micrograph of an apoptotic mouse embryonic fibroblast. 
Apoptosis was induced with TNFα (50 ng/ml) and cycloheximide (10 μg/ml). After 2 hours the 
cells were fixed with paraformaldehyde and plasma membrane stained with fluorescent lipid dye 
DiO (green) and nucleus is stained with DAPI (blue). The cell has many apoptotic blebs some of 
which contain nuclear fragments (white arrows). Image acquired at 63X oil immersion objective 
with a laser scanning confocal microscope. (b) Diagram illustrating the mechanism of bleb 
generation and retraction in apoptotic cells. Black lines indicate cellular membrane and dotted 
red line underneath is the cytoskeletal cortex. As a result of cortical contraction intracellular 
pressure builds and blebs spontaneously form and expand. Actin rapidly polymerizes into the 
newly formed blebs and then acto-myosin contractility retracts the protrusion. Cellular 
components become packaged in the bleb which can eventually fragment into apoptotic bodies.    39 
 
Figure 1.4. Non-canonical activation of ROCK1/2 
Schematic illustration of cleavage of ROCK1 and ROCK2 induced by caspase 3 and granzyme B 
respectively. Cleavage generates constitutively active kinases that induce contractility and 
blebbing.    40 
 
Figure 1.5. Apoptotic blebbing in efferocytosis and auto-immune disease 
Schematic illustration of apoptotic cell blebs in concentrating eat-me factors and aiding 
clearance. Alternatively blebs concentrate nuclear antigens and participate in auto-immune 
disease. MØ, macrophage; DC, dendritic cell, PS, phosphatidyl serine.  
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2. Consequences of apoptotic blebbing: ROCK1 
cleavage and auto-immune disease 
2.1 Introduction 
During apoptosis ROCK cleavage and activation appears to be not only vital for 
the formation of blebs but may be involved in the clearance of the cellular corpse 
72-74,122. As previously discussed, many of the studies investigating the importance 
of apoptotic ROCK cleavage and its numerous biological consequences have 
been limited to in vitro studies often using pharmacological inhibitors. While 
undoubtedly valuable, these reports do not provide proof that ROCK cleavage is 
necessary for apoptotic bleb formation or yield understanding of the biological 
function of blebbing. Therefore, the conclusions derived from these studies are at 
best speculative.  
In order to answer these fundamental questions about the role of ROCK1 
cleavage and activation in apoptosis, I made a genetically modified (GM) knock-in 
mouse expressing non-cleavable ROCK1 (ROCK1nc) that renders the protein 
insensitive to caspase-cleavage. The generation of this model will provide 
definitive evidence whether the cleavage of ROCK1 is essential for apoptotic 
blebbing, which could then prove to be an ideal model to assess the in vivo 
biological impact of blebbing in homeostasis. These studies could be 
fundamentally important in our understanding of auto-immune disease and either 
provide validation for the current understanding of the role of apoptotic blebbing or 
necessitate a re-analysis of current thinking.  
2.2 Results 
2.2.1  Generation of ROCK1 non-cleavable (ROCK1nc) knock-in 
mouse 
A targeting vector bearing two mutations in exon 27 (3338A>C and 3339T>A) of 
the mouse ROCK1 gene was generated with a floxed neomycin selection cassette 
in the preceding intron (Figure 2.1). The targeting vector was generated with 3.1 
kb 5’ and 5.1 kb 3’ homology arms respectively. When translated, the mutant 
ROCK1 bears a single missense substitution (D1113A), thus modifying the 
caspase cleavage site from DETD to DETA. This modification renders the kinase    42 
insensitive to caspase cleavage 
57. Following transfection of the targeting vector in 
129 mouse embryonic stem cells (mES) the cells were selected for stable insertion 
by neomycin resistance and then surviving clones were screened for properly 
targeted homologous recombination. I performed the primary screen by 
polymerase chain reaction (PCR) of genomic DNA purified from neomycin 
resistant clones with the 5’ primer within the neomycin cassette and 3’ outside the 
homology arm (Figure 2.2a). This reaction was predicted to generate a 3.5 kb 
product from homogonously recombined mES cells and no product from the wt 
ROCK1 locus (Figure 2.2a). A positive product of the expected size was detected 
in 3 out of 200 clones (6b, 7h, and 4g) indicating homologous recombination at the 
3’ arm of the mutant ROCK1 allele (Figure 2.2b). The preliminary hits were re-
confirmed and found to be positive; however, the 4g had far less reaction product 
compared to 6b and 7h (Figure 2.2c). Clones 6b, 7h, and 4g were further 
examined for 5’ homology using PCR with 5’ primer outside the homology arm and 
the 3’ primer within the neomycin cassette. This reaction was predicted to 
generate a 5.5 kb product from homologously recombined mES cells and no 
product from the wt ROCK1 locus (Figure 2.3a). Only 6b and 7h generated 
products of the expected size, indicating that these clones had a correct 
homologous knock-in of the mutant ROCK1 gene (Figure 2.3b). Clone 6b was 
used to generate animals and 7h was held in reserve. The mES 6b clones were 
injected into fertilized mouse blastocysts and then implanted into pseudopregnant 
mice. The resulting male mosaic offspring were then bred onto a wildtype female 
C57 black 6 (C57BL/6). Offspring were routinely genotyped using Transnetyx 
genotyping service to detect the mutant ROCK1nc allele for germline transmission. 
This genotyping uses a quantitative PCR reaction coupled with a specific 
fluorescent probe to determine hetero- and homozygosity (Figure 2.4). The 
construct generation, transfection and embryo manipulation was performed by The 
Beatson Institute Transgenic Technology core facility.  
2.2.2  Breeding strategy for ROCK1nc  
Mice heterozygous for the mutant ROCK1nc gene retained the neomycin selection 
cassette within the intron sequence which needed to be removed to avoid any 
interference in ROCK1 expression. As previously mentioned, the neomycin 
cassette was flanked by LoxP sequences and the cassette was removed by 
crossing female ROCK1nc
+/-, neomycin
+/- to male C57BL/6 expressing ubiquitous    43 
Cre recombinase leaving a residual LoxP site (Figure 2.5a). The resulting animals 
verified as ROCK1nc
+/-, neomycin
-/-, Cre
+/- were bred onto wild type C57BL/6 to 
remove Cre (Figure 2.5a). Deletion of neomycin and removal of Cre was 
confirmed by genotyping from Transnetyx. The resulting heterozygous ROCK1nc 
(neo and Cre null) animals were interbred to generate animals for experimentation. 
ROCK1nc mice generated from heterozygous breeding were born in the expected 
Mendelian ratios (Figure 2.5b) without gross abnormalities. ROCK1nc 
homozygous mice were also bred to generate experimental animals and found to 
be viable and thrive (data not shown).  
2.2.3  ROCK1nc mutation does not alter kinase function 
The substitution mutation that was introduced in the ROCK1 caspase cleavage 
site is not anticipated to affect kinase activity or activation. The location of the 
caspase cleavage site is outside of both the N-terminal kinase and C-terminal 
regulatory domains. Given the nature of the ROCK1nc mutation, a change in 
kinase function should only be observed following induction of apoptosis and 
caspase cleavage, under non-apoptotic conditions the kinase is expected to 
behave identically to wt ROCK1. Nonetheless, verification that ROCK activity is 
unaffected by the introduction of the D1113A mutation was necessary. To address 
this, I immunoprecipitated myc tagged ROCK1wt and ROCK1nc constructs 
expressed in HEK293 cells and analysed activity of approximately 200 ng of 
kinase in a fluorescence polarization assay (Figure 2.6a). Both ROCK1 and 
ROCK1nc induced an identical level of substrate phosphorylation (Figure 2.6b), 
thus the introduction of the D1113A mutation does not affect ROCK1 activity. 
Moreover, kinase activity in untransfected cells was similar to background, 
suggesting that no contaminating kinases were co-immunoprecipited. This work 
was performed in collaboration with Dr. Nicola Rath. I next sought to confirm that 
ROCK1nc cellular expression does not alter cellular phenotype compared to wt. In 
order to validate the in vitro biology of ROCK1nc expression I generated mouse 
embryonic fibroblasts (MEFs) from E13.5 pups in homozygous wild-type (wt) and 
ROCK1nc mice. The MEFs generated in either strain were morphologically 
identical and had similar proliferation rates (Figure 2.7a and data not shown). I 
determined the cell based activity of ROCK1nc or wt MEFs by examining the 
formation of actin stress fibres and phosphorylation of MLC (pMLC), two hallmarks 
of cellular ROCK activity, following a 5 min stimulation with 10% FBS. As can be    44 
seen in Figure 2.7a, the formation of stress fibres and pMLC is identical in either 
cell line. Furthermore, introduction of the ROCK antagonist, Y27632, similarly 
suppressed both responses in each cell line (Figure 2.7a). The effect of FBS on 
pMLC in wt and ROCK1nc MEFs was quantified using a 96 well plate in-cell 
western blot approach. Following treatment MEFs were fixed, permeabilized and 
stained for pMLC with a fluorescent secondary antibody. The fluorescence of 
pMLC in each well was quantified using a LiCOR Odyssey scanner. Cell numbers 
were normalized to total nuclear fluorescence detected by DRAQ5 (Figure 2.7b). 
Consistent with microscopic observations, MEFs expressing either wt or non-
cleavable ROCK1 behaved identically to one another following treatment with FBS 
+/- Y27632 (Figure 2.7c). These observations suggest that under growth 
conditions ROCK1nc mutation affects neither in vitro kinase activation nor its 
sensitivity to chemical inhibitors.  
2.2.4  ROCK1nc is resistant to apoptotic cleavage 
I next sought to ascertain if the ROCK1-D1113A mutant was indeed resistant to 
caspase cleavage during apoptosis. Lysates of wt and ROCK1nc MEFs treated +/- 
TNFα and cycloheximide (CHX) for 4 hours were western blotted for ROCK1. In 
non-apoptotic cells ROCK1 expression in wt or ROCK1nc MEFs was identical, 
which I expected from a ‘knock-in’ at the endogenous locus (Figure 2.8). Following 
TNFα treatment ROCK1 cleavage is apparent in ROCK1wt MEFs while in 
ROCK1nc cells no ROCK1 cleavage product was observed, indicating that the 
mutant ROCK protein is indeed caspase cleavage resistant (Figure 2.8). 
Verification that MEFs were apoptotic was confirmed by appearance of cleaved 
poly (ADP-ribose) polymerase (PARP), a classic marker of apoptosis (Figure 2.8). 
In addition, I observed that apoptosis in wt MEFs was associated with increased 
MLC phosphorylation, a hallmark of ROCK activation; however, no such increase 
was observed in the mutant cells (Figure 2.8). This work was performed in 
collaboration with Dr. Nicola Rath. As ROCK1nc MEFs express a fully functional 
kinase, the lack of apoptotic MLC phosphorylation is best explained by defective 
cleavage associated with decreasing levels of ROCK activating RhoA-GTP which 
are insufficient to activate the kinase. A clear implication of these observations is 
that, due to decreasing ROCK1 activation signals, apoptotic cells must 
constitutively activate ROCK1 (by caspase cleavage) to induce and maintain MLC 
phosphorylation. The phosphorylation of MLC would be expected to induce acto-   45 
myosin contractility which, in turn, likely causes blebbing. These observations are 
consistent with the suspected role of cleaved ROCK1 as a potent inducer of 
apoptotic blebbing.  
2.2.5  ROCK1nc expression abolishes apoptotic blebbing 
Having established that ROCK1nc is resistant to caspase cleavage, I then asked if 
its expression disturbs apoptotic blebbing. Microscopic time-lapse images 
captured on 30 second intervals clearly demonstrate a profoundly defective 
apoptotic morphology in ROCK1nc MEFs compared to wt (Figure 2.9). This defect 
is characterized by a failure to retract, condense, and bleb. In addition, the cellular 
processes which fail to retract appear to fragment and remain adhered (Figure 2.9, 
lower panel, red arrows). This fragmentation seen in ROCK1nc MEFs is in 
contrast to the highly ordered formation of free floating subcellular apoptotic 
bodies (Figure 2.9, upper panel, white arrows).  
2.2.6  ROCK1nc expression does not affect phosphatidyl serine (PS) 
externalization 
As the externalization of PS during apoptosis is reported to be independent of 
ROCK activity 
57,122 I wanted to verify if this observation is consistent in non-
blebbing ROCK1nc MEFs. Both wt and ROCK1nc MEFs were either left in starve 
medium (control) or treated with TNFα for 24 hours prior to staining with 
fluorescently labeled annexin V for FACS analysis. As can be seen in Figure 2.10 
over 80% of MEFs bind annexin V, and thus externalize PS, following 24 hour 
treatment with TNFα, indicating that the cells are highly apoptotic. Consistent with 
the previous reports no difference in annexin V binding was observed between 
MEFs expressing wt and non-cleavable ROCK1 (Figure 2.10)
73. Therefore the 
failure to cleave ROCK1 appears to affect only the morphological features of 
apoptosis and other components of the apoptotic programme progress 
independently. 
2.2.7  Homozygous ROCK1 mice are viable and thrive 
As previously mentioned homozygous ROCK1nc mice were born in expected 
ratios and had no gross phenotype. In addition, homozygous animals were 
interbred to generate experimental animals which produced viable thriving    46 
offspring (data not shown). Furthermore, homozygous females could give birth to 
multiple litters with no apparent difficulties (data not shown). 
2.2.8  Homozygous ROCK1nc mice have apoptotic cell accumulation 
Having established that expression of non-cleavable ROCK1 abolishes apoptotic 
blebbing, I sought to identify if there was a subsequent defect in efferocytosis. 
Consequently I analysed the appearance of cleaved caspase 3, a hallmark of 
programmed cell death, in the splenic lymphoid follicles of 35 week old male 
animals. Maturing lymphocytes have an extraordinarily high level of apoptosis, 
95% of which are eliminated by apoptosis. In fact, Bak and Bax knockout mice, 
whose cells cannot execute the apoptotic programme, develop massive 
splenomegaly and the organ size increases more than 30-fold due to the 
progressive accumulation of lymphocytes that fail to apoptose 
213. Thus the 
physiologically high level of apoptosis in the spleen makes it an ideal organ to 
assess the clearance of apoptotic cells in ROCK1nc mice. In wild type animals 
numerous apoptotic corpse fragments (black arrows), staining for cleaved caspase 
3, were scattered throughout the lymphoid follicle (surrounded by black dashed 
line) and very few large intact apoptotic cells were seen (red arrow) (Figure 2.11a). 
This fragmented staining pattern is consistent with the phagocytic uptake of 
apoptotic debris by surveilling macrophages. In contrast, active caspase 3 stain in 
ROCK1nc splenic follicles is associated with numerous large intact cells (red 
arrows) in addition to some fragmented staining (black arrows)(Figure 2.11a). 
Further analysis shows that ROCK1nc mice have far more unfragmented apoptotic 
cells than wild-type (Figure 2.11b). While preliminary, the accumulation of 
apoptotic cells in ROCK1nc mice is very interesting and could be caused by either 
a failure of efferocytosis and/or increased follicular apoptosis. However, further 
studies are required to conclusively determine if lack of apoptotic blebbing impairs 
corpse clearance. 
2.2.9  Homozygous ROCK1nc mice display an inflammatory/auto-
immune phenotype 
As previously discussed, mice with defective apoptotic clearance can develop an 
auto-immune phenotype characterized by: splenic enlargement (splenomegaly), 
generation of ANAs, and deposition of immune complex in the kidney. I initially 
examined formalin fixed kidney sections of 15 week old male ROCK1nc    47 
homozygous mice for IgG and found that some animals have a significant 
deposition of immunoglobulins within the glomerulus (Figure 2.12). Many of the 
glomeruli in the kidney of this animal were positive for mouse IgG. Physiologically, 
the kidney glomerulus, which is the basic filtration apparatus of the organ, is not 
associated with the deposition of immune complex and the detection of IgG on the 
glomuluar membrane is a characteristic of glomerulonephritis, a chronic kidney 
condition frequently seen in auto-immune diseases including SLE 
214,215. While the 
incident rate of auto-reactive antibodies in the kidneys of ROCK1nc mice is 
unclear, these data are the first indication that failure to cleave ROCK1 during 
apoptosis, and thus impair blebbing and potentially efferocytosis, leads to auto-
immune disease. Currently a large cohort of animals is ageing for further 
investigation. 
In collaboration with a clinical veterinary pathology lab, the haematology of wt and 
ROCK1nc animals was analysed. On pathological review the mutant ROCK1nc 
mouse erythrocytes displayed aniscytosis, which is a high variability in erythrocyte 
size. Individual red blood cells (RBC) from mutant animals can be abnormally 
small compared to the uniform erythrocyte size seen in wild-type animals (Figure 
2.13a). This observation is further supported by additional clinical haematology 
data indicating that 6 week old ROCK1nc mice have significantly reduced RBC 
numbers (haematocrit) and mean corpuscular volume (MCV), an indication of 
erythrocyte size (Figure 2.13 and c). In addition, female mutant mice have a 
further significant reduction in MCV compared to their male littermates (Figure 
2.13c). While the reduction in haematocrit was significant the magnitude of the 
reduction would not be considered clinically anaemic. Nonetheless, homozygous 
ROCK1nc mice have a significant defect in either erythrocyte generation or 
destruction. While a reduced erythrocyte production cannot be ruled out the 
observed reduction in circulating RBC and MCV is consistent with macrophage 
phagocytosis, suggesting that ROCK1nc may be increasing erythrocyte 
destruction.  
The approximate lifespan of a mouse erythrocyte is 50 days and they are usually 
removed from circulation by resident macrophages in the spleen 
216. Despite a 
high level of continuous erythrocyte phagocytosis in the spleen, the removal is 
hard to detect due to efficiency of disposal. However, increases in the rate of 
erythrocyte removal lead to an accumulation of iron within the splenic    48 
macrophages, this iron is then stored in the phagocytes’ cytoplasm in an iron-
strorage complex called haemosiderin. The deposition of haemosiderin is 
associated with numerous pathologies including haemorrage and haemolytic 
anaemieas, and is detected with the histochemical stain Perls Prussian Blue 
217. 
To this end I examined splenic haemosiderin deposits in 10 week old wt and 
ROCK1nc male and female mice to determine if the mutant mice had an increased 
rate of RBC destruction. As expected, no haemosiderin could be detected in the 
spleens of wild-type animals, while homozygous ROCK1nc mice had significant 
accumulation of haemosiderin in the splenic red pulp (RP), the physiological 
compartment for erythrocyte removal (Figure 2.14a). Quantitation of the splenic 
haemosiderin deposition revealed significantly more staining in female animals 
than in male littermates (Figure 2.14b). I next analysed whether the appearance of 
haemosiderin in the ROCK1nc spleen is associated with age. As can be seen in 
Figure 2.15 (top panels) 4 week old female ROCK1nc mice display no 
accumulation of iron in the spleen while at 25 weeks haemosiderin is not only 
visible in the red pulp but positive cells are also visible within the white pulp (WP) 
(Figure 2.15, black arrows). The appearance of haemosiderin in the WP indicates 
the presence of highly invasive phagocyte that is engulfing large numbers of 
erythrocytes in the splenic red pulp before migrating into the white pulp. This is 
possibly the result of an on-going inflammatory response in which erythrocytes are 
inappropriately phagocytosed by inflammatory macrophages activated by 
secondarily necrotic cells. To ascertain the identity of these cells I stained fixed 
splenic sections with antibodies against F4/80, a transmembrane protein 
expressed on mouse macrophages. Given the importance of macrophages in 
erythrocyte phagocytosis they are known to be abundant in the splenic red pulp, 
this was confirmed in both wt and ROCK1nc animals (data not shown and Figure 
2.15, middle panels). However, by 25 weeks ROCK1nc spleens show an 
accumulation of invasive macrophages in the white pulp that is not seen in 
younger or wild-type animals (Figure 2.15, middle panel, black arrows). This 
invasive population of macrophages appears to co-localize with WP haemosiderin. 
Preliminary observations also suggest that these invasive macrophages 
phagocytize nuclear material and thus are engulfing not just erythrocytes, but 
other nucleated cells as well (data not shown). Finally, heamatoxilyn and eosin 
staining demonstrates that the WP in 25 week ROCK1nc animals has a reduced 
cellularity compared to 4 week old animals (Figure 2.15, bottom panels). 
Collectively these observations are consistent with the haematology data and    49 
suggest that ROCK1nc mice have an increased rate of erythrocyte phagocytosis. 
Furthermore, this increased phagocytic signature in the spleen is characterized by 
the presence of an invasive macrophage population that is likely engulfing more 
than RBCs. Moreover, the enhancement of this phenotype in female animals is 
highly suggestive of an auto-immune disease. The causes of increased splenic 
phagocytosis are unclear and may be due to autoimmune disease such as auto-
immune haemolytic anaemia (AIHA) or other pro-inflammatory triggers. A large 
cohort of animals is ageing to investigate these possibilities.    50 
 
Figure 2.1. Homologous recombination targeting strategy to generate ROCK1 non-cleavable 
allele  
Line diagram of mouse genomic ROCK1 wild type (ROCK1wt) locus with numbered ROCK1 exons 
indicated by blue boxes (top). Targeting vector homology arms to ROCK1 wildtype locus is 
indicated by black crosses. Targeting vector contains mutations 3338A>C and 3339T>A in ROCK1 
exon 27 (yellow box, indicated by asterisk) and a neomycin (neo) selection cassette in red 
flanked by LoxP sequences (blue triangles). Targeting vector is transfected into mouse embryonic 
stem cells that are then selected for stable vector insertion with neomycin. After homologous 
recombination the expected mutant ROCK1 non-cleavable (ROCK1nc) genomic locus is shown on 
bottom.  
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Figure 2.2. 3’ homologous recombination screening strategy and results 
(a) Line diagram of PCR screening strategy of genomic DNA from neomycin resistant mouse 
embryonic stem cells (mES). 5’ PCR primer is indicated with black arrow and is within the Neo 
cassette, 3’ primer is outwith the targeting vector homology arm. These primers should generate 
a 3.5 kb PCR reaction product from mES cells with correct 3’ recombination, while no product 
should be evident from wildtype ROCK1 or incorrect targeting vector insertion (in table). (b) 
Representative agarose gel electrophoresis of PCR products from the genomic screening 
reactions. Each lane represents a separate reaction from individual neomycin resistant clone. 
PCR reaction from sample 6b (highlighted in red) yielded an expected reaction product of 3.5 kb 
suggesting correct 3’ homologous recombination while the remainder of samples were negative. 
(c) Agarose gel electrophoresis of confirmatory PCR reactions from positive samples identified in 
initial screening reactions. Clones 6b, 7h, and 4g all confirmed positive for 3’ ROCK1nc 
homologous recombination.     52 
 
Figure 2.3. 5’ homologous recombination screening strategy and results 
(a) Line diagram of PCR screening strategy of genomic DNA from neomycin resistant mouse 
embryonic stem cells (mES). 5’ PCR primer (indicated with black arrow) is outwith the targeting 
vector homology arm, 3’ primer is within the neo selection cassette. These primers should 
generate a 5.5 kb PCR reaction product from mES cells with correct 5’ recombination, while no 
product should be evident from wildtype ROCK1 or incorrect targeting vector insertion (in table). 
(b) Representative agarose gel electrophoresis of PCR products from samples with correct 3’ 
homologous recombination (6b, 7h, and 4g). Samples 6b and 7h both produced a PCR product of 
expected size while clone 4g had no reaction product. mEs clones 6b and 7h demonstrate correct 
homologous recombination of the mutant ROCK1nc targeting vector.    53 
 
Figure 2.4. Animal genotyping using quantitative PCR 
Representative traces of quantitative PCR (qPCR) reactions used to routinely genotype animals 
potentially bearing the mutant ROCK1 allele. ROCK1 locus spanning the 3338A>C and 3339T>A 
mutations was amplified in the presence of complimentary fluorescent tracers against wild type 
and mutant ROCK1. The resulting fluorescent signal over 40 reaction cycles determines individual 
animal genotype.     54 
 
Figure 2.5. ROCK1nc breeding strategy and Mendelian ratios 
(a) Genetic line diagrams indicating genetic status and animal breeding. Matings are indicted 
with an X, and resultant desired offspring with an arrow. (b) Summary of offspring genotypes 
from ROCK1nc heterozygous matings n=129 animals from 4 mating pairs. (c) Pie chart of offspring 
genotypes from matings in (b) with indicated percentages.     55 
 
Figure 2.6. ROCK1nc function is identical to wild type kinase 
(a) Representative polyacrylamide gel of immunoprecipitated (IP) myc-tagged ROCK1wt and 
ROCK1nc expressed in HEK-293 cells. 200 ng bovine serum albumin (BSA) ran in indicated lane 
and is used to estimate kinase mass used in subsequent assay. (b) Fluorescence polarization 
assay of 200 ng IP myc-tagged constructs. Bars represent mean +/- SEM of ROCK1 activity relative 
to untransfected. n=4. Figure courtesy of Nicola Rath.    56 
 
Figure 2.7. Cellular ROCK1 activity is identical in viable homozygous ROCK1wt and ROCK1nc 
fibroblasts 
(a) Representative immunofluorescent confocal micrographs showing thr18/ser19 myosin light 
chain phosphorylation (pMLC) and f-actin in homozygous ROCK1wt and ROCK1nc mouse 
embryonic fibroblasts (MEFs). MEFs were starved overnight before treatment with 10% FBS for 5 
min +/- 10 μM Y27632 then fixed and stained. Cells were incubated with Y27632 for 30 min prior 
to serum stimulation were appropriate. Images acquired on 40x oil objective using an Olympus 
FV1000 laser scanning confocal microscope. (b) Representative images of in-cell-western blot 
detecting pMLC (green) and cell nuclei (DRAQ5, red). MEFs were plated in 96 well plates and 
treated identically as in (a). Total cellular fluorescence of pMLC and DRAQ5 was captured on 
Odyssey scanner using infrared fluorescent secondary antibodies. (c) Quantitation of in-cell-
western pMLC fluorescence normalized to cell number (DRAQ5 fluorescence). Bars represent 
mean + SEM. Statistical comparison performed by ANOVA followed by Dunnetts multiple 
comparison test. (n=3)(*, p<0.05; **, p<0.01).    57 
 
Figure 2.8. ROCK1nc is resistant to apoptotic cleavage 
Representative western blot of homozygous wild type and non-cleavable MEF lysates from cells 
treated with and without TNFα+CHX for 4 hours as indicated. Blotting paper was probed for 
ROCK1, poly ADP-ribose polymerase (PARP), phosphorylated myosin light chain (pMLC), and α-
tubulin. Apoptotically cleaved ROCK1 (ΔROCK1) and PARP (ΔPARP) is detected as 
immunoreactive lower molecular weight bands as indicated. Figure courtesy of Nicola Rath.    58 
 
Figure 2.9. Apoptotic ROCK1nc MEFs fail to bleb 
Representative time lapse images of apoptotic ROCK1wt and ROCK1nc MEFs. Following overnight 
starvation MEFs were treated with TNFα+CHX and then differential interference contrast (DIC) 
images were captured every 30-60 seconds for several hours. Discreet sub-cellular apoptotic 
bodies are indicated with white arrows. Cellular fragmentation due to failed contraction is 
indicated with red arrows. Images acquired using a 20x DIC objective lens. During microscopy 
cells were maintained at 37°C in 5% CO2 atmosphere.     59 
 
Figure 2.10. Externalization of phosphatidyl serine is not dependent on ROCK1 cleavage 
(a) Representative FACS dot plots of ROCK1wt and ROCK1nc MEFs treated + TNFα for 24 hours. 
Cells were collected and stained with annexin V, to detect phosphosphatidyl serine (PS) 
externalization, and PI to determine membrane function. (b) Quantitation of annexin V positive 
MEFs as in (a). Bars represent mean + SEM of percentage of cells externalizing PS after treatment 
(n=3). Statistical comparison performed by t-test.    60 
 
 
Figure 2.11. Apoptotic cell accumulation in ROCK1nc mice 
(a) Representative images of formalin fixed spleens from 35 week old male ROCK1wt and 
ROCK1nc mice. Tissue is stained for cleaved caspase 3 (brown) and haematoxylin (blue nuclei). 
Lymphoid follicles outlined by dashed black line. Red arrows indicated non-fragmented apoptotic 
cells and black arrows indicate fragmented apoptotic cell debris which has been largely 
phagocytised. Bright field images acquired using a 20x objective lens on Olympus BX51 upright 
microscope. (b) Zoom of boxed area in (a) (c) Mean number of unfragmented apoptotic cells 
(cleaved caspase 3 positive) per splenic lymphoid follicle in 35 week old ROCK1wt and ROCK1nc 
male mice (n=1, 12-13 follicles/spleen).     61 
 
Figure 2.12. ROCK1nc mice have auto-immune kidney IgG deposition 
Representative confocal micrographs of formalin fixed kidney sections from two 15 week old 
male ROCK1nc mice. Tissue is immunofluorescently stained for mouse IgG (green) and cell nuclei 
(blue). Images captured with 60x oil immersion objective with an Olympus FV1000 laser scanning 
confocal microscope.     62 
 
Figure 2.13. ROCK1nc mice have reduced erythrocyte volume and haematocrit 
(a) Representative bright field images of giemsa stained peripheral blood smear from ROCK1wt 
and ROCK1nc mice. Red blood cells are stained red and reticulocytes (immature erythrocytes) 
blue. Black arrows indicate smaller erythrocytes. Cellular spicules are indicated with green 
arrows and are artefacts of sample preparation. (b) and (c) Box and whisker plots of clinical 
haematology results from ROCK1wt and ROCK1nc mice demonstrating reduced haematocrit and 
mean corpuscular volume (MCV), respectively. Statistical comparison performed by ANOVA 
followed by Tukey Kramer multiple comparison test (n=4-5)(***, p<0.001).     63 
 
Figure 2.14. ROCK1nc mice have increased erythrocyte phagocytosis 
(a) Representative images of formalin fixed spleens from 10 week old male ROCK1wt and 
ROCK1nc mice. Tissue is stained for haemosiderin (blue) and counter stained with eosin (pink 
nuclei). Lymphoid follicles outlined by dashed black line. WP indicates white pulp, RP indicates 
red pulp. Bright field images acquired using a 4x objective lens on Olympus BX51 upright 
microscope. (b) Quantitation of splenic haemosiderin deposits in spleen expressed as a 
percentage of splenic area. Bars represent mean + SEM and statistical comparison performed by 
t-test (n=3)(**, p<0.01).    64 
 
Figure 2.15. ROCK1nc mice accumulate splenic follicular haemosiderin and invasive 
macrophages with age 
Representative images of formalin fixed spleens from 6 and 25 week old female ROCK1wt and 
ROCK1nc mice. Tissue is stained for haemosiderin (top panels, blue stain), macrophages (middle 
panels, F4/80-brown stain), and haematoxylin and eosin (bottom panels). Lymphoid follicles 
outlined by dashed black line. WP indicates white pulp, RP indicates red pulp. Black arrows 
indicate intra-follicular haemosiderin stain (top panels) and invasive macrophages (middle 
panel), respectively. Boxed area in middle panel shown in greater magnification in far right 
images. Bright field images acquired using a 10x objective lens on Olympus BX51 upright 
microscope. 
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2.3 Discussion 
While there is much speculation about the role of apoptotic ROCK1 cleavage 
towards the clearance of dying cells there is very little clarity. These data I present 
conclusively demonstrate that the cleavage of ROCK1 is a necessary prerequisite 
for apoptotic blebbing and further suggests that these morphological changes are 
important for efficient efferocytosis and the maintenance of self tolerance. While a 
complete characterisation of the ROCK1nc phenotype has yet to be elucidated, 
the animals appear to be developing auto-immunity. In particular the female 
dominance of splenic haemosiderin deposition and the appearance of glomerular 
immune complexes strongly indicate the development of autoimmune disease. 
While the cause of erythrocyte destruction in ROCK1nc mice remains undefined, 
the phenotype may be caused by auto-immune haemolytic anaemia (AIHA) which 
is characterized by auto-antibody opsonisation of circulating erythrocytes thus 
targeting them for phagocytosis 
218. Interestingly, AIHA is observed in 10% of SLE 
patients and may be the only presenting symptom of SLE 
219. However, alternative 
explanations for the reduction in haematocrit and splenic iron deposition in 
ROCK1nc mice cannot be excluded.  
In a recent paper Gabet and colleagues demonstrate that ROCK activity is 
necessary for the differentiation of erythrocytes 
220. They show that in vitro 
erythroblast differentiation is impaired with the ROCK antagonist Y27632 which 
prevents cellular condensation into uniform small cells. It was further reported that 
during erythroblast maturation ROCK activation is Rho independent and that the 
kinase is partially cleaved by activated caspase 3. The activation of caspases has 
been previously identified as a vital component of erythrocyte terminal 
differentiation and this reports suggests that ROCK cleavage may be an important 
physiological phenomenon associated with erythropoiesis 
221. As the spleen is an 
active site of erythropoiesis in adult mice it is possible that failure to cleave 
ROCK1 triggers a differentiation defect leading to apoptosis and phagocytosis 
which over time causes the haematological phenotype seen in ROCK1nc mice 
222. 
While interesting, these observations are limited; they demonstrate an association 
between ROCK1 cleavage and erythroblast maturation but fail to prove causation. 
In fact, a significant pool of full length ROCK1 remains in the maturing 
erythroblasts and the relative contribution of cleavage remains unclear. If ROCK1 
cleavage was truly vital to erythropoiesis this paper would predict that ROCK1nc    66 
mice have profound changes in the mature population of circulating erythrocytes, 
characterized by increased size. In fact the exact opposite is seen in homozygous 
ROCK1nc mice: circulating RBC are quantitatively smaller that those in wild type 
littermates. Moreover, the female dominant phenotype and the appearance of 
glomerulonephritis seen in ROCK1nc mice cannot be explained by defective 
erythropoiesis. Thus the collection of pathologies observed in ROCK1nc mice is 
better explained by the development of autoimmune disease rather than faulty 
erythropoiesis. 
One of the outstanding issues remaining to be investigated is the effect non-
blebbing apoptotic cells have on phagocytic clearance. As outlined previously 
apoptotic blebbing may affect multiple aspects of efferocytosis including; the 
externalization/localization of eat-me molecules, and cellular fragmentation that 
have traditionally proven very difficult to investigate. As a result the literature has 
an unexplained conflict; apoptotic blebbing is simultaneously important for rapid 
efferocytosis and the generation of auto-antibodies, two outcomes which appear 
opposed to one another. The generation of non-cleavable ROCK1 knock-in mice 
can now provide the conclusive experimental evidence to address the in vitro and 
in vivo importance of apoptotic blebbing. Preliminary data suggest that ROCK1 
cleavage driven apoptotic blebbing is important to avoid auto-immune disease and 
I expect this model will provide many more valuable insights, such as the potential 
role of apoptosis and inflammation during tumour growth and progression. 67 
3. ROCK mediates apoptotic cell protein release to 
modulate innate immune responses  
3.1 Introduction 
The clearance of apoptotic corpses is clearly a vital process that is largely dictated 
by the dying cell. As previously discussed, apoptotic cells are active participants in 
efferocytosis and undergo dramatic membrane changes to help facilitate 
recognition and phagocytosis. In addition to these modifications, apoptotic cells 
release chemoattractant molecules that encourage macrophages to locate the 
suicidal cell prior to clearance. Thus, the release of ‘find-me’ factors can be seen 
as the first critical step for efferocytosis. While research has provided a great deal 
of insight into the mechanisms of phagocyte engagement and engulfment of 
apoptotic cells, there are only a handful of apoptotic chemo-attractant signals that 
have been identified 
223. These come-find-me factors are composed of a wide 
range of molecules including: proteins (e.g. tyrosyl tRNA synthetase (TyrRS) and 
dimer of ribosomal protein S19 (dRP S19)), lipids (e.g. lysophosphatidylcholine 
(LPC) and sphingosine-1-phosphate (S1P)), or nucleotides (e.g. ATP)
62,223,224. In 
addition, apoptotic micro-blebs, which are small membranous sub-cellular particles 
released from B-cells (the micro-bleb nomenclature is from the referenced paper, 
for consistency, these structures will now be referred to as micro-apoptotic 
bodies), have also been described as potent monocyte chemoattractants 
225. 
Regardless of their composition, all these factors are soluble and diffuse from 
apoptotic cells to encourage monocytes and macrophages to find the suicidal cell 
and phagocytose it. Curiously, some of these factors (e.g. TyrRS and dRP S19) 
are intracellular proteins and the release of such factors from apoptotic cells, with 
presumably intact membranes, has not been adequately characterised. These 
apparently conflicting observations make the search for new proteinacious 
apoptotic chemoattractant factors problematic as a mechanism for their release 
also needs to be provided. 
While ROCK induced apoptotic blebbing appears to be important for macrophage 
recognition and engulfment the importance of blebbing and apoptotic body 
formation in the release of ‘find-me’ factors remains to be investigated. The ability 
of micro-apoptotic bodies, whose generation is likely ROCK dependent, to attract    68 
monocytes suggests that ROCK may be an active participant in the release of 
chemoattractant factors from apoptotic cells.  
3.2 Results 
3.2.1  Apoptotic bodies and blebs lose membrane integrity 
As discussed, apoptotic cells are presumed to have intact plasma membranes that 
are important in limiting the release of pro-inflammatory intracellular molecules. 
However, there have been several reports suggesting that apoptotic blebs can 
lose membrane integrity independently of the cell body 
126,226. Importantly, these 
cells have functional plasma membranes and thus would be regarded as early 
apoptotic and not secondarily necrotic despite the loss of membrane integrity in a 
sub-set of extruded blebs. These observations suggest a potential role for ROCK, 
via loss of bleb integrity, in the release of factors from apoptotic cells that may in 
turn impact efferocytosis. 
To confirm whether apoptotic blebs lose membrane integrity, time-lapse images of 
apoptotic NIH 3T3 cells were acquired in the presence of propidium iodide (PI), a 
fluorescent membrane impermeable stain for RNA and DNA. Treatment of NIH 
3T3 with TNFα and cycloheximide rapidly and uniformly induced programmed cell 
death with pronounced blebbing and apoptotic body formation within 3 hours 
(Figure 3.1). Initially, both the parental cell and newly formed blebs and apoptotic 
bodies have stable intact membranes as indicated by their exclusion of PI. 
However, within an hour of the onset of blebbing (4 hours after induction), the 
newly formed apoptotic bodies and blebs have the potential to rapidly lose 
membrane integrity and take up PI, this process can occur while still tethered to 
the parental cell or at distance following release of free floating membrane clad 
bodies (Figure 3.1 arrows and Figure 3.2). The loss of membrane stability of these 
newly formed structures precedes the loss of integrity, and thus secondary 
necrosis, of the remaining cellular corpse by several hours (Figure 3.1). This 
observation is consistent with several previous reports which indicate that 
apoptotic blebs lose membrane function well in advance of the cell body 
126,226,227.  
In order to further quantify the loss of membrane integrity of apoptotic bodies we 
assessed PI staining of NIH 3T3 apoptotic bodies at 4 hours after treatment with    69 
TNFα and cycloheximide by fluorescence activated cell sorting (FACS). At this 
time point, and consistent with the time-lapse microscopy data, a significant 
number of cells were visually executing programmed cell death (actively blebbing 
and generating apoptotic bodies), but were not yet secondarily necrotic (Figure 
3.6a and b). FACS gating on the small (low forward scatter) (Figure 3.3a) sub-
cellular debris revealed that 20% of the apoptotic bodies were positive for PI, 
indicating that a significant number of these sub-cellular particles had lost 
membrane integrity (Figure 3.3b). Treatment of the apoptotic bodies with RNaseA 
alone or a combination of RNaseA+DNase1 reduced PI staining to 9% and 5.5%, 
respectively (Figure 3.3c). The reduction in PI staining of apoptotic bodies 
following treatment with RNase and DNase suggests that membrane permeability 
is sufficient to permit nuclease diffusion. RNaseA and DNase1 were found to be 
10 and 34 kDa, respectively, suggesting that apoptotic body membranes are 
permissive to molecules with at least these masses. (Figure 3.3d). The loss of 
membrane integrity in apoptotic bodies was further validated using NIH 3T3 cells 
expressing membrane tagged GFP (mGFP). Following induction of apoptosis in 
mGFP-NIH 3T3 cells, 30% of the resulting apoptotic bodies had detectable levels 
of GFP (Figure 3.4a). Treatment of this sample with proteinase K, a broad 
spectrum serine protease with a mass of 28 kDa, significantly reduced the GFP 
positive apoptotic bodies by 69%, indicating that the majority of detectable 
particles have compromised membranes (Figure 3.4b). Taken together these 
observations suggest that many sub-cellular particles released from apoptotic cells 
have significantly compromised membranes that fail to exclude molecules as large 
as 34 kDa.  
3.2.2   ROCK activity triggers apoptotic body formation but does not 
affect membrane integrity 
While ROCK1 is important for triggering the formation of apoptotic blebs, its role 
modulating membrane stability during apoptosis is less clear. Within four hours of 
NIH 3T3 cell exposure to TNFα, there was a significant increase in the number of 
apoptotic bodies (Figure 3.5). When apoptosis was initiated in the presence of the 
ROCK inhibitor Y27632 or the myosin ATPase antagonist blebbistatin, the 
formation of apoptotic bodies was significantly impaired suggesting that the 
formation of these sub-cellular particles is dependent upon ROCK activation of 
acto-myosin contractility (Figure 3.5). Further analysis of apoptotic body    70 
permeability to PI suggests that inhibition of ROCK does not affect the percentage 
of particles that take up the vital dye (Figure 3.6). However, it is interesting to note 
that PI staining in apoptotic bodies generated in the presence of blebbistatin is 
48% of the staining observed in TNFα alone (Figure 3.6). This reduction in 
apoptotic body PI staining might be attributed to either increased membrane 
stability or impaired loading of RNA/DNA in apoptotic bodies. Nonetheless, it 
appears that during apoptosis, ROCK activity induces blebbing and apoptotic 
bodies, which then lose membrane integrity via ROCK independent mechanisms.  
3.2.3  ROCK antagonism does not affect time course of apoptotic 
cell membrane disruption 
Having established that up to 20% of apoptotic bodies have permeable 
membranes within 4 hours of TNFα treatment, we sought to determine if the much 
larger apoptotic cells shared a similar level of membrane disruption and were 
therefore secondarily necrotic. Traditionally the analysis of apoptotic stage is 
determined by co-staining with annexin V and PI. Cells that are double negative 
are non-apoptotic, annexin positive are early apoptotic, and double positive are 
secondarily necrotic. This approach, while widely accepted, may overestimate the 
necrotic population size. FACS analysis of cells with PI positive apoptotic bodies 
would be scored as necrotic, while timelapse microscopic analysis would indicate 
otherwise (Figure 3.7a). Thus we assume necrosis only in the population of highly 
PI positive cells, as indicated by the gating in Figure 3.7a. We found that PI uptake 
in large apoptotic cells was limited to 3.7% at 4 hours and was not significantly 
altered by either ROCK or myosin inhibition (Figure 3.7b). This suggests that, 
while a high degree of apoptotic bodies lose membrane integrity, their associated 
parental cell bodies remain largely intact. This is consistent with time-lapse images 
demonstrating apoptotic body PI uptake in advance of secondary necrosis. In 
addition, we examined the release of HMGB1, an established pro-inflammatory 
cytokine released only during primary and secondary necrosis 
228. Accumulation of 
HMGB1 in the extracellular compartment was only detectable 24 hours after TNFα 
induced programmed cell death, while at 12 hours all the protein appears to be 
retained within the cellular corpse (Figure 3.7c). This is consistent with published 
reports showing delayed HMGB1 release following apoptosis and a role for the 
protein as a proinflammatory molecule 
228. Treatment with either Y27632 or 
blebbistatin did not affect HMGB1 release. Taken together the failure of Y27632    71 
and blebbistatin to alter the rate of secondary necrosis further confirms that their 
activity is limited to the suppression of apoptotic body generation.  
3.2.4  Apoptotic cells release intracellular proteins in a ROCK 
dependent manner 
The loss of apoptotic body membrane integrity raises several interesting 
possibilities: first, the intracellular contents of these particles may be passively 
released and accumulate in the extracellular space; second, the suppression of 
apoptotic body generation by ROCK may have a significant, albeit indirect, impact 
on protein release. To test these possibilities, we generated apoptotic cell 
conditioned medium (AC-CM) at 2, 4, 12, and 24 hours following treatment with 
TNFα and cycloheximide with and without the addition of Y27632 or blebbistatin 
and assessed the samples for lactate dehydrogenase (LDH) activity. Although 
LDH release is commonly regarded as an indicator of cytotoxicity and cell lysis, we 
hypothesized that its release may also be associated with programmed cell death 
via passive liberation from decaying apoptotic bodies. As suspected, apoptosis led 
to a significant release of LDH within 2 hours that continued to accumulate through 
24 hours (Figure 3.8). Interestingly, antagonism of ROCK or myosin ATPase 
significantly decreased apoptotic LDH release at 2 and 4 hours. However, the 
effectiveness of these compounds diminished over time; at 12 hours only 
blebbistatin is effective, and by 24 hours neither treatment altered AC-CM LDH 
activity (Figure 3.8). The ability of Y27632 and blebbistatin to suppress acute, but 
not prolonged, LDH release is best attributed to the reduction in apoptotic body 
numbers available for protein release and is consistent with the passive release of 
protein due to apoptotic body degradation during programmed cell death.  
3.2.5  Proteomic analysis of AC-CM by quantitative mass 
spectrometry 
Having established a mechanism through which intracellular protein can be 
released from apoptotic cells, we next sought to identify proteins that are released 
and whether ROCK activity, and thus blebbing, is an important factor in that 
release. To accomplish this, we performed a quantitative proteomic analysis using 
a stable isotope labeling with amino acids in cell culture (SILAC) approach. This 
technique relies upon labeling proteins with arginine (Arg) and lysine (Lys) 
residues with stable, yet heavier, carbon and nitrogen isotopes. When cells are    72 
cultured in media supplemented with these specific amino acids, they eventually 
become incorporated into newly translated proteins. Importantly, this heavy amino 
acid incorporation does not affect the physical or biochemical properties of the 
proteins. After multiple cell divisions the entirety of the cell proteome will be 
bearing heavy Arg and Lys residues. Individual proteins, due to their increased 
mass, can then be easily differentiated from unlabelled or alternately labeled 
proteins using liquid chromatography and mass spectrometry (LC-MS). The ability 
to discriminate individual protein species based on SILAC label then allows 
multiple samples, each with a different experimental condition and label, to be 
simultaneously analysed and the relative abundance of individual protein species 
to be quantitated.  
Individual populations of NIH 3T3 fibrobasts were grown in defined SILAC medium 
containing, light (no isotope label), medium (Lys-4, Arg-6), or heavy (Lys-8, Arg-
10) amino acids (Figure 3.9). Within 5 passages more than 95% of the cellular 
proteins incorporated the isotope labeled amino acids (data not shown). Each 
population of labeled NIH 3T3 cells was assigned a specific experimental 
treatment: light-control (no apoptosis); medium-TNFα (apoptosis); heavy-
TNFα+Y27632 (apoptosis without blebbing). After 4 hours the AC-CM was 
prepared as indicated in Figure 3.9 and protein fragments subjected to LC-MS. I 
was able to reliably identify 60 proteins in the AC-CM as listed in Table 3.1, 
including LDH, a protein previously found to be released from apoptotic cells. 
Using LDH as a cutoff for SILAC ratio ranked proteins, 77% were enriched in AC-
CM (in blue) compared to medium from non-apoptotic cells (SILAC ratio: 
medium/light) (Table 3.1, Figure 3.10a). Furthermore, the release of proteins 
during apoptosis appears to be highly dependent upon ROCK. In fact, up to 70% 
of the proteins released during apoptosis were suppressed with the ROCK 
antagonist, Y27632, to varying degrees (in orange) (Table 3.2, Figure 3.10b). 
Taken together, these data suggest that, not only do a wide range of intracellular 
proteins escape from apoptotic cells, but that release was dependent upon ROCK 
activity. 
3.2.6  Validation of SILAC data 
In order to validate the SILAC results, I western blotted NIH 3T3 lysate and 4 hour 
AC-CM for gelsolin and actin, two of the most highly enriched proteins identified in    73 
the SILAC screen. While NIH 3T3 AC-CM contained large amounts of actin, no full 
length gelsolin was seen despite a robust cellular expression (Figure 3.11a). 
Nonetheless, a low molecular weight protein was detected with anti-gelsolin 
antibodies, suggesting that gelsolin may be released from apoptotic cells in a low 
mass form (Figure 3.11a). This is consistent with the SILAC data as the highly 
enriched gelsolin signal was detected in much lower molecular weight bands than 
expected (Table 3.1). We confirmed that the low molecular weight band seen in 
AC-CM was gelsolin by siRNA knockdown (Figure 3.11a). Interestingly, gelsolin is 
a substrate for caspase 3 which cleaves the protein into two fragments of 48 and 
40 kDa, consistent with the gelsolin fragments detected in AC-CM 
229. To verify if 
gelsolin was released following caspase cleavage, I induced apoptosis in the 
presence of the caspase inhibitor z-VAD-fmk and found no protein release (Figure 
3.11a). Importantly, the knockdown of gelsolin did not affect actin release and thus 
was unlikely to have affected either blebbing, apoptotic body formation, or the 
timecourse of programmed cell death (Figure 3.11a).  
Although the AC-CM was visually verified to be clear of cells and apoptotic bodies 
there remained a possibility of sample contamination with intact apoptotic bodies 
that were subsequently lysed and the intracellular protein detected, yielding a false 
positive artifact of protein release. To address these concerns, purified AC-CM 
was given an additional high speed spin and was found to still contain both 
cleaved gelsolin and actin, suggesting that this protein is legitimately released 
from apoptotic cells (Figure 3.11b).  
In order to determine whether gelsolin release was dependent upon membrane 
blebbing, we used the selective ROCK inhibitor Y27632 or the myosin ATPase 
inhibitor blebbistatin to reduce actomyosin contractility and hence blebbing. Both 
Y27632 and blebbistatin significantly reduced cleaved gelsolin release at all time 
points from 4 to 24 hours, although at 12 and 24 hours the magnitude of 
suppression was reduced (Figure 3.12). In addition, the pattern of actin release 
from apoptotic cells was identical to that of gelsolin (Figure 3.12a).  
3.2.7  ROCK inhibition does not affect caspase cleavage 
To confirm that ROCK antagonism does not affect gelsolin cleavage, and thus its 
release, we examined cellular lysates of NIH 3T3 at multiple time points following    74 
treatment with TNFα +/- Y27632. As seen in Figure 3.13 both gelsolin and ROCK1 
were readily cleaved by caspase 3 in apoptotic cells within 2 hours and cleavage 
was nearly complete by 4 hours, this cleavage remained unaffected in the 
presence of Y27632.  
3.2.8  Apoptotic protein release alters macrophage migration 
The release of protein from apoptotic bodies and blebs raises an interesting 
possibility that this material may participate in directing macrophages towards a 
dying cell to mediate corpse clearance. To provide proof of principle that apoptotic 
protein release is participating in extracellular signaling events, we chose gelsolin 
as a particularly promising candidate protein. Not only was gelsolin the most 
enriched protein discovered in NIH 3T3 AC-CM but has a clear extracellular role. 
While generally regarded as an intracellular F-actin binding and severing protein, 
gelsolin is also an abundantly secreted plasma protein with the capacity to bind, 
and modulate lysophospholipid signaling molecules 
230. Plasma gelsolin and 
gelsolin fragments have high affinity binding domains for several lysophospholipids 
including: lysophosphatidic acid (LPA), sphingosine-1-phosphate (S1P), and 
platelet activating factor (PAF) 
231,232. In fact, gelsolin binding directly to PAF can 
dose dependently attenuate neutrophil oxidative bursts 
232. Interestingly, plasma 
gelsolin may be particularly important in the regulation of inflammation, as plasma 
gelsolin levels invariably decline prior to the development of complications in a 
wide array of insults including; sepsis, trauma, and rheumatoid arthritis. In 
addition, there is a strong correlation between declining plasma gelsolin levels and 
poor prognosis for survival 
233-237. Furthermore, exogenous gelsolin reduces injury 
and lowers mortality in animal models of sepsis, inflammation, and injury 
238,239. 
Although plasma gelsolin is clearly implicated as a natural suppressor of many 
pro-inflammatory events there has been no known mechanism for the acute 
regulation of extracellular gelsolin levels. These observations may provide such a 
mechanism. Taken together, the release of gelsolin from apoptotic cells may be an 
important molecule mediating extracellular macrophage migration signals. To test 
this possibility, we assessed murine Raw264.7 macrophage transwell migration 
towards 4 hour NIH 3T3 AC-CM with or without gelsolin knockdown (Figure 
3.14a). Raw264.7 macrophages had a robust migratory response towards AC-CM 
from NIH 3T3 transfected with non-targeting siRNA (Figure 3.14b and c). The 
macrophage migration towards AC-CM was significantly impaired by    75 
approximately 70% following knockdown of gelsolin suggesting that gelsolin 
release from the apoptotic cells is an important factor aiding macrophage homing 
towards dying cells (Figure 3.14b and c).     76 
 
Table 3.1. Apoptotic protein release 
Protein Accession  MASCOT 
Score 
SILAC Ratio 
(M:L)
Gelsolin (light)  P13020  147  3.29 
Vimentin  P20152  364  2.81 
Lamin-A/C (isoform C)  P48678  411  2.56 
Actin, cytoplasmic 1 or/and 2  P60710  2474  1.89 
Calmodulin  P62161  181  1.57 
Macrophage-capping protein  Q6AYC4  273  1.55 
Heterogeneous nuclear ribonucleoproteins A2/B1  A7VJC2  184  1.47 
Protein disulfide-isomerase A3  P27773  399  1.44 
Vinculin  Q64727  448  1.41 
Ubiquitin-like modifier-activating enzyme 1  Q02053  257  1.41 
Glyceraldehyde-3-phosphate dehydrogenase  P04797  191  1.39 
Phosphoglycerate kinase 1  P09411  558  1.39 
Elongation factor 1-alpha 1  P10126  337  1.36 
Peroxiredoxin-1  P35700  744  1.36 
Filamin-C  Q8VHX6  389  1.34 
14-3-3 protein theta  P68254  193  1.29 
Latexin  P70202  183  1.28 
14-3-3 protein zeta/delta  P63101  602  1.27 
Rho GDP-dissociation inhibitor 1  Q5XI73  173  1.25 
Transketolase  P40142  246  1.25 
Phosphatidylethanolamine-binding protein 1  P70296  342  1.25 
14-3-3 protein epsilon  P62259  758  1.25 
Triosephosphate isomerise  P48500  173  1.24 
Rab GDP dissociation inhibitor beta  P50399  587  1.24 
Peroxiredoxin-2  Q61171  325  1.24 
Phosphoglycerate mutase 1  Q9DBJ1  361  1.23 
6-phosphogluconate dehydrogenase, decarboxylating  Q9DCD0  311  1.23 
Aldose reductase  P45376  209  1.21 
Malate dehydrogenase, cytoplasmic  O88989  147  1.20 
Filamin-A  Q8BTM8  735  1.19 
Importin subunit beta-1  P52296  128  1.18 
14-3-3 protein gamma  P61982  478  1.18 
Peptidyl-prolyl cis-trans isomerase A  P17742  1577  1.17 
Nucleoside diphosphate kinase B  Q01768  230  1.17 
Glutathione S-transferase A4  P24472  392  1.17 
Macrophage migration inhibitory factor  P30904  127  1.17 
Heat shock cognate 71 kDa protein  P63017  1464  1.14 
Alpha-actinin-4  Q9QXQ0  1335  1.14 
Cofilin-1  P18760  1025  1.14 
Pyruvate kinase isozymes R/L  P53657  148  1.14 
Aspartate aminotransferase, cytoplasmic  P05201  171  1.14 
Alcohol dehydrogenase [NADP+]  Q9JII6  650  1.14 
Destrin  Q7M0E3  137  1.13 
Prostaglandin reductase 1  Q91YR9  265  1.13 
Pyruvate kinase isozymes M1/M2  P52480  925  1.12 
L-lactate dehydrogenase A chain  P06151  656  1.12 
Alpha-actinin-1 Q7TPR4  808  1.11 
Glutathione S-transferase Mu 1  P10649  199  1.08 
Transaldolase Q93092  196  1.08 
Ubiquitin P62976  194  1.05 
Tropomyosin alpha-3 chain  Q63610  108  1.05 
Malate dehydrogenase, mitochondrial  P04636  138  1.05 
GTP-binding nuclear protein Ran  P62827  416  1.04 
Eukaryotic initiation factor 4A-II  Q5RKI1  190  1.01 
Heat shock 70 kDa protein 4  Q61316  145  0.96 
Tubulin alpha-1C chain  Q6AYZ1  221  0.95 
Clathrin heavy chain 1  Q68FD5  110  0.95 
Glutathione S-transferase omega-1  O09131  75  0.95 
Gelsolin (heavy - Cytoplasmic)  P13020  73  0.57 
Collagen alpha-1(I) chain  P11087  439  0.57 
    77 
 
Table 3.2. ROCK dependent apoptotic protein release 
Protein SILAC  Ratio 
(M:L) 
SILAC Ratio 
(H:L) 
% TNFα 
(H:L)/(M:L) 
Malate dehydrogenase, cytoplasmic  1.20  0.59  49 
Calmodulin  1.57  0.81  51 
Rho GDP-dissociation inhibitor 1  1.25  0.65  52 
Latexin  1.28  0.73  57 
Glutathione S-transferase A4  1.17  0.70  59 
Phosphoglycerate mutase 1  1.23  0.76  62 
Heterogeneous nuclear ribonucleoproteins A2/B1  1.47  0.91  62 
Phosphoglycerate kinase 1  1.39  0.87  62 
Gelsolin (light)  3.29  2.07  63 
Aldose reductase  1.21  0.78  65 
Phosphatidylethanolamine-binding protein 1  1.25  0.81  65 
Peptidyl-prolyl cis-trans isomerase A  1.17  0.76  65 
Macrophage migration inhibitory factor  1.17  0.76  65 
Alpha-actinin-4  1.14  0.76  67 
Protein disulfide-isomerase A3  1.44  0.96  67 
Vinculin  1.41  0.95  67 
Peroxiredoxin-1  1.36  0.91  67 
Rab GDP dissociation inhibitor beta  1.24  0.86  69 
14-3-3 protein zeta/delta  1.27  0.88  69 
Heat shock cognate 71 kDa protein  1.14  0.80  70 
Ubiquitin-like modifier-activating enzyme 1  1.41  0.99  70 
Prostaglandin reductase 1  1.13  0.80  71 
Cofilin-1  1.14  0.83  73 
Filamin-C  1.34  0.98  73 
14-3-3 protein epsilon  1.25  0.91  73 
Vimentin  2.81  2.09  74 
Pyruvate kinase isozymes R/L  1.14  0.85  75 
14-3-3 protein gamma  1.18  0.88  75 
Actin, cytoplasmic 1 or/and 2  1.89  1.43  76 
Triosephosphate isomerase  1.24  0.95  76 
Nucleoside diphosphate kinase B  1.17  0.91  78 
L-lactate dehydrogenase A chain  1.12  0.87  78 
Lamin-A/C (isoform C)  2.56  2.04  80 
Peroxiredoxin-2 1.24  1.01  81 
6-phosphogluconate dehydrogenase, decarboxylating 1.23  1.02  83 
Alcohol dehydrogenase [NADP+]  1.14  0.95  83 
Transketolase 1.25  1.06  84 
Pyruvate kinase isozymes M1/M2  1.12  0.95  84 
Filamin-A 1.19  1.08  91 
Importin subunit beta-1  1.18  1.09  92 
14-3-3 protein theta  1.29  1.24  96 
Macrophage-capping protein  1.55  1.53  99 
Destrin 1.13  1.15  102 
Aspartate aminotransferase, cytoplasmic  1.14  1.45  128 
Glyceraldehyde-3-phosphate dehydrogenase  1.39  2.16  155 
Elongation factor 1-alpha 1  1.36  3.53  260    78 
 
Figure 3.1. Apoptotic bodies lose membrane integrity before secondary necrosis 
Confocal timelapse images of apoptotic NIH 3T3 cells demonstrating the generation of propidium 
iodide (red) positive apoptotic bodies. Arrows track discreet apoptotic bodies. Time index is 
indicated in hr:min:sec following application of TNFα.     79 
 
Figure 3.2. Apoptotic blebs lose membrane integrity before secondary necrosis. 
Confocal images of live apoptotic NIH 3T3 cells in the presence of the fluorescent lipid stain DiO 
(green) and propidium iodide (PI)(red) and merge. Images acquired with a 60x oil immersion lens    80 
 
Figure 3.3. Apoptotic bodies are permeable to nucleases. 
(a) Representative FACS dot plot of forward (FSC) and side (SSC) scatter of apoptotic NIH 3T3 
cells at 4 hours. Gate indicates area of cellular debris containing apoptotic bodies. (b) 
Representative FACS plots of apoptotic bodes exposed to propidium iodide (PI) plotted versus 
FSC. Reduction of PI staining in apoptotic bodies treated with TNFα + RNase or RNase+DNase as 
indicated. Gate indicates population and percentage of cells positive for PI stain. (c) Mean + SEM 
percentage of PI positive apoptotic bodies treated with TNFα +  RNase or RNase+DNase as 
indicated. Statistical comparison performed by ANOVA followed by Tukey-Kramer multiple 
comparison test (n=3)(*, p<0.05; ***, p<0.001). (d) Coomasie stained SDS-PAGE demonstrating 
approximate molecular mass of commercial recombinant RNase and DNase as indicated.    81 
 
Figure 3.4. Apoptotic bodies are permeable to proteinase K. 
(a) Representative FACS histogram plots of GFP fluorescence in NIH 3T3 cells transduced with 
CaaX box tagged GFP (left panel) and 4 hr apoptotic bodes from those cells (right panel). Cutoff 
indicates detectable GFP labelled apoptotic bodes. (b) Mean + SEM of GFP positive apoptotic 
bodies + 50 ug/ml proteinase K for 2 hours. Statistical comparison performed by t-test (n=3)(**, 
P<0.01).    82 
 
Figure 3.5. ROCK induced acto-myosin contractility induces apoptotic body formation. 
(a) Representative forward (FSC) and side (SSC) scatter FACS dot plots of 4 hour apoptotic NIH 
3T3 cells following indicated treatments. Gates indicate apoptotic body population and 
exogenous FITC labelled beads used to aid quantitation. 10 000 beads counted in each 
treatment. (b) Representative FACS histogram demonstrating the number of apoptotic bodies 
generated following treatment with TNFα + Y27632 or blebbistatin as indicated. (inset) Mean + 
SEM of apoptotic body numbers generated with indicated treatments. Statistical comparison 
performed by ANOVA followed by Dunnetts multiple comparison test (n=3)(***, p<0.001).    83 
 
Figure 3.6. ROCK does not affect apoptotic body membrane stability. 
(a) Representative FACS dot plots of 4 hour apoptotic body PI fluorescence following treatment 
with TNFα +  Y27632 or blebbistatin as indicated. Gate indicates apoptotic body population 
positive for PI. (b) Mean + SEM of PI positive apoptotic bodies, relative to TNFα alone, following 
indicated treatments. Statistical comparison performed by ANOVA followed by Tukey-Kramer 
multiple comparison test. (n=3)(*, p<0.05; **, p<0.01)    84 
 
Figure 3.7. ROCK and acto-myosin contractility do not alter onset of secondary necrosis. 
(a) Representative FACS dot blots of 4 hour apoptotic cells stained with PI and fluorescent 
annexin V (AnX) following treatment with TNFα. Quadrants, with indicated population 
percentages, indicate classic division used to determine apoptotic stage: PI-/AnX-, non-
apoptotic; PI-/AnX+, early apoptotic; PI+/AnX+, secondacrily necrotic. Quadiant indicates 
population of cells, with percentages, that are highly PI positive and taken as truly necrotic. (b) 
Mean + SEM of percent necrotic NIH 3T3 cells following treatment with TNFα +  Y27632 or 
blebbistatin as indicated (n=3). No significance was detected by ANOVA between TNFα treated 
groups. (c) Representative western blot of SDS-PAGE 12 and 24 hour NIH 3T3 whole cell lysate, 
freeze-thaw necrosis lysate, starvation supernatant, and concentrated apoptotic cell conditioned 
medium (AC-CM) + Y27632 or blebbistatin as indicated probed with anti-HMGB1 antibody. 
Cellular samples were prepared using centrifugal concentrators with 10 kDa cutoff and were 
normalized to exogenous GFP addition prior to concentrating sample. Bands corresponding to 
HMGB1 and GFP are indicated     85 
 
Figure 3.8. Acto-myosin dependent release of lactate dehydrogenase from apoptotic cells 
Mean + SEM of lactate dehydrogenase (LDH) activity in NIH 3T3 apoptotic cell conditioned 
medium at indicated times treated with TNFα + Y27632 or blebbistatin. AC-CM was concentrated 
and normalized to exogenous GFP. Sample activity is normalized as a percent of LDH activity 
detected in freeze-thaw necrosis sample at each time point. Statistical comparison performed by 
ANOVA followed by Dunnetts multiple comparison test versus TNFα alone at each time point 
(n=3) (*, p<0.05; **, p<0.01; ***, p<0.001).    86 
 
Figure 3.9. Experimental flow chart for quantitative SILAC mass spectrometry. 
AC-CM, apoptotic cell conditioned medium. LC-MS, liquid chromatography and mass 
spectrometry.    87 
 
Figure 3.10. ROCK catalyses release of many proteins during apoptosis 
(a) Pie chart illustrating percentage of proteins identified by SILAC in 4 hr NIH 3T3 AC-CM that 
were enriched during TNFα induced apoptosis. (b) Pie chart illustrating the percentage of 
apoptotic released proteins that are ROCK dependent as determined by SILAC.    88 
 
Figure 3.11. Apoptotic cells release gelsolin following caspase cleavage. 
(a) Representative western blot of NIH 3T3 lysate and concentrated AC-CM probed with anti-
gelsolin and anti-actin antibodies and visualized with specific fluorescent antibodies using LiCor. 
Cells were transfected as indicated with either non-targeting (NT) or gelsolin (GSN) siRNAs. z-
VAD-fmk (20 μM) supplemented in media with TNFα. (b) Western blot of concentrated AC-CM 
subjected to additional high speed (16,000x g) centrifugation. Blot probed with gelsolin and actin 
antibodies and visualized as indicated above.     89 
 
Figure 3.12. Apoptotic gelsolin release is dependent on acto-myosin contractility. 
(a) Representative western blots of concentrated NIH 3T3 AC-CM collected at 2, 4, 12, and 24 
hours as indicated. Blots probed for gelsolin (left panels) and actin (right panel), the band 
corresponding to caspase cleaved gelsolin (ΔGeslolin) is indicated. Exogenous GFP, added before 
sample concentrating, is used as loading control. Imaging performed using LiCor. (b) 
Quantitation of cleaved gelsolin band intensity mean + SEM at indicated time and treatments. 
Statistical comparison performed by ANOVA followed by Dunnetts multiple comparison test 
versus TNFα alone at each time point (n=3) (*, p<0.05; **, p<0.01; ***, p<0.001).    90 
 
Figure 3.13. Rock inhibition does not affect apoptotic gelsolin cleavage. 
Representative western blot of apoptotic NIH 3T3 lysate at indicated times following treatment 
with TNFα +  Y27632. Blots probed for gelsolin (upper) and ROCK1 (lower). Full length and 
caspase cleaved gelsolin (ΔGelsolin) and ROCK1 (ΔROCK1) products are indicated.    91 
 
Figure 3.14. Apoptotic gelsolin release ensures macrophage migration. 
(a) Schematic diagram of transwell migration cell. Mouse Raw264.7 macrophage in starve 
medium are deposited in upper chamber and exposed to conditioned medium in lower chamber 
for 2 hours. Migrated cells are fixed, stained and microscopically scored. (b) Representative 4x 
images of migrated RAW 264.7 macrophages exposed to the indicated NIH 3T3 conditioned 
media. NIH 3T3 cells were transfected with either non targeted (NT) or gelsolin (GSN) siRNA 72 
hours prior to induction of apoptosis with low dose TNFα and UVB. Migrated macrophages are 
stained with PI after fixation and permeabilization. (c) Quantitation of RAW 264.7 transwell 
migration to indicated conditioned medium. Bars indicate the mean sum of the number of 
migrated macrophages from three fields (as in b) normalized to medium only migration. 
Statistical comparison performed by ANOVA followed by Tukey-Kramer multiple comparison test 
(n=3) (*, p<0.05).    92 
 
Figure 3.15. Schematic model of apoptotic gelsolin release 
Apoptotic blebs and bodies indicated in grey and red. Red structures indicate loss of membrane 
integrity and protein leakage. ΔGeslolin-caspase cleaved gelsolin. LPA-lysophosphatidic acid. 
S1P-sphingosine-1-phosphate.     93 
3.3 Discussion 
One of the defining features of apoptotic cells is their intact and functional 
membranes which appear to prevent pro-inflammatory activation by limiting the 
release of intracellular protein. As such, apoptotic protein release has not been 
considered to be a component of efferocytosis. In fact, protein release is generally 
regarded to occur only during secondary necrosis. Our data demonstrate that 
acute protein release from apoptotic cells is a bona fide apoptotic process and is 
indirectly influenced by ROCK-induced actomyosin contractility. The mechanism of 
apoptotic bleb and body degradation in early apoptosis provides a simple and 
robust route for intracellular protein to participate in complex extracellular signaling 
events during apoptosis. Furthermore, these observations highlight a novel 
biological role for ROCK induced apoptotic body formation and blebbing. The 
generation of independent sub-cellular apoptotic bodies which diffuse away from 
the apoptotic cell prior to membrane breakdown and release of their intracellular 
contents would dramatically increase the range at which macrophages detect 
apoptotic cells. The behavior of these sub cellular particles as “suicide notes” to 
attract surveilling macrophages may be a common and important mechanism to 
mediate safe and rapid clearance, thus avoiding unwarranted inflammatory 
activation (Figure 3.15). This possibility suggests that the release of protein from 
apoptotic cells does not appear to necessarily lead to immune activation and may 
in fact be an active participant in acute corpse clearance. A further implication is 
that protein released during apoptosis is likely to have limited inflammatory 
potential and that only during primary and secondary necrosis are specific pro-
inflammatory mediators released. Indeed, in post apoptotic cells the release of the 
pro-inflammatory cytokine HMGB-1 is only observed hours after the onset of 
secondary necrosis 
228.  
Due to the existing dogmatic preconceptions of apoptotic membrane integrity, the 
focus in the search for come-find-me signals has largely ignored the potential 
contribution of many intracellular proteins. As previously mentioned, the release of 
TyrRS and dRP S19, two intracellular proteinaceous come-find-me factors, from 
apoptotic cells conflicts with the current model of early apoptotic cell membrane 
impermeability. The insight we now provide may resolve this long standing 
dilemma and expand the scope of come-find-me factors to include more 
intracellular proteins. Although we failed to find either TyrRS or dRP S19 as part of    94 
our systematic quantitative SILAC survey of AC-CM, we identified the release of 
46 proteins from early apoptotic NIH 3T3, none of which have previously been 
identified as come-find-me factors. Critically, many of these proteins are 
dependent upon ROCK induced blebbing and apoptotic body formation for their 
release, recapitulating the importance of these structures in the proposed 
mechanism of apoptotic protein release. Such an acute and dramatic release of 
protein is likely to have an important biological impact in the surrounding 
microenvironment and several of these molecules may be apoptotic come-find-me 
factors. As proof of principle, we investigated the potential role of gelsolin, the 
most abundantly enriched protein in NIH 3T3 AC-CM, and found that it 
encourages macrophage migration towards apoptotic cells. Gelsolin itself may 
behave as a come-find-me-factor, or may act by modifying additional extracellular 
signals to affect responses 
240,241(Figure 3.15). The ability of plasma gelsolin to 
bind and modify the activity of lysophospholipids has been well established and 
release of caspase cleaved gelsolin from apoptotic cells may be a significant 
modifier of such lipid signals. As previously mentioned, apoptotic cells release a 
variety of lipid chemoattractant signals including S1P that, in turn, affect 
macrophage migration and survival 
241-244. Alternatively apoptotic release of S1P 
has also been shown to mediate extrusion of apoptotic cells by initiating 
contraction of an epithelial sheet, thus preserving barrier function 
245. Whatever the 
mechanism, the release of gelsolin from apoptotic cells would be expected to 
modify the existing lysophospholipid signaling networks and thus mediate 
profound changes in the extracellular environment. While we have demonstrated 
that released gelsolin has the potential to act as an apoptotic come-find-me factor, 
it may not be a universal signal. Nonetheless, it is interesting to note that actin, 
which is abundant and ubiquitously expressed, was also highly enriched in AC-
CM. Extracellular actin has been proposed to act as reservoir to retain circulating 
plasma gelsolin near sites of tissue damage where it can modulate immune 
responses, such a mechanism could be identical following apoptotic actin release 
230. While a gelsolin knockout mouse was first described in 1995 there are no 
reports specifically demonstrating defective apoptotic cell clearance 
246. There are 
however several reports which suggest that apoptosis in the knockout mouse is 
altered 
247-249. Induction of apoptosis in mice with the Fas stimulatory antibody Jo-2 
has been shown to dramatically increase hepatocyte apoptosis in gelsolin
-/- mice 
compared to gelsolin
+/+ littermates 
247. This observation is curious because gelsolin 
expression in the liver is limited to sinusoidal lining cells while the bulk of the    95 
tissue, such as hepatocytes, express little or no protein 
247. Thus gelsolin appears 
to be an important factor limiting apoptosis, even in tissues where it is not 
expressed which suggests that the protein has a potentially important extracellular 
function. While it remains unclear precisely how gelsolin mediates this effect, the 
possibility remains that extracellular gelsolin, either plasma and/or caspase 
cleaved, may be mediating important anti-inflammatory signals associated with 
apoptosis and its absence leads to increased programmed cell death and tissue 
damage. It is important to note that the gelsolin knockout eliminates both the 
plasma and cytoplasmic isoforms. Due to the systemic deficiency of gelsolin in this 
model the relative importance of plasma versus apoptotically released gelsolin in 
the attraction of macrophages and the resolution of cell death cannot be 
determined.  
Clearly gelsolin was only one of many molecules identified in NIH 3T3 cells AC-
CM, any of which may modulate macrophage and immune responses towards 
apoptotic cells. The actual protein content of extracellular supernatant following 
apoptotic body and bleb breakdown is likely to be highly dependent upon cell type. 
This work is a first step in systematically identifying the range of proteins released 
from apoptotic cells and extensive further investigation is required to determine; 
how consistent protein release is across cell types; which proteins in AC-CM have 
extracellular roles; and what their mechanism of actions might be.  
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4. Activating Somatic ROCK1 Mutations in Cancer 
(Text extracted from Lochhead, P*., Wickman, G*., Mezna, M., Olson, M.F. Activating Somatic 
mutations in human cancer. Oncogene (2010) 29, 2591-2598. *Co-first authors.) 
4.1 Introduction 
The identification of mutated genes that drive human oncogenesis is an ongoing 
major objective worldwide. The development of high-throughput detection 
methodologies has facilitated the identification of novel somatic mutations 
associated with numerous cancers (http://www.sanger.ac.uk/genetics/CGP/ and 
http://cancergenome.nih.gov/). Statistical analysis of mutation frequency can be 
used to classify them as active “driver” mutations that provide a selective 
advantage during cancer initiation and progression, or silent “passengers” which 
are expanded from progenitor cells, yet provide no overt selective advantage. 
While this approach has tremendous value in identifying important genes in 
cancer, it remains incomplete until the biological consequences of detected 
mutations are determined to differentiate drivers from passengers.  
 
The Cancer Genome Project has thus far identified 3 nonsynonymous mutations in 
the ROCK1 gene, an essential effector kinase downstream of Rho GTPases that 
is an important mediator of cell migration. ROCK1 is an unusual AGC kinase 
family member as its kinase domain assumes an active conformation without 
activation loop phosphorylation 
9. Instead, ROCK1 activity is restrained by its 
inhibitory C-terminus; relief from auto-inhibition results from Rho-GTP binding or 
by caspase cleavage at a C-terminal site 
46,57. There is a wealth of data implicating 
Rho GTPases in human cancer 
148,250 suggesting that ROCK1 and ROCK2, as key 
mediators of Rho signaling, may play important roles in oncogenesis 
154,202,251. In 
support of this, pre-clinical studies have demonstrated beneficial effects of ROCK 
inhibition on tumour incidence rates, volume, invasiveness and metastasis 
53,206,209,210,252-254. In addition, elevated ROCK1 and/or ROCK2 expression have 
been detected in several human cancers, which positively correlates with poor 
outcome 
151,152,255,256. While alterations in the regulation of ROCK1 signaling as a 
contributory factor to human cancer may be well-accepted, this is the first report of 
ROCK1 activation as a direct consequence of somatic mutations.    97 
I found that these somatic ROCK1 mutations lead to elevated kinase activity and 
drive actin cytoskeleton rearrangements that promote increased motility and 
decreased adhesion; both characteristics of cancer progression. Mapping of the 
kinase-interacting regions of the carboxy-terminus combined with structural 
modeling provides insight into how these mutations likely affect the regulation of 
ROCK1. Consistent with the frequency of ROCK1 mutations in human cancer, 
these results support the conclusion that there is selective pressure for the 
ROCK1 gene to acquire “driver” mutations that result in kinase activation.  
4.2 Results 
4.2.1  Cancer Associated Mutations in ROCK1 
As previously mentioned, cancer genome sequencing has revealed three novel 
ROCK1 mutations in human malignant disease (http://www.sanger.ac.uk/cgi-
bin/genetics/CGP/cosmicsearch?_q=rock1). The 3 somatic mutations in ROCK1 
are: AA insertion between base pair (bp) 1214-1215, resulting in frameshift and 
premature termination at Y405*; C to G transition at bp 3377, resulting in 
premature termination at S1126*; and C to T transversion at bp 3577, resulting in 
the amino acid substitution P1193S (Figure 4.1). The Y405* and S1126* mutants 
were both identified in primary human breast cancers, while the third mutation, 
P1193S, was identified from the established human non-small cell lung carcinoma 
line NCI-H1770) 
257. 
4.2.2  Cancer associated somatic mutations of ROCK1 are activating 
To determine how ROCK1 mutations affected activity, MYC-tagged wild-type 
(WT), kinase-dead K105G, and Y405*, S1126* and P1193S proteins were 
expressed in NIH 3T3 mouse fibroblast cells. WT, K105G and P1193S migrated at 
158 kDa, while Y405* and S1126* migrated as expected at 47 kDa and 113 kDa, 
respectively, as determined by western blotting (Figure 4.2). In vitro kinase assays 
of the MYC-immunoprecipitated proteins revealed that the activity of all three 
ROCK1 mutants was increased significantly (2.5-3.5 fold) relative to WT (Figure 
4.2). The kinase-dead K105G mutant had no detectable activity, indicating that the 
active forms possessed intrinsic kinase activity that did not result from 
contaminating MYC-tag co-immunoprecipitating kinases (Figure 4.2). This work 
was performed in collaboration with Dr. Pam Lochhead.    98 
4.2.3  ROCK1 Mutations are Constitutively Active in Cells 
To further explore the cellular consequences of ROCK1 mutations the enzymes 
were transiently expressed in NIH 3T3 fibroblasts. The activity of ROCK1 was 
assessed by immunofluorescence microscopy of actin stress fibres and 
phosphorylation of the regulatory myosin light chain (pMLC) at serine 18 and 19, 
two hallmarks of ROCK activation. Co-staining for MYC-tag ROCK1 and F-actin 
revealed large increases in both the number and thickness of actin stress fibres, in 
cells transfected with Y405*, S1126*, and P1193S but not with K105G (Figure 
4.3). Expression of WT ROCK1 appeared to increase the appearance of stress 
fibres although to a much lesser extent than the more biochemically active 
mutants. Examination of pMLC in MYC-tag positive cells reveals a staining pattern 
identical to that seen with actin stress fibres. Interestingly, the enhancement of 
pMLC and actin stress fibres appear far more pronounced following transfection 
with Y405* and S1126* versus P1193S. 
Following transfection of NIH 3T3 fibroblasts with the ROCK1 mutants significant 
changes in the cells were observed. Within six hours of transfection the cellular 
area of NIH 3T3 cells that expressed ROCK1 Y405*, S1126*, or P1193S was 
reduced to 52, 39, and 59%, respectively, of cells expressing GFP (Figure 4.4a).  
While the active ROCK1 mutants clearly initiated a contractile phenotype the 
kinase dead K105G construct appeared to increase cell spreading compared to 
GFP, suggesting a dominant negative activity over native wild type ROCK1 (Figure 
4.4a). When the effects of the active ROCK1 mutants on cell morphology were 
examined, Y405*, S1126*, and P1193S expression markedly modified cell shape, 
shifting the distribution of morphologies from predominantly spread to contracted 
and rounded (Figure 4.4b). Furthermore, the magnitude of the distribution shift is 
consistent with cellular activity observed in previous experiments. 
4.2.4  ROCK1 mutants enhanced motility and migration 
Given the prominent role of ROCK1 in tumour cell invasion and metastasis 
258, I 
sought to assess the effects of the somatic ROCK1 mutations on motility and 
adhesion. Expression of the MYC-tagged ROCK1 proteins in NIH 3T3 fibroblasts, 
assessed by flow-cytometry, was comparable for WT, S1126* and P1193S, while 
expression of K105G and Y405* was lower (Figure 4.5a and b). Analysis of 
individual cell motility by time-lapse microscopy over 20 hours revealed that    99 
S1126* and P1193S expressing NIH 3T3 cells were more motile than GFP-
expressing control cells, with significantly longer cumulative track lengths (Figure 
4.6a and b). Although track lengths of WT ROCK1 expressing cells were 
apparently longer than GFP-control cells, they were not statistically significant 
(Figure 4.6b), while Y405* expression was insufficient to reliably assess its effects. 
Expression of S1126* also increased Euclidean distance travelled and cell velocity 
(Figure 4.7a and b). No effect on cell persistence was observed following 
transfection with any ROCK1 construct (Figure 4.7c). I next examined the effects 
of ROCK1 mutants on adhesion using a transwell dissociation assay 
259. This 
assay relies upon the migration of ROCK1 expressing NIH 3T3 cells in an FBS 
gradiant through an 8 μm pore transwell membrane followed by dissociation, and 
adherence to the bottom of the well (Figure 4.8a). Cellular dissociation is then 
quantitated by counting the number of cells adhered to the plate. All three ROCK1 
mutants significantly increased the number of cells that had crossed and 
dissociated from the transwell membrane (Figure 4.8b) indicating reduced cell 
adhesiveness, a property associated with increased metastatic potential. 
Expression of S1126* also was sufficient to further increase dissociation of the 
highly-metastatic MDA MB 231 breast cancer cell line in this assay (Figure 4.8c). 
4.2.5  C-terminus of ROCK1 contains multiple kinase interacting 
Domains 
Next I addressed how the three ROCK1 mutations; Y405*, S1126*, and P1193S 
led to kinase activation. Since these three ROCK1 mutations affect the C-terminus 
it is likely that they trigger activation by disrupting inhibitory interactions between 
N- and C-terminal domains. While the role of the C-terminus in ROCK1 
autoinhibition is thoroughly established, the kinase interacting regions mediating 
inhibition had not previously been mapped. Thus, I probed a 21-mer peptide array 
(Figure 4.9a) comprised of amino acids 1-75 containing the N-terminal 
dimerization region and amino acids 853-1354 of the C-terminus with [
35S]-labeled 
ROCK1 kinase domain (amino acids 1-404). As expected, the probe bound to the 
ROCK1 N-terminal residues 27-75 that mediate kinase dimerization (Figure 4.9b 
and c)
9. In addition, the kinase domain strongly bound 4 C-terminal regions (Figure 
4.9b; regions 2d, 2f, 2h and 2i), indicating that potentially there are multiple sites 
engaged in kinase regulation. Region 2d overlapped with the latter half of the 
RBD. The first segment of the split Pleckstrin Homology (PH) domain contained    100 
regions 2f, while the second segment overlapped with 2i. Binding region 2h was 
contained within the cysteine-rich C1 domain. Kinase binding to the region 
containing P1193 (2g) was weak though detectable (Figure 4.9b). To further 
characterize these kinase binding regions, I expressed FLAG-tagged protein 
fragments in E. coli and tested their abilities to bind recombinant GST-ROCK1 
kinase domain (200 ng) spotted onto nitrocellulose membranes (Figure 4.10a). 
Regions 2g, 2h and 2i significantly bound ROCK1 kinase domain, while 2d binding 
was detectable but did not achieve significance (Figure 4.10b). Region 2f could not 
be tested due to protein insolubility. The P1193S mutation significantly reduced 
kinase binding by over 30% (Figure 4.9b) 
4.2.6  Specific ROCK1 C-terminal Interacting Domains Mediate Kinase 
inhibition 
To test the role of these domains in kinase regulation, representative 21-mer 
peptides from each binding region were synthesized and tested in an IMAP 
fluorescence-polarization ROCK1 kinase assay. Kinase activity was significantly 
inhibited by peptides 2f and 2g (31 and 68% of control respectively) while peptides 
corresponding to regions 2d, 2h, and 2i failed to inhibit ROCK1 activity (Figure 
4.11a). Analysis of ROCK1 inhibition by mutant 2g (P1193S) revealed a significant 
reduction in kinase inhibition compared to wild type 2g (Figure 4.11b). 
4.2.7  ROCK1 C-terminal Interacting Domain Modeling 
While the data presented above make it easy to conceive how the Y405* and 
S1126* mutants, which respectively lack all or most of the kinase-interacting and 
autoinhibitory regions 2f, 2g and 2h, would be constitutively activated, the 
mechanism of kinase activation due to P1193S mutation is unclear. Thus, given 
the high degree of conservation between the ROCK1 and ROCK2 PH-C1-PH 
domains in general, and the 2f, 2g and 2h regions in particular (Figure 4.12), the 
ROCK1 kinase-interacting and inhibitory regions were modeled onto the NMR 
solution structures of the PH-C1-PH domains of ROCK2 in order to gain greater 
insight into potential structural modifications induced by P1193S 
260(Figure 4.13). 
As can be seen in Figure 4.13a P1193 breaks a short α-helix prior to a β-sheet 
that leads on towards the C1 domain (highlighted in green). I predict that the 
P1193S mutation does not provide the appropriate α-helix break, and as a 
consequence will disorder the split PH domain and likely disrupt the C1 domain as    101 
well. In addition, the structural rigidity provided by a proline residue would be 
reduced when substituted with a serine residue, which might result in less ordered 
folding. Such structural alterations are likely responsible for the reduced kinase 
domain binding and attenuation of kinase inhibition observed in domains bearing 
the P1193S mutation.  In addition, modeling of the 2f, 2g and 2h regions reveals 
that they form multiple surfaces located directly opposite to a series of charged 
lysine and arginine residues that cooperate to mediate lipid interaction and to 
orientate the PH-C1-PH domains in membrane bilayers (Figure 4.13b). As a result, 
the critical kinase interaction and inhibitory domains would be exposed to the 
cytosol and thus accessible for interaction and inhibition of the ROCK catalytic 
domain (Figure 4.13b). These results indicate that multiple surfaces in the ROCK1 
C-terminus likely contribute to kinase-domain binding and regulation. These 
interactions range from relatively weak and non-regulatory (2d) to strong and 
inhibitory (2g). In addition to the significant contribution of region 2g that contains 
P1193, region 2h and 2i appear to be an important kinase binding regions, 
possibly contributing to stabilizing N and C-terminal interactions. 
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Figure 4.1. ROCK1 domain structure for wild-type (WT) and cancer associated mutations. 
RBD=Rho binding domain. Split Pleckstrin Homology (PH) domains (yellow) have an inserted C1 
domain (dark blue). Asterisk indicates position of amino acid substitution (red). Drawn to scale.    103 
 
Figure 4.2. ROCK1 somatic cancer mutants are active. 
Upper panel, ROCK1 kinase activity of indicated MYC-tagged constructs immunoprecipitated, as 
described previously (coleman et al., 2001), from transfected NIH 3T3 cells. Results are mean ± 
SEM vs. WT (n=3)(*, p<0.05 vs WT, by t-test). Lower panel, cellular lysates were separated by 
SDS-PAGE and immunoblotted with anti-MYC antibody. Arrows indicate ROCK1 proteins.  , non-
specific bands. Results are mean + SEM activity (n=3)(* p<0.05, relative to WT, by t-test). Figure 
courtesy of Pam Lochhead.    104 
 
Figure 4.3. ROCK1 mutants are active in cells. 
Representative immunofluorescence confocal images of serum starved NIH-3T3 fibroblasts 
stained for actin (left panels) and phosphorylated myosin light chain (pMLC; right panels). 
Cellular nuclei, stained with DAPI, are shown in blue. Arrows indicate cells positive for MYC-tag 
ROCK1. Scale bars represent 50 µm. After transfection, cells were serum starved overnight then 
fixed and stained as described previously (Coleman et al., 2001). Confocal images were obtained 
using an Olympus FV1000 using a 60x oil-immersion objective.    105 
 
Figure 4.4. ROCK1 somatic cancer mutants promote cellular actin rearrangements. 
(a) Mean cell area of ROCK1 transfected NIH 3T3 cells. For cell size determinations, 6 random 
fields of MYC-tag positive cells were captured per treatment. Images were analysed for 
percentage MYC-tag positive area divided by the cell number. Data are mean + SEM (n=3), 
statistical comparisons determined by ANOVA followed by Dunnett’s multiple comparison test. (* 
p<0.01 vs GFP). (b) Representative images of cell morphologies (spread, contracted, and 
rounded) stained for F-actin (red) and ROCK1-expression (MYC; green). For cell morphology, 
images were captured and scored for spread, contracted or rounded. Average distribution of 
morphologies from 3 experiments for each ROCK1 variant in bottom panel. 
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Figure 4.5. Expression of MYC-tagged ROCK1 constructs in NIH 3T3 mouse fibroblasts. 
(a) Representative FACS expression profiles of cells positive for expression of MYC-epitope 
tagged ROCK1 plasmids. After transfection, cells were incubated overnight in 10% FBS medium. 
The following day the cells were collected and fixed in 2% paraformaldehyde for 10 minutes. 
Cells were then washed and permeabilized with 0.1% Triton X-100 for 5 minutes. MYC-tagged 
ROCK1 constructs were detected with an anti-MYC (9B11) antibody conjugated with AlexaFluor 
647. 10,000 events were collected on a BD FACScaliber and MYC-tag positive cells were gated 
against blank transfected cells. Traces represent histograms of MYC-tag positive cell number vs 
MYC-tag intensity.  (b) Representative expression profile of MYC-tag positive cells as determined 
by FACS. Data represent percentage of MYC-tagged positive cells relative to WT ROCK1 
expression.    107 
 
Figure 4.6. ROCK1 somatic cancer mutants promote cell migration. 
(a) Representative cell tracks of 10 cells expressing indicated ROCK1 constructs. Cells were co-
transfected with ratio of 1:2 of GFP and ROCK1 constructs and plated into a glass bottom 6 well 
plate in complete medium. 3h after nucleofection the medium was replaced with reduced serum 
(3.3% FBS) medium. Three bright field and GFP timelapse images were captured for each 
treatment every 2 minutes for 20 h. In those fields the motility of 10 cells in all 3 fields was 
analysed using Metamorph and Image J. (b) Mean cumulative tracklengths + SEM of NIH 3T3 
analysed an in (a). Statistical comparison performed by ANOVA followed by Dunnett’s multiple 
comparison test (n=4)(* p<0.05 vs GFP; ** p<0.01 vs GFP).    108 
 
Figure 4.7. ROCK1 somatic cancer mutants promote random cell motility. 
(a) Data represent mean Euclidean distance travelled + SEM. (b) Data represent mean cell 
velocity + SEM over 20 hours. (c) Data represent mean persistence (Track length/Euclidean 
distance) + SEM. Euclidean distance and persistence were calculated from individual cell tracks 
obtained with the Chemotaxis and Migration Tool plugin for ImageJ from time-lapse image 
stacks. Statistical analysis performed by ANOVA followed by Dunnett’s multiple comparison test 
(*, p<0.05; ** p<0.01 vs GFP).    109 
 
Figure 4.8. ROCK1 somatic cancer mutants encourage cellular dissociation. 
(a) Schematic diagram of transwell dissociation assay. Cells were co-transfected with a ratio of 
1:2 of GFP and ROCK1 constructs and incubated in 10% FBS medium within an 8 μm pore 
Transwell insert for 3h. Following incubation, the insert medium was aspirated and replaced with 
serum free medium, insert was placed in fresh well containing 10% FBS media and incubated 18 
h. The number of GFP positive cells that invaded and dissociated from the membrane were then 
counted from five independent 20x fields. (b) Mean number of dissociated cells following 
chemotaxis of ROCK1 transfected NIH 3T3 cells through Transwell membranes. Results are mean 
+ SEM, statistical analysis performed by ANOVA followed by Dunnett’s multiple comparison test 
(n=4)(** p<0.01 vs GFP). (c) Mean number of dissociated cells following chemotaxis of ROCK1 
transfected MDA MB 231 breast cancer cells. Results are mean + SEM. Statistical analysis 
performed by ANOVA followed by Dunnett’s multiple comparison test (n=3)(*, p<0.05 vs WT).    110 
 
Figure 4.9. ROCK1 kinase domain has multiple and distinct c-terminal interacting sites. 
(a) Schematic representation of ROCK1 domain structure, regions analysed on peptide array, and 
the probe used (upper panel). The probe consisted of MYC-tagged ROCK1 kinase domain (amino 
acids 1-404). 21-mer peptides offset by 2 amino acids covered region 1 (red) amino acids 1 – 75 
and region 2 (black) amino acids 853-1354. (b) Autoradiogram of the peptide array probed with 
35S labelled protein MYC-tagged ROCK1 kinase domain (upper panel). The 5 binding regions are 
outlined with pink, green, brown, orange, blue and red. The locations of these regions in ROCK1 
are indicated in the schematic diagram (lower panel). (c) Ribbon diagram showing the N-terminal 
kinase interacting region 1 (red or brown) modeled onto the ROCK1 kinase domain (blue or 
yellow) dimer structure (PDB ID:2etr) using protein co-ordinates imported from PDB into 
DeepView (v4.0.1) for modeling. Images were generated following export to POV-Ray (v3.6).     111 
 
Figure 4.10. Validation of ROCK1 C-terminal interacting regions. 
(a) Representative dot blots of protein fragments binding to immobilized ROCK1 kinase domain. 
Membranes were probed with rabbit anti-GST and mouse anti-FLAG antibodies to detect ROCK1 
and FLAG-labelled binding proteins respectively. Infra-red fluorophore conjugated secondary 
antibodies were detected at 700 and 800 nm using a Li-Cor Odyssey. Surface plot indicates signal 
intensity for each condition in third dimension. (b) Mean dot blot signal intensities over blank. 
Statistical analysis calculated by ANOVA followed by Bonferroni’s multiple comparison test (n=3-
9) (*p<0.05 vs blank; **, p<0.01 vs blank, ***, p<0.001 vs blank).    112 
 
Figure 4.11. ROCK1 kinase-binding regions inhibit kinase activity. 
(a) Mean + SEM of ROCK1 activity in fluorescent polarization assay following incubation with 100 
μM of the indicated synthetic ROCK1 peptides (corresponding to the following spots on the 
peptide array 2d (d17), 2f (f16), 2g (g15), 2h (h12), and 2i (i12)). (b) Mean + SEM of ROCK1 
activity in fluorescent polarization assay following incubation with 100 μM of the synthetic 
peptides 2g, 2g P1193S, and with 10 μM Y-27632. Statistical analysis calculated by ANOVA 
followed by Dunnett’s multiple comparison test (n=2-5)(*, p<0.05; **, p<0.01 ***; p<0.001 vs 
control).    113 
 
Figure 4.12. ROCK1 and ROCK2 are highly conserved in the C-terminal regulatory domain. 
Amino acid sequence alignment of the PH-C1-PH domains of mammalian ROCK1 and ROCK2. Non-
conserved amino acids are highlighted in green. ROCK protein domains, according to ROCK1 NCBI 
reference sequence NP_005397, are indicated above alignment. Kinase interaction regions are 
indicated above alignment with percent homology. Mutated residues, S1126 and P1193, are 
highlighted in red.    114 
 
Figure 4.13. Structural modelling of the ROCK1 interacting regions. 
(a) Ribbon diagram demonstrating that P1193 (green) is located between an α-helix and a β-
sheet in the PH domain (yellow). A part of the kinase interacting region 2g is highlighted in 
orange. In full length ROCK the interrupting C1 domain would be expected to continue from the 
orange ribbon (2g) and re-join the PH domain at the indicated residue in blue. Residues and 
domains modeled and rendered onto the ROCK2 PH structure (PDB ID: 2rov) from PDB co-
ordinates using Pymol. (b) Surface modelling of PH and C1 domains with predicted membrane 
orientation. ROCK1 binding and inhibitory domains 2g (orange), 2f (brown), and 2h (light blue) 
modelled onto separately solved PH (yellow) and C1 (dark blue) structures of ROCK2 (PDB ID: 
2rov and 2row, respectively). Location of P1193 is indicated in green. Residues highlighted in red 
mediate lipid binding
260. Charged headgroups of the inner leaflet of a phospholipid bilayer are 
drawn in gray. Dashed lines indicate the expected structural attachments between the PH and 
C1 domains. Structures were modelled and rendered in Pymol.    115 
4.3 Discussion 
In summary, the three ROCK1 mutations, Y405*, S1126*, P1193S have enhanced 
kinase activity, promote contraction, increase motility and decrease adhesion; 
indicating that these mutations are all constitutively active, consistent with them 
being active cancer drivers. These kinase mutations associated with cancer have 
revealed 2 ROCK1 mutants similar to previously characterized activating 
deletions; caspase-cleavage 
57 and an experimentally derived truncation 
53. In 
addition, a novel activating single amino acid substitution was identified revealing 
new information about ROCK1 regulation. Mapping of the C-terminal kinase 
interacting regions and structural modeling has revealed that ROCK1 likely keeps 
kinase activity in check via interactions with multiple surfaces. 
In a recent paper the phosphorylation of myosin light chain was also found to be 
altered in cancer cells bearing somatic mutations in death-associated protein 
kinase 3 (DAPK3)
261. Expression of the kinase dead mutants of DAPK in several 
cancer cell lines was found to significantly decrease MLC phosphorylation, which 
was then associated with increased proliferation, survival, and adhesion leading 
the authors to conclude that somatic DAPK mutations are drivers of cancer. 
Although the effect on myosin light chain phosphorylation following mutant DAPK 
expression is the opposite of what I see with mutant ROCK1 the results are not in 
direct contradiction. Firstly, both kinases have multiple substrates and the 
importance of pMLC in the cancer promoting effects of either mutant kinase was 
not assessed in either report. Secondly, while I used NIH 3T3 cells almost 
exclusively, the DAPK3 report makes frequent use of many different cancer cell 
lines, any one of which, is likely to have altered signaling pathways. Finally, neither 
study attempts to assess the in vivo relevance of ROCK1 or DAPK mutation in 
tumour growth, survival, or metastasis. Combined these differences make a 
meaningful interpretation of a role for pMLC (either increased or decreased) in 
driving cancer impossible. Nonetheless, somatic mutation of either ROCK1 or 
DAPK3 does seem to promote the generation and/or progression of malignant 
disease. 
Three somatic mutations have also been described in the ROCK2 gene in human 
cancers; a T to C transversion at position 3508 in the LB2518 malignant 
melanoma cell line that results in a S1194P substitution (equivalent to S1162 in    116 
ROCK1) in the first PH domain, insertion of A at 3518-3519 in the CP50-MEL-B 
malignant melanoma cell line resulting in a frameshift and termination at Y1174* 
(equivalent to Y1142 in ROCK1) in the first PH domain, and deletion of T at 412 
resulting in a frameshift and termination at W138* in a primary stomach carcinoma 
(http://www.sanger.ac.uk/cgi-bin/genetics/CGP/cosmicsearch?_q=rock2). Given 
the results of this study, the clustering of the Y1174* and S1194P mutations in the 
first PH domain suggests that they would be activating mutations, although the 
W138* mutation retains little of the kinase region. As previously mentioned, the 
activation of ROCK2 in skin epithelial cells leads to contractility dependent 
hyperproliferation and promotion of a cancerous ‘niche’ 
154. It is of particular 
interest that one of the ROCK2 mutations was not only found in a malignant 
melanoma but is predicted to lead to constitutive activation. Expression of this 
mutant would be expected to cause collagen deposition and mechanical feedback 
driving tumour proliferation and survival  
There are numerous examples of kinase activation by cellular proteolysis 
262, as 
exemplified by caspase cleavage of ROCK1 
57 and granzyme B cleavage of 
ROCK2 
78. The organization of ROCK1 and ROCK2 domains containing N-
terminal kinase domains and C-terminal autoinhibitory domains lends them to 
activation by proteolysis or by mutations that result in premature termination. 
Therefore, it could be predicted that other kinases organized in a similar manner 
would also be subjected to activating mutations that affected C-terminal regulatory 
regions. Indeed, the Cdc42-regulated MRCKα (aka CDC42BPA), which plays a 
similar role in actin cytoskeleton regulation as ROCK1 and ROCK2, has an 
example of a frameshift and termination at K697* in the HCC1395 breast ductal 
carcinoma cell line that removes autoinhibitory C1 and PH-like domains 
263. 
Interestingly, 4 non-synonymous mutations were identified for MRCKβ (aka 
CDC42BPB), all of which occur C-terminal to the kinase domain and therefore are 
potentially activating, with the most likely mutation to be activating consisting of a 
frameshift and termination at R1092* found in an intestinal adenocarcinoma 
tumour.  
The increased activity of the ROCK1 mutations suggests independence from the 
upstream regulator Rho, similar to Ras-independent activating B-Raf mutations. 
Although the rate of ROCK1 mutations was low, these results justify screening a 
larger set of cancers to determine a more representative rate and indentify    117 
additional mutations. Furthermore, these observations additionally validate the 
value of high-throughput sequencing for identification of new cancer genes, and 
for providing valuable unbiased insight into protein regulation and function. 118 
5. Materials and Methods 
5.1 Chapter 2 methods 
5.1.1  ROCK1nc knock-in animal generation 
5.1.1.1 Home office project and personal licensing  
All animal work reviewed and approved of in project and personal licenses issued 
by the UK Home Office.  
5.1.1.2 Targeting vector generation 
The 5.1 kb 3’ homology arm for targeting ROCK1 was isolated from a BAC clone 
containing the murine ROCK1 gene by gap repair recombineering in DY380 cells 
as described by 
264. BAC clones were from the Sanger AB2.2 mouse genomic 
DNA library (representative of the mouse 129 strain) and identified as: 107N12, 
208K1 and 459E7.  
A retrieval vector was generated by PCR-amplifying short (approximately 500bp) 
arms that represent the extreme ends of a larger target sequence (in this instance, 
the 5.1 kb 3’ homology arm) and sub-cloning these into pCR-blunt 2.1 (Invitrogen) 
in such a way that the adjacent sequences were separated by an AscI site to allow 
linearization of the vector between the amplified arms.  
DY380 cells carrying the target BAC were grown at 30C to an OD600 of 0.5-0.6 
then shifted to 42°C for 15 minutes to heat-shock induce lambda phage 
recombination proteins which drive the retrieval. Heat-shocked cells were 
harvested and washed twice in sterile distilled H2O. Pelleted cells (25μl) were 
resuspended in residual H2O then mixed with 50-100 ng (5ul volume max) of the 
gel-purified,  AscI-linearised retrieval vector. Following, electroporation, the 
bacterial cells were allowed to recover by shaking at 30°C in 900ul SOC then 
plated on LB-agar plates supplemented with ampicillin (the antibiotic-resistance in 
the backbone of the retrieval vector).  
The 3.1 kb 5’ homology arm of ROCK1 proved refractory to recombineering and 
was generated from BAC DNA by high fidelity PCR amplification. An amino acid 
point mutation aimed at making the resultant ROCK1 caspase-resistant was then    119 
introduced into exon 27 of the ROCK1 gene using a mutated oligonucleotide 
primer with Stratagene QuickChange II XL site-directed mutagenesis kit.  
The mutated plasmid was sequenced to confirm the introduction of the desired 
mutation (which generated a novel PstI restriction site) and the conservation of 
other exons within the fragment. In sequencing, a number of polymorphisms were 
identified in the 129 strain-derived genomic DNA (confirmed by sequencing from 
independent PCR products from tail DNA) relative to the C57Bl/6 DNA sequence 
archived by Ensemble. Two changes were identified within exon 27 and were 
conservative with reference to the encoded amino acid sequence. The 5’ and 
mutated 3’ arms were cloned directionally into pDupDel Neo (gift of Prof. Oliver 
Smithies and available commercially from Open Biosystems) using restriction sites 
introduced during PCR cloning and recombineering respectively. This placed the 
mutated exon 27 proximal to the selection cassette to decrease the chance of loss 
of the mutation during homologous recombination (Figure 2.1). Since pDupDel 
Neo contains a high activity form of the neomycin resistance gene, the original 
selection cassette was removed by Cre deletion in EL350 cells 
264 and a low 
activity version (expressed from a PGK/EM7 hybrid promoter) from pL452 
265 was 
inserted by the reverse process and selection on kanamycin. The resultant 
targeting vector was linearised with NotI restriction enzyme in preparation for 
transfection of mouse embryonic stem cells. This work was performed by the 
Beatson Institute Transgenic Technology core service.  
5.1.1.3 Mouse embryonic stem cell (mES) vector transfection  
G4 murine embryonic stem cells (gift of Dr. Andras Nagy and Marina Gertsenstein 
266) were grown under ES medium (DMEM (high glucose), 15% FBS, 2mM 
Glutamax, 0.1 mM non-essential amino acids, 0.1 mM β-Mercaptoethanol 1000 
U/ml ESGRO (Millipore), 33 μg/ml Gentamycin) on mouse embryonic fibroblast 
(MEF) feeder layers. Cells were harvested from two T175 flasks 24hrs after their 
final split and plated for 20 minutes to remove the majority of MEFs. Cells were 
pelleted, washed once with PBS and counted.  
Following resuspension in room temperature Embryomax transfection buffer 
(Millipore) at 1x10
7 cells/ml, five volumes of 8x10
6 cells were mixed with 40μg of 
linearised targeting vector and the mixtures transferred to 4mm electroporation    120 
cuvettes (Biorad) before electroporation at 250V, 500μF and infinite resistance. 
After recovery at room temperature for 20 minutes, cells were washed out of the 
cuvettes with regular ES medium and the contents of each cuvette split across 
four 10cm plates of MEFs. After 24 hrs, medium was changed to ES medium 
supplemented with 240 μg/ml G418. The plates were maintained under this 
medium (with daily changes) for 6 days.  
Colonies selected for G418 resistance were picked onto five 96-well plates of 
MEFs and grown under selection for 3 days. Plates were then archived for 
subsequent recovery and cells grown on parallel gelatinized plates. 96-well plates 
containing expanded ESC colonies were washed twice with 200μl PBS per well 
and 50μl of trypsin added. Following 5 minutes at 37
oC, cells were pipetted up and 
down then 50μl of ES medium added to terminate trypsinisation. A 50μl volume of 
trypsinised cells was transferred to a parallel round-bottomed 96-well plate 
containing 50μl of 2x freezing medium (40%FBS-40% ES medium-20% DMSO) to 
act as a master-plate. The plate was overlaid with 100μl of embryo-tested mineral 
oil, sealed and frozen in a polystyrene box at -80
 o C before transfer to liquid 
nitrogen storage. The remaining trypsinised cells were transferred to gelatinized 
plates prepared thus: 50μl of 0.1% (w/v) porcine gelatin in PBS was applied to 
each well of a 96-well plate and allowed to stand at RT for 20 minutes. After this 
time, the plate was drained and 50μl of ES medium added. Cells from the 
trypsinised 96-well plate were transferred to the parallel gelatinized plate with 
additional ES medium (up to a final volume of 250μl) and allowed to grow for 4 
days whereupon the medium was yellowed. The plates were then drained and 
washed twice with PBS. 50μl of lysis buffer (10mM Tris.HCl, pH 7.5, 10mM EDTA, 
10mM NaCl, 1mg/ml proteinase K, 0.5%(w/v) SDS) was added to each well, the 
plates sealed with adhesive sheets and incubated in a humidified chamber at 55 
oC overnight. The genomic DNA was precipitated by the addition of 100μl of ice-
cold ethanol-salt mix (75 mM NaCl in 100% ethanol) to each well. Plates were 
allowed to stand for a minimum of 1 hour at room temperature before being 
drained by careful inversion onto paper towels. The plate was then washed three 
times with 200μl/well of 70% ethanol and allowed to air-dry for 20-30 minutes. This 
work was performed by the Beatson Institute Transgenic Technology core service.    121 
5.1.1.4 mES screening for homologous recombination 
Screening of neomycin resistant mES cells for homologous recombination was 
accomplished with separate PCR reactions against the 3’ and 5’ homology arms of 
the insert vector. Spotted genomic DNA was diluted in 50 ul TE buffer (Tris 10mM 
pH 8.0, and EDTA 1mM) for 24 hours at 37°C and then screened, remaining DNA 
was re-frozen. The primary screen tested recombination in the 3’ targeting vector 
homology arm and used primers within the neomycin selection cassette and 
outside the homology arm (Figure 2.2), this reaction is expected to yield a 3.5 kb 
product in correctly recombined samples. PCR reaction used 200 ng template 
DNA, 1 unit Phire hotstart DNA polymerase (Finnzymes), 0.2 mM dNTP, and 1 μM 
primers. Positive samples were re-analysed. Samples verified positive for 3’ 
recombination were then tested for 5’ homology arm recombination and used 
primers outside the homology arm and within the neomycin selection cassette 
(Figure 2.3). This secondary screening reaction is expected to yield a 5.5 kb 
product in correctly recombined samples. PCR reaction used the Expand high 
fidelity PCR system (Roche) with 400 ng template DNA, 1 unit polymerase, 0.5 
mM dNTP, and 500 nM primers. All PCR reactions were examined for product by 
agarose gel electrophosesis visualized with ethidium bromide. Product size was 
estimated from DNA ladders (Hyperladder I, Bioline). Successfully targeted clones 
were then expanded and stocks generated for subsequent injection into mouse 
blastocysts. 
5.1.1.5 mES blastocyst injection and embryo implantation 
Targeted stem cells were grown on MEF monolayers and harvested for injection 
following plating out of MEFs. Stem cells (8-15) were injected into C57Bl/6 
blastocysts and then implanted into the uteri of pseudo-pregnant female ICR mice. 
Male chimeras of high ESC contribution were identified in the subsequent litters by 
coat colour. These were crossed with C57Bl/6 females and the offspring 
genotyped for ROCK1nc. Genotypically positive mice were then crossed to a Cre-
deleter strain (on a C57Bl/6 background) to remove the neomycin selection 
cassette. Mice homozygous for ROCK1nc were then interbred to generate a 
homozygous strain for use in our proposed studies. This work was performed by 
the Beatson Institute Transgenic Technology core service.    122 
5.1.1.6 Animal genotyping 
For routine genotyping the animals were tail clipped at weaning and samples sent 
to Transnetyx genotyping service for analysis.  
5.1.2  In vitro ROCK1 kinase assay 
ROCK1 kinase assays were performed with purified full length MYC-tagged wild 
type and D1113A ROCK1 expressed in HEK 293T cells. These MYC-tag ROCK1 
constructs were generated as previously reported 
73. Briefly, confluent HEK 293 
cells were transfected with 10 μg of plasmid with lipofectamine2000 (Invitrogen) in 
10 cm plates and incubated at 37°C for 24 hours. Control sample had no plasmid 
transfected. The transfected cells were then washed, collected, and lysed with 
RIPA buffer. Anti-MYC-tag antibody was added to approximately 450μg of cellular 
lysate overnight at 4°C. Protein bound to antibody was precipitated with protein G 
sepharose and washed in kinase wash buffer (50 mM Tris pH 7.5, 10 mM MgCl2, 
0.1 mM PMSF, 1 mM Na Vanadate, 50 mM NaCl, 1 mM DTT, 10% glycerol, 
0.03% Brij-35) divided into 4 20 μl aliquots and frozen at -20°C. Uniformity of 
protein expression was determined by Coomasie staining of PAGE gels. 200 ng of 
purified BSA was loaded on gel to verify protein concentration. Kinase activity was 
then analysed with a fluorescence polarization assay. Briefly, 200 ng of MYC-
tagged ROCK1 in kinase buffer was supplemented with 100 μM ATP and 500 nM 
Fluorescein-tagged ROCK1 peptide substrate derived from S6Kinase (5FAM-
AKRRRLSSLRA). The reaction was incubated for 1 hour at room temperature in a 
plate shaker. Following incubation 1:400 dilution of IMAP binding reagent 
(Molecular Devices) in kinase buffer was added and further incubated for 1 hour at 
room temperature on plate shaker. Kinase activity was then determined by reading 
fluorescence peptide polarisation in a Tecan Safire
2 multimode microplate reader 
by exciting the sample at 470 nm and measuring the emission at 525 nm. 
5.1.3  Mouse embryonic fibroblast (MEF) generation 
MEFs were generated from E13.5 embryos resulting from homozygous ROCK1wt 
and ROCK1nc breeding pairs. The appearance of the mating plug indicates 
embryonic day 0.5 (E0.5) and 13 days later the pregnant females are euthanized 
by cervical dislocation and uterine horns containing embryos extracted. Further 
dissection of the embryos takes place in laminar flow hood to minimize bacterial    123 
contamination. Briefly, the embryos are dissected from the uterus and washed in 
PBS. Embryonic heads and livers were removed and sent for genotyping. The 
remaining tissue from all embryos was pooled and roughly chopped before 
incubation in 0.05% trypsin (1ml trypsin/embryo) for 10 min at 37°C. Embryos 
were then further dissociated by trituration in serological pipettes of decreasing 
size, then counted and plated at 5x10
6 cells in a 180 cm flask. Cells were cultured 
in DMEM supplemented with 10% FBS, penicillin/streptomycin (100 units/ml, 100 
μg/ml, respectively) and maintained at 37°C in 5% CO2 atmosphere. Cells were 
split twice before cryopreservation. Typically ROCK1wt and ROCK1nc MEF 
cultures proliferated to passage 8-10 before senescing. No difference in 
proliferation rate or senescing age was seen in either ROCK1 genotype.  
5.1.4  Microscopy 
5.1.4.1 Fluorescent 
After plating on glass coverslips ROCK1wt and ROCK1nc MEFs were serum 
starved overnight then treated with 10% FBS for 5 min + 10 μM Y27632. The cells 
were then fixed and permeabilized with paraformaldyhyde with 0.5% triton X-100 
at room temperature for 5 min before washing and staining. Following fixation the 
samples were blocked with 1.5% BSA and 10% normal goat serum in PBS for 10 
min. Fixed cells were probed with rabbit anti-phosphorylated myosin light chain 
(pMLC) (thr18/ser19) antibody (cell signaling) diluted 1:100 in blocking buffer for 1 
hour at room temperature. Following washing the cells were stained with anti-
rabbit IgG antibody conjugated to Alexa Fluor 488 (1:1000, Invitrogen) and f-actin 
filaments were visualized with Texas Red conjugated phalloidin (1:250, Invitrogen) 
in PBS. Samples were then washed and mounted with Vectashield hard set 
mounting medium with DAPI (Vector labs). Fluorescent microscopic images were 
acquired with a 60x oil immersion lens on an Olympus FV1000 laser scanning 
confocal microscope. 
5.1.4.2 Timelapse 
ROCK1wt and ROCK1nc MEFs were plated on glass bottom dishes (Iwaki) then 
serum starved overnight prior to induction of apoptosis with TNFα and 
cycloheximide (CHX) (50 ng/ml and 10 μg/ml, respectively). Bright field differential 
interference contast (DIC) time-lapse microscopy images were acquired with a 20x    124 
objective using a Nikon Eclipse Ti microscope with a heated stage and 5% CO2 
gas line. Immediately after induction of apoptosis the cells were relocated to the 
microscope and time lapse images were taken every 30-60 seconds for several 
hours.  
5.1.5  In-cell western blot 
MEFs (50,000/well) were plated in a 96 well plate and then serum starved 
overnight before stimulation with 10% FBS for 5 min + 10 μM Y27632. Staining for 
pMLC was performed as previously described. Total cell number was determined 
by nuclei staining with the fluorescent marker DRAQ5 (1:700, Biostatus). 
Fluorescence was determined by imaging the plate with an Odyssey LiCOR 
scanner and signal intensity with Odyssey software. pMLC signal was normalized 
to DRAQ5 signal.  
5.1.6  Western blot 
Apoptotic ROCK1wt and ROCK1nc MEFs were generated with TNFα and CHX as 
previously indicated. Four hours after treatment the cells were collected by 
scraping centrifuged and lysed in RIPA buffer (10 mM TRIS pH 7.5, 5 mM EDTA, 
150 mM NaCl, 40 mM NaPPi, 50 mM NaF, 1% (v/v) NP-40, 0.5% (v/v) sodium 
deoxycholate, 0.025% (w/v) SDS, 1mM Na3VO4, 1 mM PMSF). Samples were 
then normalized to total protein concentration determined by Bradford colorimetric 
assay (BCA) and separated on a 10% SDS-PAGE gel. Gel was then transferred to 
nitrocellulose blotting paper and blocked with BSA. Multiple membranes were 
probed for ROCK1 (BD-transduction labs), PARP (BD Pharmingen), pMLC (Cell 
Signaling), and α-tubulin as a housekeeping protein (Santa Cruz). Antibody 
binding was visualized with fluorescent secondary antibodies using an Odyssey 
LiCOR scanner.  
5.1.7  Flow cytometry 
Apoptotic MEFs were generated as indicated. After 24 hours samples were 
collected, centrifuged, and diluted to 1e5 cells/ml in a total volume of 100 μl in 
binding buffer (100 mM HEPES pH 7.4, 140 mM NaCl, 2.5 mM CaCl2) prior to 
staining with with 5 μg/ml PI and 5 μl commercial annexin V-alexafluor 488 
conjugate for 10 min at room temperature. Samples are then diluted to 0.5 ml in    125 
binding buffer then 10,000 apoptotic cells were gated using forward (FSC) and 
side scatter (SSC), PI and annexin fluorescence determined in channel FL1 and 
FL3. Quadrant gating was determined from stained non-apoptotic NIH 3T3 
sample. 
5.1.8  Histological tissue collection, fixation, processing, and 
staining 
Animals were euthanized by either cervical dislocation or rising concentrations of 
CO2 and tissues were rapidly dissected and fixed by immersion in 10% buffer 
formaldehyde. Fixed tissue was then processed by histology core service (paraffin 
embedding, sectioning, and stained). Prior to staining the samples are de-waxed 
in xylene and re-hydrated in 97% ethanol then washed in tap water. Samples were 
then stained with haematoxylin and eosin (H&E) and Perls prussian blue. Perls 
Prussian blue stain uses an equal part solution of ferrocyanide and hydrochloric 
acid for 10 min before washing and counterstaining with eosin. In addition, fixed 
tissue sections were also probed for the presence of cleaved caspase 3, mouse 
IgG, and F4/80 antigen (mouse macrophages) with specific antibodies. Cleaved 
caspse 3 is detected in fixed spleen following antigen retrieval with commercial 
proteinse K solution (DAKO) for 5 minutes and incubation with rabbit anti-cleaved 
caspase 3 antibody (1:200, Abcam) for 1 hour at room temperature. Cleaved 
caspase 3 is then visualized with commercial vectastain anti-rabbit IgG (Vector 
Labs) ABC immunoperoxidase kit which produces a brown precipitate on sample. 
Samples are then counter stained, dehydrated and mounted. The presence of 
mouse IgG in fixed kidney sections was detected directly with anti-mouse IgG 
antibodies conjugated to Alexa Fluor 488 (Invitrogen) and then mounted in 
vectashield hard set mounting medium with DAPI (Vector Labs). Mouse 
macrophages were detected in fixed spleen by staining with rat anti-F4/80 (1:100, 
Abcam) in PBS for 30 minutes at 37°C following proteinase K antigen retrieval. 
F4/80 antibody binding was detected with commercial vectastain anti-rat IgG 
(Vector Labs) ABC immunoperoxidase kit. Samples are then counter stained 
(haematoxylin), dehydrated and mounted. 
5.1.9  Haematology 
After CO2 euthanasia 0.5 ml whole blood was withdrawn from descending 
abdominal aorta and dispensed in clinical potassium-EDTA tube. Samples were    126 
then immediately sent to clinical veterinary pathology lab at the University of 
Glasgow Veterinary School for a complete clinical haematology analysis.  
5.2 Chapter 3 methods 
5.2.1  Cell culture 
NIH 3T3 cells were maintained in DMEM supplemented with 10% donor bovine 
serum. Murine RAW 264.7 macrophages were maintained in DMEM 
supplemented with 10% fetal bovine serum.  
5.2.2  Western blot 
Cell lysates were generated with RIPA lysis buffer (10 mM TRIS pH 7.5, 5 mM 
EDTA, 150 mM NaCl, 40 mM NaPPi, 50 mM NaF, 1% (v/v) NP-40, 0.5% (v/v) 
sodium deoxycholate, 0.025% (w/v) SDS, 1mM Na3VO4, 1 mM PMSF). Cell 
lysates and concentrated conditioned medium was diluted 1:4 with sample buffer 
and warmed to 70 °C for 10 min. Samples were run on 10% SDS-polyacrylamide 
gels, transferred to polyvinylidene fluoride membranes blocked in 5% (w/v) skim 
milk in TBS prior to probing with anti-GFP (BD Biosciences), anti-gelsolin (Abcam), 
anti-HMGB1 (Cell Signaling), anti-actin (Santa Cruz), anti-ROCK1 (Transduction 
Labs). Primary antibodies were probed with alexafluor 680 (Invitrogen) and IR800 
(Rockland) conjugated secondary antibodies and analysed using LiCOR-odyssey. 
Band intensity analysed using odyssey application software. 
5.2.3  Creation of membrane tagged GFP expressing NIH 3T3 cells 
Generation of ecotropic virus for CaaX-GFP transduction was carried out as 
previously described 
267. NIH 3T3 cells were infected with 1 ml of virus and 4 μl 
polybrene (4 mg/ml) overnight. The next day the medium was replaced and cells 
selected with puromycin. GFP fluorescence was verified by FACS.  
5.2.4  Induction of apoptosis, and generation of conditioned medium 
NIH 3T3 apoptosis was induced with a combination of 50 ng/ml tumour necrosis 
factor alpha (TNFα)(R&D Systems)) and 10 μg/ml cycloheximide (CHX)(Sigma), 
unless otherwise indicated, and diluted in unsupplemented DMEM medium 
following an overnight starvation. Cells were then incubated at 37°C for 2-24    127 
hours. Medium was further supplemented with: Y27632 (10 μM)(EMD), 
blebbistatin (50 μM)(Tocris), z-VAD-fmk (20 μM)(R&D Systems) where 
appropriate. 
Apoptotic cell conditioned medium (AC-CM) was generated by pelleting apoptotic 
cells in media at 2000x gravity for 10 min. AC-CM was routinely determined to be 
clear of cells and debris by microscopic examination. Necrotic cell supernatant 
was generated from starved cells by 3 freeze thaw cycles in dry ice. AC-CM was 
concentrated by centrifugation with 10 kDa cutoff Millipore centrifugal filter units at 
4500x gravity for 30 min. Samples were concentrated approximately 30 fold. Prior 
to concentrating, 0.260 μg of recombinant GFP was added to each sample as an 
internal standard.  
5.2.5  Microscopy  
Timelapse microscopy images were acquired with a 20x objective using a Nikon 
A1R confocal microscope with a heated stage and 5% CO2 gas line. Grey scale 
image is transmitted light. Cells were grown on optical glass coverslips and 
apoptosis was induced in starve medium supplemented with TNFα, CHX and 5 
μg/ml propidium iodide (PI). Immediately after induction of apoptosis, cells were 
relocated to confocal microscope and time lapse images were taken every 30 
seconds for 8 hours in both transmitted light and red fluorescence.  
High resolution still images of unfixed apoptotic cells were acquired with a 60x oil 
immersion objective using same conditions as above. The medium was further 
supplemented with FAST DiO (3,3'-dilinoleyloxacarbocyanine perchlorate) diluted 
1:500 from 2.5 mg/ml dissolved in 100% DMSO.  
5.2.6  Flow cytometry 
5.2.6.1 Apoptotic body PI permeability 
For the assessment of apoptotic body PI permeability 4 hour apoptotic NIH 3T3 
samples were generated with the further addition of 5 μg/ml PI (Sigma), 100 μg/ml 
RNaseA (Qiagen), and/or 200 units/ml DNase1 (Roche). Non-apoptotic NIH 3T3 
cells were collected following trypsinization, quenched in growth medium and used 
as control. Apoptotic samples were analysed with a BD FACSCalibur flow    128 
cytometer. 100,000 apoptotic bodes were gated using forward (FSC) and side 
scatter (SSC), and PI fluorescence determined in channel FL3. PI stained non-
apoptotic control was used to gate samples.  
5.2.6.2 Apoptotic body proteinase K permeability 
Apoptotic body proteinase K permeability was assessed in NIH 3T3 cells 
expressing membrane tagged GFP. 2 hours after addition of TNFα and CHX, 
proteinase K (50 μg/ml) (Melford) was added to the cells and incubated for a 
further 2 hours. The apoptotic samples were analysed with a BD FACSCalibur flow 
cytometer. 100,000 apoptotic bodes were gated using forward (FSC) and side 
scatter (SSC), and GFP fluorescence determined in channel FL1. GFP positive 
apoptotic bodies gated against non-GFP expressing apoptotic bodies. 
5.2.6.3 Apoptotic body generation 
The generation of apoptotic bodies from NIH 3T3 cells at 4 hours was assessed 
following treatment with TNFα, CHX, and Y27632 (10 μM) or blebbistatin (50 μM). 
Apoptotic samples were collected, diluted 2:3 in PBS and an equivalent volume of 
FITC-calibrite beads added to each sample. Apoptotic bodes were gated on 
forward (FSC) and side scatter (SSC). FITC beads were gated based on 
fluorescence. The number of apoptotic bodies is counted alongside 10,000 gated 
FITC beads.  
PI permeability of apoptotic bodies generated in the presence of Y27632 and 
blebbistatin was assessed following the addition of PI to the sample and 
incubating for 10 min at room temperature. PI fluorescence of 25,000 apoptotic 
bodies for each treatment was scored in channel FL3. PI stained non-apoptotic 
control was used to gate samples. 
5.2.6.4 Apoptotic cell permeability 
Apoptotic NIH 3T3 samples were generated as indicated. After 4 hours samples 
were incubated with 5 μg/ml PI and 5 μl annexin V-alexafluor 488 conjugate 
(Invitrogen) for 10 min at room temperature. 10,000 apoptotic cells were gated 
using forward (FSC) and side scatter (SSC), PI and annexin fluorescence    129 
determined in channel FL1 and FL3. Quadrant gating was determined from 
stained non-apoptotic NIH 3T3 sample. 
5.2.7  Lactate dehydrogenase activity measurements 
LDH activity measured with Roche cytotoxcity detection kit according to 
manufacturers recommendations. After concentration, the samples were diluted 
1:10 in DMEM prior to LDH activity measurement. After normalization to GFP, as 
determined by western blot, 100 μl of sample mixed with equal concentration of 
dye solution and incubated for 20 min in the dark in 96 well plate. Reaction 
stopped with 50 μl stop solution and solution absorbance measured with TECAN 
safire2 at 490 nm. Sample activity expressed as a percentage of activity detected 
in necrotic sample. 
5.2.8  SILAC 
NIH 3T3 cells were grown in DMEM supplemented with dialysed FBS containing 
specific labeled arginine (Arg) and lysine (Lys) amino acids for 5 passages. Cells 
were labeled with light/unlabeled (Lys-0, Arg-0), medium (Lys4, Arg6), and heavy 
(Lys8, Arg10) medium. Amino acids are labeled with the following isotopes: Lys4, 
2H4; Lys8, 
13C6, 
15N2; Arg6, 
13C6; Arg10, 
13C6, 
15N4 (Silantes). Label incorporation 
was determined to be >95% by mass spectrometry. Labeled populations of labeled 
NIH 3T3 assigned the following treatments: Light, control; Medium, TNFα+CHX; 
Heavy, TNFα+CHX+Y27632. After 4 hours the supernatant was processed and 
concentrated as mentioned. Samples were normalized to GFP internal standard 
by western blot and 10 ml of each sample was mixed and run on 10% SDS-PAGE. 
The gel was stained with Coomassie and destained in acetic acid. Gel was then 
processed and subjected to mass spectrometry and database search by Beatson 
Institute Mass Spectometry Service staff, Willie Bienvenut, Sergio Lilla, and David 
Sumpton.  
5.2.9  Gelsolin knockdown 
Gelsolin was knocked down by nucleofection of NIH 3T3 cells with Dharmacon on-
target plus smart pool against mouse gelsolin (L-057211-00-0005). 1x10
6 cells 
were transfected in solution R with 3 μg non-targeted or gelsolin siRNA. After 
nucleofection the cells were incubated in DMEM+10% FBS for 72 hours prior to    130 
induction of apoptosis. 60-70% gelsolin knockdown was typically observed by 
western blot. 
5.2.10 RAW 264.7 transwell migration 
AC-CM was generated from NIH 3T3 at 4 hours after induction of apoptosis with or 
without gelsolin knockdown by siRNA nucleofection. AC-CM was used as a 
chemoattractant for 5x10
5 Raw264.7 macrophages in starve medium were seeded 
in the top chamber of 8 μm transwell insert. Cells were incubated for 2 hours at 
37°C and then fixed with ice cold methanol, cells that failed to migrate were 
removed by swab. Migrated cells were stained with PI (5μg/ml) and then 
quantitated by counting migrated macrophages in 3 random fluorescent 
microscopy fields (10x). 
5.3 Chapter 4 methods 
5.3.1  Cell culture, transfections and plasmids 
  NIH 3T3 cells were maintained and transient transfections were performed as 
described previously (Coleman et al., 2001). For Nucleofection, cells were 
prepared according to the Amaxa™ protocol. 
pCAG MYC ROCK1 was described previously 
57 and mutations were introduced 
using QuikChange (Stratagene) site-directed mutagenesis kit according to 
manufacturer’s protocol. 
5.3.2  Cell extraction and immunoblotting 
Whole cell lysates were prepared and western blotted as described previously 
57. 
Rabbit anti-MYC 9B11 (Cell Signaling Technology) and Alexa-Fluor680 (Molecular 
Probes) antibodies were used and detected by infra-red imaging (Li-Cor Odyssey). 
5.3.3  Immunoprecipitations and kinase assays 
MYC-ROCK1 was immunoprecipitated from transfected NIH 3T3 cells with rabbit 
anti-MYC antibody and Protein G Sepharose (Sigma) for 2 h at 4 C, beads were 
washed 3x with lysis buffer. Immunoprecipitated ROCK1 was assayed at 30°C for 
10 min in a total volume of 50 μl containing 50 mM Tris/HCl, pH 7.5, 0.1 mM    131 
EGTA, 0.1% (v/v) 2-mercaptoethanol, 10 mM MgCl2, 0.1 mM [γ-32P]ATP (2×106 
c.p.m./nmol) and 50 μM LIMKtide (LKKPDRKKRYTVVGNPYWMA). The reaction 
was stopped by spotting onto p81 paper and submerging in 1% (v/v) 
orthophosphoric acid. The papers were washed 3 times, dried and Cerenkov 
counted. 
5.3.3.1 Fluorescence polarization ROCK1 kinase assay 
50 ng recombinant GST-ROCK1 fusion (Invitrogen) was incubated with 100nM 
Fluorescein-tagged ROCK1 peptide substrate derived from S6Kinase (5FAM-
AKRRRLSSLRA), 100 μM ATP and 100 μM of interacting peptides or Y-27632 as 
indicated in a total 50μl kinase buffer (10mM Tris/HCl pH 7.2, 10mM MgCl2, 0.05% 
NaNO3 and 0.1% Phospho-free BSA). The reaction was incubated for 30-45 
minutes at room temperature in a plate shaker. Following incubation 65 μl of 1:400 
IMAP binding reagent in kinase buffer was added to each well. The mixture was 
further incubated for 30min at room temperature with gentle shaking then 
fluorescence polarisation was read in a Tecan Safire
2 multimode microplate reader 
by exciting the sample at 470nm and measuring the emission at 525nm. 
5.3.4  Peptide arrays 
In vitro transcribed and translated (IVTT) [
35S]-Methionine-labeled ROCK1 was 
generated from pcDNA3 using the TNT kit (Promega) according to the 
manufacturer’s protocol. 21-mer peptides offset by 2 amino acids covering amino 
acids 1-75 and 853-1354 of human ROCK1 were arrayed onto membranes 
(Cancer Research UK, London, UK). Arrays were blocked in 5% (w/v) bovine 
serum albumin/Tris-buffered saline (BSA/TBS) for 1 h prior to incubation with 50 μl 
[
35S]-Methionine labeled IVTT ROCK1 in 5% (w/v) BSA/TBS for 1 h. Membranes 
were washed three times in TBS/0.1% (v/v) Tween, dried and exposed to film. 
5.3.5  Immunofluorescence 
Following nucleofection the cells were incubated for 3 hours in growth medium and 
then serum starved overnight. Cells were fixed and stained as described 
previously 
57. Confocal images were obtained using an Olympus FV1000 using a 
60x oil-immersion objective.    132 
For cell size, 6 random fields of MYC-tag positive fluorescence cells were captured 
per treatment with a 20x objective, subsequently the images were analysed for 
percentage MYC-tag positive area divided by cell number. 
For cell morphology, 6 random fields of MYC-positive and actin were captured per 
treatment with a 10x objective and the number of cells with spread, contracted or 
rounded morphology were determined. 
5.3.6  FACS expression 
After transfection, cells were incubated overnight in growth medium (DMEM 
supplemented with 10% FBS). The following day the cells were collected and fixed 
in 2% paraformaldehyde for 10 minutes. Cells were then washed and 
permeabilized with 0.1% Triton X-100 for 5 minutes. MYC-tagged ROCK1 
constructs were detected with an anti-MYC (9B11) antibody conjugated with 
AlexaFluor 647. 10,000 events were collected on a BD FACScaliber and MYC-tag 
positive cells were gated against blank transfected cells. 
5.3.7  Protein fragment production 
The binding peptide sequences were amplified by PCR from wild type pCAG 
ROCK1 constructs and subcloned into modified p-GEX-6-P1 expression vector 
containing a FLAG sequence. The P1193S mutation was introduced within the 2g 
construct using the quickchange XL site directed mutagenesis kit. The expression 
vectors were then used to transform BL21 e-coli strain. Peptide expression was 
induced with 0.1 mM IPTG from 5-18 h. Following bacterial lysis the samples were 
centrifuged to remove debris at 10000 g for 20 min, the supernatant was then 
mixed with PBS equilibrated glutathione-sepharose beads overnight at 4C. The 
beads were then washed 5x in PBS and finally re-suspended in protease buffer 
(50 mM TRIS-HCL, 150 mM NaCl, 1 mM EDTA, 1 mM DTT pH 7.0), the 
expressed peptides were then liberated from GST by cleavage with an overnight 
incubation at 4°C with PreScission protease (GE Life Sciences). Following 
cleavage the supernatant was collected by centrifugation and the protease 
removed with p-aminobenzamidine beads. The resulting protein was assessed by 
coomasie staining of PAGE gels as well as anti-flag western and dot blot.    133 
5.3.8  Cell motility 
NIH 3T3 cells were co-transfected with 1:2 ratio of GFP and pCAG ROCK1 
constructs. Following Nucleofection, cells were incubated for 3 h in a 6 well glass 
bottom dish in complete medium followed by incubation in serum reduced medium 
(3.3% FBS). Three bright and GFP timelapse fields were captured with a 10x 
objective for each treatment every 2 min for 20 hours. Individual cell motility was 
analysed using Metamorph and Image J. 
5.3.9  Protein binding assay 
Approximately 200 ng of recombinant GST fusion ROCK1 (Invitrogen) was spotted 
directly onto nitrocellulose blotting paper and briefly allowed to dry. The membrane 
was then blocked in 5% milk in TBS for 20 min at room temperature. The 
membrane was then cut into individual spots and separately incubated with 
individual binding proteins diluted in 5% milk TBS and incubated at 4C overnight. 
Following washing, ROCK1 and bound protein were detected with Anti-GST and 
Anti-FLAG antibodies respectively. Membranes were imaged and quantitated 
using 2 colour infra-red imaging (Li-Cor Odyssey). 
5.3.10 Transwell dissociation assay 
  NIH 3T3 cells were co-transfected with 1:2 ratio of GFP and pCAG ROCK1 
constructs. Following nucleofection, 2x10
5 cells were incubated with growth 
medium for 3 h in a 24 well transwell insert (8 μm pore). Following incubation, the 
growth media in each insert was aspirated and replaced with serum free medium 
and insert was placed in new well containing 10% FBS medium and incubated 18 
hours. Inserts were then discarded and the number of GFP positive cells in the 
well bottom was assessed. Three GFP fields were captured with a 20x objective 
for each treatment and the number of positive cells was scored across all fields. 
5.3.11 Protein modeling 
The ROCK1 kinase interacting regions were modeled onto the ROCK1 kinase 
domain (2ETR), followed by alignment and identification of corresponding amino 
acids with the ROCK2 sequence onto the ROCK2 PH (2ROV) and C1 domains    134 
(2ROW). The protein co-ordinates as indicated were imported from PDB into 
Pymol for modeling and rendering. 
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